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Abstract
Fas (CD95) is a member o f the death receptor superfamily o f proteins that are involved 
in the initiation o f apoptosis as induced by the binding o f extracellular ligands. At 
present, little is known about the precise mechanism by which the signal initiated by the 
interaction between Fas ligand (FasL) and Fas is transduced across the cell membrane to 
start the apoptotic signalling cascade. The first step in this pathway is the recruitment of 
the Fas-associated death domain protein (FADD) to the cytoplasmic death domain of 
Fas via a homotypic protein/protein interaction. This binding event occurs after receptor 
ligation apparently without any post translational modification such as phosphorylation. 
In order to better understand this event we have investigated the interaction between the 
death domains o f the human Fas and FADD proteins both in vitro and in a cellular 
context.
The reported interaction between the Fas and FADD death domains (Fas-DD and 
FADD-DD) was recapitulated using the yeast 2-hybrid assay. Recombinant proteins 
were then produced for NMR spectroscopy experiments. FADD-DD is highly 
expressed, and easy to isolate soluble at physiological pH. This domain is readily 
expressed as a histidine tagged domain. Fas death domain expresses at low levels and 
produces soluble aggregates when concentrated at a pH above 4. However, it was found 
that using a Gbl fusion protein to express Fas-DD overcomes these problems and 
allowed the production o f Fas-DD for NMR experiments. NMR titration experiments 
showed that when these two proteins interact a large, soluble complex is formed. This 
may be significant in relation to the increasing evidence for the importance o f Fas- 
receptor clustering in its signalling.
Mutational analysis o f the Fas death domain was also carried out. Here, various 
previously described as well as several novel point mutations were made on the surface 
of the Fas death domain to investigate their effect on FADD-DD binding. These 
mutations were assayed using yeast 2-hybrid methods, NMR analysis and in a cell based 
assay. In the cell based assay wild type and mutant Fas receptors were overexpressed in 
a human cell line with no endogenous surface Fas expression. These cells were then
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assayed for their ability to undergo FasL-induced apoptosis. It was found that residues 
from many surface regions o f Fas-DD are crucial for the FADD-DD interaction. This 
observation has potentially important implications for the nature o f the organisation of 
the death domains in the death inducing signalling complex (DISC) formed at the Fas 
receptor.
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Chapter 1
Introduction
1.1 Apoptosis
THE balance between cell proliferation and death is essential for the developm ent o f multicellular organisms (Jacobson et al., 1997) as well as in the m aintenance 
o f homeostasis in adult tissues (DeLong, 1998) and the fight against pathogens (Arends 
and Wyllie, 1991). It has been estimated that, in the human body, upwards o f  100,000 
cells are produced every minute and hence a similar number die in order to ensure the 
cellular populations remain constant (Vaux and Korsmeyer, 1999). Therefore, to assist 
in the control o f  cellular populations, multi-cellular organisms have evolved methods o f 
removing damaged, unwanted or infected cells in a controlled m anner that is non­
detrimental to the surrounding tissues.
This concept, known as programmed cell death (PCD), has existed since 1842 when it 
was noticed that cells are removed during the normal development o f  am phibians (Vogt, 
1842) The importance o f PCD can be illustrated by its significant role in the 
development o f  multicellular organisms. For example, during the form ation o f  the 
limbs, individual digits are sculpted by massive cell death o f  the interdigital 
mesenchymal tissue (Zuzarte-Luis and Hurle, 2002). Also, it is estim ated that up to 50 
percent o f neurons that are initially created will be removed by PCD before the adult 
brain is fully formed (M eier et al., 2000). However, as will be discussed in the 
following sections, PCD also plays significant roles in the m aintenance o f  homeostasis 
and disease.
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1.2 The m orphological aspects o f apoptosis
During the 1900’s the idea o f PCD was “rediscovered” on several occasions but it was 
not until the 1970s that these ideas were unified. The term apoptosis was coined in a 
paper by Kerr, Wyllie and Currie in 1972 to describe a quite characteristic variety o f 
PCD involving a series o f specific morphological changes (Kerr et a l., 1972). Cells 
being removed during embryonic development or through population regulation in 
normal human tissue as well as cells dying in pathological situations w ere all observed 
to undergo the exact same series o f  morphological changes. The sequence o f gross 
rearrangements that have been identified -  cellular shrinking, m embrane blebbing, 
chromatic condensation, nuclear fragmentation and, finally, cellular fragmentation -  
have now become the hallmarks and, in many ways, the defining characteristics o f 
apoptotic cell death (Hacker, 2000).
The concept o f apoptosis is perhaps best illustrated by com parison with a separate 
variety o f  pathological cell death called caused by gross injury or uncontrolled 
infection. This second mode o f  cell death, known as necrosis, is characterised by 
swelling o f the cell and its organelles, due to a loss o f m em brane potential control, 
which results in the dying cell bursting and releasing its contents into the local 
environment (Saraste and Pulkki, 2000). During necrosis there is no nuclear 
rearrangement or m embrane blebbing, as seen in apoptosis, but perhaps the m ost crucial 
difference between these forms o f cell death can be observed in the latter stages o f 
apoptosis during which there is the formation o f small m em brane bound cellular 
fragments, known as “apoptotic bodies”, which are subsequently phagocytosed by cells 
in the surrounding tissue. Since these apoptotic bodies serve to contain most, if  not all, 
o f the original contents o f the now dead cell, there is no dam age to the surrounding 
tissues and indeed the cellular contents can be reused following phagocytosis o f  the 
apoptotic bodies by other cells. This recycling process is in stark contrast to necrotic 
cell death whereby bursting o f the plasma membrane and the release o f cellular contents 
leads directly to a damaging, inflammatory response in the local tissue. A diagram m atic 
comparison o f the morphological differences between apoptosis and necrosis, 
illustrating both the mechanism and consequences o f  these two distinct forms o f  cell 
death, is shown in Figure 1.1.
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APOPTOSIS NECROSIS
I
Healthy cell
Apoptotic
stimulus
Cellular shrinkage 
Cytoplasmic condensation 
Chromatin condensation
Membrane blebbing
Chromatin compaction 
Nuclear fragmentation
I
Healthy cell
Gross 
injury or 
infection
Cellular and organelle swelling
Cellular fragmentation
Formation of apoptotic 
bodies
PHAGOCYTOSIS
Cell bursts releasing contents into 
the surrounding tissue
INFLAMMATION
Figure 1.1: Comparison of apoptotic and 
necrotic cell death based on the series of 
characteristic morphological changes that 
define these two distinct forms of cell death. 
The controlled, tightly regulated apoptotic 
process that results in the formation of 
apoptotic bodies that are readily phagocytosed 
is contrasted with the uncontrolled nature of 
necrotic cell death that ends in the release of 
inflammatory molecules from the ruptured cell.
17
1.3 Apoptosis in the immune system
The immune system contains one o f the most dynamic cell populations in the human 
body and provides several excellent examples o f the necessity to control the balance 
between cell proliferation and cell death. This is seen most dramatically in the huge 
fluctuations in lymphocyte populations in response to antigenic stimulation. A typical 
host immune response to challenge by a foreign antigen is characterised by a m ulti­
stage process: T-lymphocytes (T cells) are initially activated when presented with a 
foreign antigen (in the context o f other co-stimulatory molecules) by specialised 
antigen-presenting cells. Once activated the T cells differentiate and undergo massive 
clonal expansion -  in some cases this can result in a 100,000-fold increase in a specific 
T cell clone (Krueger et al., 2003). However, although some o f these activated T cells 
may differentiate further to become memory cells following the peak o f  infection, it is 
necessary that the majority o f this expanded T cell population be removed in order to 
maintain overall lymphocyte homeostasis. This process o f T cell elim ination during the 
termination o f an immune response is known as activation induced cell death (AICD) 
and it occurs by apoptosis (see Figure 1.2).
Clonal 
expansion 
phase /
Memory
phaseCell
number
Deletion
phase:
apoptosis
Time
Antigen
challenge
Figure 1.2: Diagrammatic representation of a time course of a T cell immune response. 
The cell population expands dramatically following antigen challenge. The removal of T 
cells following this clonal expansion is effected by apoptosis and is known as activation 
induced cell death. Adapted from (Krueger et al., 2003).
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A second, equally important, role for apoptosis in the im mune system is in the 
development and maintenance o f  T cell self-tolerance. T cells recognise antigens via an 
interaction between their own T cell receptor (TCR) and a m ajor histocom patibility 
complex (M HC)-peptide complex that is present on the surface o f  an antigen-presenting 
cell. Since the process that creates TCRs is an essentially random genetic recom bination 
event it is inevitable that some T cells will be produced that recognise self-anti gens. 
These self-reactive T cells are deleted by apoptosis both in the thym us by complex 
mechanisms o f  positive and negative selection, where the vast m ajority o f  tolerance is 
developed, and almost certainly also in the peripheral organs where a num ber o f  self­
antigens are present which are not encountered in the thymus (Stuart and Hughes, 
2002).
The tight control o f  the combination o f proliferative and apoptotic events in the T cell 
population ensures that there is always a relatively constant num ber o f  functional but 
non-self reactive immune cells.
1.4 Apoptosis signalling
It is clear that in order for cells to undergo apoptosis in such a consistent m anner in such 
a wide variety o f physiological situations there must be a highly conserved set o f  
underlying biochemical processes that control this mode o f  cell death. Reinforcing this 
hypothesis is the observed evolutionary conservation o f apoptosis throughout 
multicellular invertebrate and vertebrate species (Jacobson et al., 1997).
Despite intricate knowledge o f  the gross morphological changes that have now com e to 
define apoptotic cell death, fifteen years ago the intracellular processes that control 
apoptosis were not well understood (Arends et al., 1991). Since that time, however, 
there has been a vast effort to improve the understanding o f  the precise m olecular 
mechanisms that underpin apoptosis and this is reflected in the exponential growth in 
the number o f  publications in the field since the early 1990’s. A com bination o f  cell 
biology, biochemical and genetic research has lead to the discovery that the w ay in 
which cells die by apoptosis is the consequence o f highly organised and finely regulated
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series o f intracellular signalling pathways (see such reviews by M artin and Green, 1995; 
Chinnaiyan and Dixit, 1996; Strasser et al., 2000; Hengartner, 2000).
The major impetus behind the deconstruction o f these biochemical pathways was the 
genetic study o f the nematode Ccenorrabditis elegans that uncovered several genes 
(denoted genes) which were found to be essential for the famously defined 131 
PCD events that occur during the development o f  this organism. O f particular interest 
from this genetic research were several o f the ced genes such as ced-3, ced-4 and ced-9 
as these genes were subsequently found to have mammalian hom ologues (reviewed in 
(Metzstein et al., 1998). The major route o f initiation o f  apoptosis in C. elegans is the 
heterodimerisation o f  the ced-3 and ced-4 gene products. This complex can be 
negatively regulated by the ced-9 gene product, the activity o f which can, in turn, be 
blocked by the egl-1 gene product. The ced-3 gene was discovered to encode a protein 
that is homologous to the human interleukin-ip-converting enzyme, ICE (Yuan et al.,
1993). ICE belongs to a family o f  proteases, o f which 14 have been identified in 
mammals, which are now referred to as caspases as they are cysteine proteases that 
cleave their respective substrates on the C-terminal side o f aspartic acid residues. The 
ced-4 gene product is homologous to a mammalian protein known as apoptotic protease 
activating factor 1 (APAF-1) which is now known to be part o f  a caspase-activating 
signalling complex known as the apoptosome. The ced-9 gene product, m eanwhile, is 
homologous to Bcl-2, a mammalian inhibitor o f  apoptosis (H engartner and Horvitz,
1994). The EGL-1 protein consists solely o f a Bcl-2 homology 3 (BH3) domain and 
interacts with the CED-9 protein, directly inhibiting its function (Kaufm ann and 
Hengartner, 2001).
Whilst evolution has led to an increase in the numbers o f genes in the different “death 
gene” families recognised in C. elegans (exemplified by the inventory o f  14 m ammalian 
caspases and the large number o f  mammalian BH3-only proteins, such as Bid, Bad, Bik, 
Bim, Noxa and Puma), the conservation o f  these proteins is underlined by the presence 
o f homologues not only in nematodes and mammals but also in D rosophila  (Kaufm ann 
et al., 2001; Richardson and Kumar, 2002). The Drosophila PCD pathways are found to 
be o f intermediate com plexity relative to worms and mammals, as m ay be expected 
from the respective levels o f complexity o f these organisms.
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Figure 1.3: Apoptotic signaling pathways in (a) C. elegans, (b) D. melanogaster and (c) H. 
sapiens. The conservation of theses pathways is indicated in this diagram by the use of 
identical coloured boxes for homologous proteins across the different species. The C. elegans 
pathway is the least complex, involving direct interaction between CED-4 and CED-3 
resulting in CED-3 (a caspase enzyme) activation. This action can be blocked by the Bcl-2 
homologue CED-9 through direct binding to CED-4. The BH3-only protein EGL-1, can, in 
turn, interact directly with CED-9, blocking its activity (and is therefore indirectly pro- 
apoptotic). Mammals have evolved to have two sets of caspase enzymes, the initiators, such 
as caspase-8 and caspase-9 and the effectors, such as caspase-3 and caspase-6. These 
caspases are negatively regulated by the IAP family of proteins by direct interaction. IAP 
activity can, in turn, be blocked by smac and omi following the release of these pro-apoptotic 
proteins from the mitochondria. As in C. elegans, the activity of APAF-1 (the mammalian 
CED-4 homologue), can be blocked by Bcl-2 (as well as other anti-apoptotic members of this 
family, such as Bcl-xL) and mammals have many BH3-only proteins that are capable of 
inhibiting these proteins in the same way as EGL-1. However, mammals have also evolved 
the use of the mitochondria in apoptotic signalling which is not observed in worms. Another 
set of pro-apoptotic Bcl-2 family members, Bax and Bak, control the release o f cytochrome 
c, and other factors, from the mitochondria after receiving an apoptotic signal, often through 
the BH3-onIy proteins. Cytochrome c subsequently activates APAF-1 to form a complex 
known as the apoptosome that is responsible for procaspase-9 activation. Moreover, 
mammals have evolved a second pathway for the activation of caspases. The extrinsic 
pathway involves the activation o f death receptors and proceeds via the adaptor protein 
FADD, which carries out a similar role to APAF-1 in activating initiator caspases (see 
Section 1.5). Drosophila show intermediate complexity in their apoptotic signalling. 
Although, like mammals, they have two sets of caspases, IAPs and smac homologues (such 
as grim and reaper), they have no extrinsic pathway (despite the presence o f dFadd), no 
known BH3-only proteins and a poorly defined mitochondrional pathway.
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Hence, the core components o f  the apoptotic pathway, as identified in C. elegans are 
present in higher organisms, but the regulatory genes are more diverse. For example 
Drosophila has several caspases, such as Dredd, Drone, and drICE as well as a Bcl-2 
homologue Debcl. However, these insects also contain genes from the inhibitor o f 
apoptosis (IAP) family -  such as Diap-1. Members o f  the IAP family specifically inhibit 
caspases by directly binding to their active site (Deveraux and Reed, 1999). W hilst C. 
elegans has no IAPs, this protein family is diverse in mammals and includes members 
such as XIAP and CIAP-1 and -2. Figure 1.3 outlines the overall conservation, but 
increase in complexity, o f  apoptotic signalling pathways through evolution.
1.4.1 The importance of caspase activation
It is now well recognised that the activation o f protease activity o f  the caspase enzymes 
is o f absolutely central importance to any apoptotic signalling pathw ay (Leist and 
Jaattela, 2001). O f the 14 mammalian caspase enzymes, caspase-2, -3, -6, -7, -8, -9 and 
-10 have been shown to have roles in apoptotic signalling pathways. The others, such as 
caspase-1 (ICE) are m ainly involved in the processing o f  cytokines (this topic is 
reviewed extensively elsewhere, (for example see, Martin et al., 1995; Li and Yuan, 
1999; Budihardjo et al., 1999).
All caspases are synthesised as essentially inactive zymogens, know n as procaspases, 
which are activated by proteolytic cleavage and/or oligomerisation. Once activated each 
caspase recognises and cleaves target substrates at tetrapeptide motifs on the C-term inal 
side o f an aspartate residue; for example caspase-8 attacks proteins that contain the 
amino-acid sequence Leu-Glu-Thr-Asp (Strasser et al., 2000). It is both the mode o f 
activation and the identity o f its substrates that defines the role o f  the individual caspase 
in its particular apoptotic pathway. The apoptotic caspases can be divided into two main 
groups; those that initiate the individual apoptotic signalling pathways (caspase-2, -8, -9 
and -10) and those that are themselves cleaved by the initiator caspases (caspase-3, -6 
and -7) and go on to target the so-called “death substrates” for proteolysis (N icholson 
and Thomberry, 1997).
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All procaspases contain large and small subunits separated by a variable length linker 
peptide. As part o f the activation process this linker is cleaved, thereby releasing the two 
subunits and allowing tetramerisation o f two small and two large subunits to form the 
active caspase enzyme. As well as these two catalytic subunits, the initiator caspases are 
distinguished by their N-terminal prodomains. These prodomains contain 
protein/protein interaction motifs -  a tandem pair o f death effector domains (DEDs) in 
the case o f caspase-8 and caspase-10 and a caspase recruitment domain (CARDs) in the 
case o f caspase-2 and caspase-9. These protein/protein interaction domains are 
discussed in greater detail in Section 1.7.1. The role o f  the prodomains in the activation 
o f the initiator caspases is to recruit the procaspases to death inducing signalling 
complexes (DISCs) where oligomerisation leads to their activation (Salvesen and Dixit,
1999). In contrast, the effector procaspases do not contain a functional prodomain. 
Rather, this set o f  procaspases is activated through cleavage by initiator caspases (see 
Figure 1.4).
- (  pep )—( pep y LCS SCS
LCS SCS
Active site
 Procaspase-8, 10
|—  Procaspase-2, 9 
—  Procaspase-3, 6, 7
Active
Caspase
Active site
Figure 1.4: Schematic diagram of the domain architecture of mammalian apoptotic 
procaspases and the generalised form of an active caspase indicating the positions of the 
two active sites (white circles). LSC -  large catalytic subunit, SCS -  small catalytic 
subunit, DED -  death effector domain, CARD -  caspase recruitment domain.
The three dimensional structures o f  several human caspase enzymes have been solved,
each o f  which exhibits a conserved topology consisting o f a twisted p-sheet flanked by a
series o f a-helices (see Figure 1.5). The only available procaspase structure is that o f
procaspase-7 (see Figure 1.5a) (Chai et al., 2001). Comparison o f  this zym ogen
structure with the 3D structure o f  active caspase-7 (Wei et al., 2000), reveals that,
following zymogen cleavage, it is the rearrangement o f  several flexible loops that
connect the secondary structure elements that is responsible for the form ation o f  the
caspase active site (see Figure 1.5b). Also, the determination o f  3D structures o f
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caspases with bound inhibitory peptides, such as the structure o f  caspase-8 bound to Ile- 
Glu-Thr-Asp (Watt et al., 1999) (see Figure 1.5c) has improved the understanding o f 
these enzym es’ substrate specificities (Wei et a l ,  2000).
a) Procaspase-7 b) Active caspase-7
Active site
Active site
Initiator caspase 
cleavage site
Acetyl-IETD-aldehyde
Figure 1.5: Three dimensional structures of caspase enzymes. Caspase-7 is shown in (a) 
the zymogen form (the only available 3D procaspase structure) and (b) the active, cleaved 
form. It can be seen how proteolytic cleavage of the flexible loop highlighted in (a) 
exposes the active site (highlighted in (b)) thereby activating the caspase enzyme. The 3D 
structure of active caspase-8 bound to a tetrapeptide (Ile-Glu-Thr-Asp) inhibitor is shown 
in (c). This inhibitor binds the active site of caspase-8. The homodimeric pairs shown in 
red and yellow in these figures each consist of one large and one small catalytic subunit 
which combine to form single globular entities as outlined in Figure 1.4. Figures generated 
with MolScript (Esnouf, 1997).
c) Caspase-8 with peptide inhibitor
Acetyl-I ETD-aldehyde
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It is the specific proteolysis o f death substrates by the effector caspases that is ultimately 
responsible for most o f  the morphological changes observed during apoptosis (Hacker,
2000) and for this reason the activation o f caspases is one o f  the most critical events in 
apoptosis signalling. Effector caspases cleave numerous vital cellular proteins such as 
DNA repair enzymes, cytoskeletal proteins (such as lamin and gelsolin), cell signalling 
proteins (such as MDM2 and protein kinase C) as well having a more direct effect by 
break down of the caspase-activated DNase (CAD) inhibitor, iCAD. Cleavage o f iCAD 
leads to the activation o f  CAD, the enzyme responsible for the characteristic 
intemucleosomal DNA fragmentation that is on o f the hallmarks o f  caspase dependent 
apoptosis (Strasser et al., 2000).
1.4.2 The initiation of apoptosis
In mammals, there are two main pathways by which the initiator caspases are activated; 
one that is intrinsic to the cell and one that occurs as a result o f  external stimuli (the 
extrinsic pathway). Generally, infected or damaged cells that undergo apoptosis will do 
so by the action o f  an intrinsic activation pathway which proceeds via the release o f 
cytochrome c from mitochondria. Stimuli such as DNA damage or oxidative stress lead 
to the release o f cytochrome c and subsequently to the formation o f  the apoptosom e, a 
cytosolic death signalling complex which consists o f APAF-1, procaspase-9 and dATP 
as well as cytochrome c itself (Salvesen and Renatus, 2002) -  see Figure 1.6. The 
apoptosome acts as a scaffold for the activation o f the initiator caspase-9 almost 
certainly through dimerisation o f the procaspase (Denault and Salvesen, 2002).
The extrinsic apoptotic pathway involves the activation o f a family o f  cell surface 
receptors known as the death receptors. The death receptors are activated by specific, 
extracellular ligands and this pathway is vital for the regulation o f  cellular populations 
in the immune system where there is a need to send death signals between cells. This 
“death by communication” can be contrasted to the intrinsic pathw ay (which is 
essentially a means o f autonomous cellular suicide).
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Figure 1.6: Three dimensional structure of the apoptosome. Upon release from the 
mitochondria, cytochrome c binds to APAF-1. This process (a model for which is shown 
diagrammatically in (c)) causes a conformational change in APAF-1, releasing its caspase 
recruitment domain (CARD) -  shown in red -  and allowing it to oligomerise with other 
APAF-1 molecules via homotypic CARD/CARD interactions. The cytochrome c/APAF-1 
heterodimer heptamerises to form the apoptosome structure (shown in (a) and (d)). The 
position of cytochrome c is diagrammatically represented in these figures by yellow 
circles. The apoptosome subsequently recruits caspase-9 via the homotypic interaction 
between the CARD domains of caspase-9 and APAF-1. Diagram (b) shows the structure 
of the procaspase-9-bound form of the apoptosome. Following interaction with the 
apoptosome, procaspase-9 is activated by autoproteolysis. The 3D structures shown in (a) 
and (b) were solved by electron cryomicroscopy and are taken from (Acehan et al., 2002).
Upon activation, the death receptors recruit several proteins to their cytoplasmic 
domains -  to form DISCs -  and these complexes include the initiator procaspase-8 and 
(in some cases) procaspase-10. Again, once activated by oligom erisation and 
autoproteolysis, the initiator caspases go target activation by proteolysis o f  effector 
procaspase-3, -6, and -7 in the caspase cascade that results in apoptosis (Thorbum , 
2004). Figure 1.7 schematically outlines the two main apoptotic initiation pathways and 
their point o f convergence at the stage o f  effector caspase initiation.
The aim o f this project was to study one member o f the death receptor family, nam ely 
the protein Fas, and its signalling pathway -  o f particular interest is the precise
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molecular mechanisms by which the ligation o f Fas leads to the activation o f  the 
procaspases-8 and -10.
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Figure 1.7: Comparison of the intrinsic (yellow boxes) and extrinsic (blue boxes) 
apoptotic signalling pathways. Both pathways converge at the point of effector caspases 
(caspase-3, -6,and -7) activation to initiate the final stages of apoptotic cell death. DISC= 
death inducing signalling complex.
1.5 The death receptor family
Death receptors (DRs) are type I transmembrane glycoproteins and are m embers o f  the 
tumour necrosis factor receptor (TNF-R) superfamily. The TNF-R family is 
characterised by the presence o f two or more repeats o f a specific cysteine rich dom ain 
(CRD) in the extracellular region o f  the receptor. The feature that sets the death 
receptors apart from the rest o f the TNF-R family is the presence in the form er o f  a 
conserved -100  amino acid cytoplasmic domain. This domain governs the initiation o f  
apoptotic signalling cascades and is known as the death domain (DD).
So far eight members o f the death receptor family have been described -  Fas (also 
known as CD 95/Apo-l), TNF receptor-1 (TNF-R 1/CD 120a/p55R), TNF-related 
apoptosis-inducing ligand (TRAIL)-receptor 1 (DR4/Apo-2), TRAIL receptor 2 
(DR5/KILLER/TRICKB), death receptor 3 (DR3/TRAM P/LARD/TR3/W SL1 / Apo3), 
death receptor 6 (DR6/TR7), nerve growth factor receptor (N GFR/ p75) and the 
ectodysplasin receptor (EDAR). Each death receptor plays specific roles in the immune
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system and accordingly has unique downstream signalling pathways (as reviewed 
extensively elsewhere, e.g. (Gravestein and Borst, 1998; W allach et a l., 1999; Schneider 
and Tschopp, 2000; Locksley et al., 2001). It is in the interests o f  this thesis, however, 
to consider the Fas receptor in more detail.
1.6 Fas ( Apo-l/CD95)
The Fas receptor was first identified in 1989, by two independent laboratories, as the 
antigen for the cytolytic antibodies named Fas (Yonehara et al., 1989) and Apo-1 
(Trauth et al., 1989). After successful cloning o f the receptor, subsequent analysis led to 
the identification o f  Fas as a member o f the TNF-R family able to initiate apoptosis in 
both a calcium ion and nuclear -  and therefore transcription -  independent manner.
Following the discovery o f a ligand for Fas, FasL (Suda and Nagata, 1994) and its 
ability to induce cell death, the Fas/FasL system has becom e the m ost intensively 
studied o f the death receptor/ligand combinations and hence has becom e the m ajor 
model for ligand-induced apoptotic signalling.
The discovery o f mutations in the murine Fas (the Ipr mutation) (W atanabe-Fukunaga et 
al., 1992) and FasL (the gld  mutation) (Roths et al., 1984) genes was largely 
responsible for the unravelling o f the physiological role o f Fas induced apoptosis. The 
Ipr mutation impairs the transcription o f Fas due to the insertion o f  a transposable 
element into one o f  the gene’s introns, whereas gld  is a point m utation in the FasL  gene 
resulting in the FasL protein being unable to interact with Fas. Interestingly both o f  
these mutations result in mice with the same phenotype, nam ely the accum ulation o f  
lymphocytes in the lymph nodes and spleen. This data led to the conclusion that the 
major role o f Fas-induced apoptosis is in the control o f lym phocyte populations, and 
this has subsequently been shown to be the case. FasL-induced apoptosis is o f  particular 
importance in reducing the numbers o f T- and B-cells in the periphery after antigen 
exposure-induced immune cell proliferation -  as illustrated in Figure 1.2 (Ju et al., 
1995; Dhein et al., 1995; Brunner et al., 1995 and reviewed in K rammer, 2000).
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As with all apoptotic pathways the Fas/FasL system must be tightly regulated so as to 
avoid adventitious depletion o f immune surveillance and this is achieved on several 
levels. First, whilst the tissue distribution o f Fas expression is almost ubiquitous, it 
appears that the transcription o f  FasL is only activated by signals specifically arising in 
the immune system compartment such as exposure to IL-2 and TCR activation 
(Lenardo, 1991) thereby keeping Fas-induced apoptosis specific to cells o f  the immune 
system. Also, as well as at the level o f gene expression, both Fas and FasL are 
expressed into micro-vesicles before being translocated to the cell surface (Ivanov et a l., 
2003) allowing scope for number o f Fas and FasL molecules being expressed on the cell 
surface to be tightly controlled at in a post translational fashion.
These complex regulatory mechanisms are important for several reasons. Firstly, it is 
essential for the survival o f  an organism that the point at which a cell dies must be the
correct one; having several points o f regulation improves stringency for this process.
Also, in the case o f  death receptors, these wide ranging methods o f  regulation allow for 
increased flexibility in response to activation (ligand binding). For exam ple, as well as 
initiating apoptosis, the activation o f Fas (and other death receptors) can induce the 
upregulation o f transcription factors NF-kB and JNK which m odulate the expression o f 
many genes involved in inflammatory responses and cell survival (reviewed in Beyaert 
et al., 2002). It is perhaps unusual for a single receptor to be able to initiate responses 
that are clearly in opposition to each other (in this case cell death and cell survival) and 
the balance o f these effects may depend on the context in which activation occurs. 
However the precise mechanism by which one signalling pathway wins out over the 
other are not well understood.
1.6.1 Fas Receptor Signalling
1.6.1.1 Ligand binding
As Fas is a member o f  the TNF-R family it contains several extracellular, cysteine-rich 
domain (CRD) repeats characteristic o f this family which govern ligand-binding. Fas 
contains three such CRD repeats, o f which the second and third govern ligand binding 
(Starling et al., 1997). Upon binding o f FasL to Fas the intracellular part o f  the receptor, 
which is comprised mainly o f  the death domain, recruits intracellular signalling adaptor
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proteins and, via a series o f  protein/protein interactions activates caspase-8 and caspase- 
10 (Algeciras-Schimnich et al., 2002). Although both o f  these caspases-8 are known to 
be activated at the Fas receptor during Fas-dependent apoptosis it is only essential that 
caspase-8 is activated for apoptosis to take place (Sprick et al., 2002) and hence the 
precise role o f caspase-10 in this context activation remains unknown. Nevertheless, 
mutations in caspase-10 lead to a phenotype similar to that associated with Fas 
mutations (see Section 1.8), so it would appear that caspase-10 m ust play a significant, 
if not essential, role in Fas signalling.
The ligand binding event is key in any variety o f receptor-mediated signalling process 
and the death receptors are no exception. The three dimensional crystal structures o f two 
death receptor/ligand combinations are currently available, nam ely the ectodomain o f 
TNF-R1 bound to TNF-p (Banner et al., 1993) and the ectodomain o f  TRAIL-R2 bound 
to TRAIL (Cha et al., 2000). These two 3D structures show hom otrim eric ligands, TNF- 
p or TRAIL, bound to three separate receptor molecules, associated with the interface 
regions between the ligand protomers (see Figure 1.8). Since the three dim ensional 
structures o f other TNF family members, such as receptor activator o f  N F-kB ligand, 
RANKL, (Lam et al., 2001), ectodysplasin (Hymowitz et al., 2003), and CD40 
(Karpusas et al., 1995), have been shown to exhibit trimeric structures with essentially 
the same “jellyroll” topology and the receptors all appear to have a CRD repeat m odular 
structure, despite an absence direct molecular evidence, the trim er structure has becom e 
the presumed consensus model for Fas/FasL interaction.
Once the ligand binding event has occurred the activation signal m ust be transduced 
across the cell membrane to initiate the signalling cascades. It is still unclear precisely 
how the binding event is promulgated inside the cell, particularly because the initial 
steps in the cytoplasmic signalling pathways o f death receptors are governed purely by 
protein/protein interactions apparently without any requirement for post translational 
modifications such as phosphorylation. Present evidence suggests that the receptors m ay 
be constitutively oligomerised in the cell membrane through a region know n as the pre­
ligand association domain (PLAD) which exists at the N-terminal tip o f  the extracellular 
region (Siegel et al., 2000).
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Figure 1.8. 3D structures of the TNF-p/TNF-Rl and TRAIL/DR5 complexes. The two 
complexes are shown in equivalent orientations from the side (a) and from above (b). The 
orientation of (b) is indicated by the blue arrow in (a). The structures show essentially 
identical conformations consisting of a trimeric ligand exhibiting the characteristic 
jellyroll topology (TNF-p - blue, or TRAIL -  green) bound to three receptor 
molecules (TNF-R 1 -  red, or DR5 -  yellow respectively).
The PLAD may exist to aid binding o f  the trimeric ligand, but its role may also be in 
holding the receptor cytoplasmic domains in an inactive configuration. I f  this is the case 
then when the ligand binds the receptor the intracellular dom ain may change 
conformation, reorganise or otherwise expose its binding sites to the adaptor molecules 
with which they interact. Evidence for the PLAD is given weight by the three 
dimensional structure o f TNF-R1, solved without its ligand. The receptor was found to 
crystallise in two different forms -  parallel and anti-parallel hom odim ers (Rodseth et 
a l ,  1994; Naismith et al., 1995). The interaction site o f  the two m onom ers in the
TRAIL
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parallel dimer is in the CDR1 region o f the receptor (see Figure 1.9) -  the predicted site 
o f the Fas PLAD. Hence, although the precise physiological form o f  the un-ligated 
receptors is not fully understood the possibility is evident that both Fas and TNF-R 1 are 
constitutively dimerised in the cell membrane and undergo rearrangement upon binding 
o f their respective trimeric ligands.
Figure 1.9: Crystal structure o f the TNF 
receptor 1 parallel homodimer. The 
dimeric structure is formed by
interactions between the CRD1 domains 
o f the individual receptor monomers.
N-terminus
C-terminus
However, it is now suspected, in the case o f  Fas at least, that FasL hom otrim ers acting 
at the surface o f the cell are insufficient to initiate apoptosis. Rather, it has been 
elegantly shown that engineering FasL trimers into monohexamers by chem ical or 
biochemical cross linking was sufficient to induce apoptosis (H oller et a l., 2003). 
Combined with the knowledge that antibodies to Fas are sufficient to initiate apoptosis 
(presumably by cross linking the receptors) this leads to the hypothesis that it is 
aggregation o f the receptors and therefore clustering o f intra-cellular death receptor 
domains that is needed to trigger apoptosis. This argument is given weight by the 
evidence that both Fas, FasL and TNF-R1 are aggregated in ceram ide-rich membrane 
“rafts” during signalling events (Grassme et al., 2001a; Grassme et al., 2001b; Scheel- 
Toellner et al., 2002; Cottin et al., 2002).
1.6.1.2 Formation of the Fas DISC
Upon activation o f the Fas receptor by FasL, the adaptor molecule Fas associated death 
domain protein (FADD) is recruited to the receptor (Chinnaiyan et al., 1995). FADD is 
a 208 amino acid residue protein comprising an N-terminal death effector domain
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(DED) and a C-terminal death domain. FADD binds to the cytoplasmic Fas-DD through 
its own DD and subsequently recruits caspase-8 (Muzio et a l , 1996; M edem a et al., 
1997) and/or caspase-10 (Wang et al., 2001) via its DED. Embryonic fibroblast cells 
from FADD null mice are deficient in Fas-induced apoptosis (Yeh et al., 1998) and both 
transformed and non-transformed cell lines overexpressing a construct consisting o f  the 
isolated FADD death domain are resistant to FasL (Chinnaiyan et al., 1996; Newton et 
al., 1998). Also a caspase-8 deficient T cell line has been shown to be unable to undergo 
FasL-induced apoptosis (Juo et al., 1998). These data strongly indicate the requirement 
for both FADD and caspase-8 in the Fas dependent apoptotic pathway.
Figure 1.10 highlights how, through homotypic protein/protein interactions, FADD acts 
as a link between the receptor and the procaspase enzymes that execute the later stages 
o f apoptosis. Although other proteins may be involved, it is this set o f  three molecules -  
Fas, FADD and caspase-8 -  that has become characteristic o f  the formation o f  the Fas 
DISC, which, much like the APAF-1 /caspase-9/cytochrome c apoptosome, acts as a 
scaffold for initiating caspase activation (Peter and Krammer, 2003).
Fas
(  CRD1 ~X CRD2 X  CRD3 DD
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^  DED X  DEDCaspase-8, 10 |  SCS |— f LCS
Figure 1.10: Schematic diagram of the proteins involved in apoptotic Fas DISC formation 
and their respective domain architectures. The Fas ligand binding domain is in CRD’s 2 
and 3 whilst the proposed PLAD lies in CRD1 (TM -  transmembrane domain). The 
homotypic DD/DD and DED/DED protein-protein interactions between Fas, FADD and 
caspase-8 or 10 are highlighted in the grey circle.
The Fas apoptosis pathway is probably the best studied o f all the death receptors but 
there is still much that is unknown, especially at the molecular level, about the 
interactions that govern the precise mechanism o f the signalling processes. For example, 
it is known that if  caspase-8 is artificially dimerised by fusion to a protein dom ain
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responsive to non-covalent cross-linking reagents then apoptosis can be triggered 
efficiently (MacCorkle et al., 1998). In contrast to the original view that caspases are 
activated by autoproteolysis induced by dimerisation there is now evidence to suggest 
that dimerisation by itself is sufficient for activation without the proteolysis step. In this 
model the processing step occurs after activation possibly to release the active caspase 
molecule from the membrane-bound DISC to carry out its cytoplasmic functions 
(Boatright et al., 2003). How this simple requirement for caspase-8 dim erisation fits 
with the trimerised-receptor model in terms o f the stoichiometry is unclear. Several 
models have been suggested relating to how the death signals are transm itted from the 
ligand to activate the caspases (Berglund et al., 2000; W eber and Vincenz, 2001a). 
However, more work is needed to understand how these proteins jo in  together spatially 
and temporally to activate the initial PCD signal. It is the aim o f  this thesis, therefore, to 
study the interaction between Fas and FADD, and specifically the contacts made 
between the death domains o f these two proteins, in order to further the molecular 
understanding o f the transduction o f the apoptotic signal that proceeds through Fas, via 
FADD to activate caspase-8 and 10.
There are two models o f the intracellular Fas-induced apoptotic signalling pathways -  
denoted as some as Type I and Type II (Scaffidi et al., 1998). Figure 1.11 outlines the 
current knowledge these processes, highlighting the com ponents o f  the signalling 
pathways downstream o f Fas DISC formation. Not only does caspase-8 activation lead 
directly to subsequent effector caspase proteolysis but it can also lead to utilisation o f 
the mitochondrional apoptotic pathway via direct cleavage o f the Bcl-2 protein family 
member BID. Truncated BID (tBID) is translocated to the m itochondrial membrane 
where it promotes cytochrome c release and subsequent apoptosom e formation. FasL- 
induced activation o f the mitochondrial apoptotic pathway was first believed to be a 
positive feedback loop which accelerated the apoptotic response via the caspase-9 
mediated cleavage o f  caspase-3 (Martin et al., 1995). However, others have proposed 
that there is a cell type-specific dependence upon the two different pathways. Some cell- 
lines rely on DISC formation and direct caspase-3 cleavage by active caspase-8 (Type I 
cells), where as other cell line rely more heavily on utilisation o f  the m itochondrional 
pathway to induce apoptosis when stimulated with FasL (Type II cells) (Barnhart et al., 
2003).
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Figure 1.11: Canonical FasL-induced apoptotic signalling pathways. FasL binds to Fas 
leading to Fas DISC formation and subsequent caspase-8 and caspase-10 activation. 
Effector caspases are then activated either by direct caspase-8 or caspase-10-dependent 
cleavage or via the mitochondrional amplification loop following proteolytic truncation of 
BID. Effector caspases go on to cleave the “death substrates” leading to classical apoptotic 
cell death. It is postulated that, in Type I cells, direct caspase-3 cleavage is favoured over the 
mitochondrional amplification loop. Type II cells, however, produce low levels of activated 
caspase-8 and hence rely more heavily on caspase-9-mediated effector caspase cleavage.
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1.7 Structural biology of Fas DISC formation
The use o f structural biology techniques provides a means to study biological 
macromolecules with atomic scale resolution. Such techniques have been widely 
applied to the study o f apoptotic signalling pathways and have led to a partial 
understanding o f how the proteins involved in these pathways carry out their functions 
(Fesik, 2000) as well as opening up these proteins as potential therapeutic targets (as 
reviewed by (Nicholson, 2000). The following section discusses the current level o f 
structural biology knowledge o f apoptotic proteins focussing on the domains involved 
in Fas DISC formation.
1.7.1 The death fold protein family
There are several structures available o f apoptosis-related protein domains many o f  
which, especially those domains involved in apoptotic protein/protein interactions, 
exhibit the same topological polypeptide fold which has becom e known as the “death 
fold” . The death fold was first discovered with the elucidation o f  the 3D solution 
structure o f the Fas death domain (Huang et al., 1996). Fas-DD consists o f  six 
amphipathic a-helices arranged in a helical Greek-key topology that had not otherwise 
been detected (see Figure 1.12a). Further death domain structures have subsequently 
been obtained including those arising from the proteins FADD (see Figure 1.12b) 
(Jeong et al., 1999; Berglund et al., 2000), TNF-R1 (Sukits et al., 2001), p75 (Liepinsh 
et al., 1997) as well as the complex between pelle and tube death dom ains from 
Drosophila melongaster (Xiao et al., 1999). Despite a high level o f  amino acid 
sequence diversity, all o f  these death domains are structurally very sim ilar exhibiting 
the same fold and several conserved hydrophobic residues that stabilise the core o f  the 
fold structures.
The death fold is also exhibited by members o f three other protein families and 3D 
structures are available for representative examples o f each; the death effector domains, 
for example FADD (Eberstadt et al., 1998) and PEA -15 (Hill et al., 2002)), caspase 
recruitment domains, CARDs, for example caspase-9 (Qin et al., 1999) and APAF-1 
(Vaughn et al., 1999) and pyrin domains, for example NALP1 (H iller et al., 2003) and
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ASC (Liepinsh et a l 2003). The structures o f several o f these domains are shown in 
Figure 1.13.
Despite exhibiting a conserved secondary structure fold and pattern o f  buried 
hydrophobic residues, a high degree o f variation is found in the solvent exposed 
residues -  and hence the electrostatic charge distribution -  at the protein surface o f 
members o f this death fold superfamily (as illustrated in Figure 1.13). In the absence o f 
any evidence that the conformation o f the death fold domains is altered at any point in 
the apoptotic pathway, this variation is highlighted in the low levels o f  homology 
amongst the primary amino-acid sequences o f these domains (W eber and Vincenz, 
2001b).
a)
Fas-DD FADD-DD
Figure 1.12: Three dimensional solution structures of a) Fas-DD and b) FADD-DD 
showing the conserved secondary structure elements typical of the death fold domain 
protein family. Each death domain exhibits the same “helical greek-key” motif 
consisting of 6 a-helices (a l-a 6  in the above diagrams). Both domains are shown in 
the same orientation and each helix is given a separate colour to highlight the 
conservation of these structural elements. Figures generated with MolScript.
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It is highly likely that the surface characteristics o f these domains govern the nature o f 
their interactions with other proteins. At present two 3D structures are known o f 
complexes between death fold family members. The structure o f the complex between 
the caspase 9 and APAF-1 CARD domains shows the interface to lie between the 
surface o f helices 2 and 3 o f caspase-9 and the surface o f helices 1 and 4 o f  APAF-1 
(Qin et al., 1999) (see Figure 1.14a). The interface between these two domains is 
dominated by charged residues (basic residues on the caspase-9 CARD domain and 
acidic residues on the APAF-1 CARD domain) indicating the interaction is probably 
governed by electrostatic forces. Initial mutagenic evidence suggested that this type o f 
interaction is reproduced in other death fold interactions such as the pairwise Fas- 
DD/FADD-DD and TN FR -1-DD/TRADD-DD death domain interactions, and in the 
self-association o f  the pyrin domain o f ASC (Liepinsh et al., 2003). The importance o f 
helices 2 and 3 in the Fas death domain is highlighted by the three dim ensional structure 
o f a mutant form o f the death domain known as lprcg (Eberstadt et al., 1997).
The murine lprcg mutant has the same phenotype as the Ipr mutant but arises from a 
point mutation in the death domain rather than an insertion (M atsuzaw a et al., 1990). 
This A—>T point mutation in the murine Fas open reading frame changes an isoleucine 
residue to an asparagine in the death domain and results in a loss o f  function o f the 
protein. This residue is expected to be part o f the a 2 -a 3  connecting loop with its side 
chain largely buried in the interface between these two structural elements. The three 
dimensional solution structure o f the equivalent mutation in the hum an Fas death 
domain (V238N) protein showed that although the death domain was folded the regular 
structure o f helix three was completely disrupted resulting in a local “unfolding” o f  in 
the region o f the substitution (Eberstadt et al., 1997).
One other complex structure is available in this superfamily and this is o f  the death 
domains o f  pelle and tube from D. melongaster (Xiao et al., 1999). The pelle-D D / tube- 
DD complex exhibits a different binding conformation from the A PA F-1/caspase-9 
CARD/CARD complex, instead involving the insertion o f helix 4 o f  pelle-DD into a 
groove in the surface o f  tube-DD and the C-terminus o f tube-DD into a groove in the 
surface o f pelle-DD (see Figure 1.14 )
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Apaf-1
CARD
a)
FADD
DED
Fas DDo ASCpyrin
b)
Figure 1.13: The death fold family of protein domains. Secondary structure (generated 
with MolScript) and solvent accessible surface (generated with GRASP (Nicholls et al., 
1991)) representations of the CARD domain of APAF-1, the death effector domain o f 
FADD, the death domain of Fas and the pyrin domain of ASC-1 are shown in two 
separate orientations (a and b respectively). Helices 1-6 of each domain are plotted in 
separate colours as per Figure 1.12. Solvent accessible surfaces are coloured according to 
the electrostatic in a gradient from red (high density of negative potential) through white 
(no electrostatic potential) to blue (high density of positive potential). Each domain has 
the conserved death fold but exhibits dramatic differences in electrostatic surface charge 
distribution.
39
The death fold therefore utilises not only different charge distributions on the same 
surfaces but also different binding surfaces to govern a wide range o f  homotypic 
protein/protein interactions and these will be discussed in more detail in Chapter 4.
a)
Figure 1.14: 3D structures of death fold family protein complexes. The caspase-9- 
CARD/APAF-1-CARD dimer is shown in (a) and the Pelle-DD/Tube-DD complex in (b). 
The six a-helices of each of these death fold domains are coloured as in Figure 1.12. Note 
that Tube-DD contains an insertion consisting of two further a-helical segmets (coloured 
white) and has an extended C-terminus (coloured black) that forms significant contacts with 
Pelle-DD (Figures generated with MolScript).
1.8 Fas in disease
The importance o f apoptosis in the regulation o f cell populations is highlighted 
consistently by its role in disease. Dysfunction o f apoptosis plays a significant part in a 
wide variety o f  diseases and the effect o f Fas mutations in autoimm une 
lymphoproliferation syndrome (ALPS - also known as Canale-Sm ith syndrome) 
provides a fine example.
Patients with mutations in Fas (the cause o f ALPS type 0 and type la ), FasL (ALPS 
type lb) or caspase-10 (ALPS type 2) are found to have phenotypes that are very sim ilar 
to the respective murine g ld  and Ipr models, displaying at least three o f  the following 
disease manifestations: tumoral syndrome (splenomegaly or lym phadenopathy), 
autoimmunity, hypergammaglobulinemia, and detection o f  double negative (C D 4 , 
CD8') T cells in the blood (Rieux-Laucat et al., 2003b). All o f  these sym ptom s stem
Caspase-9-CARD/APAF-1 - 
CARD dimer
b) Pelle-DD/Tube-DD dimer
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from the inability o f the Fas/FasL system to induce T cell apoptosis for these 
individuals (Rieux-Laucat et al., 2003a).
O f particular interest to this study is the molecular basis o f ALPS type la. ALPS type la  
is defined by heterozygous mutations in the Fas receptor. Such mutations show a 
dominant interfering effect on the wild-type receptor (Martin et al., 1999; Vaishnaw et 
al., 1999). This specific disorder is o f particular interest as over 60% o f  patients with 
ALPS type la  have been shown to have mutations in the Fas death domain -  around 
half o f which are missense point-mutations (Rieux-Laucat et al., 2003a). The molecular 
basis for the clinical manifestations o f such mutations has been shown to be the inability 
o f Fas to interact with FADD (Martin et al., 1999; Vaishnaw et al., 1999). M utation 
sites which are associated with ALPS type la  are therefore o f  direct interest to this 
study o f the Fas-DD/FADD-DD interaction. For example, the Fas-DD amino-acid 
residue Asp 244is found to be mutated more often than any other single site in ALPS 
type la  (see Chapter 4).Structural studies have suggested that the m utation does not 
influence the folding or stability o f the Fas receptor, implying that the m utation must act 
at the level o f  interaction o f Fas with downstream effectors, for exam ple FADD (Huang 
et al., 1996). M utation D244 therefore provided a useful negative control for the 
interaction studies developed throughout this study. Also o f  interest to this study is the 
fact that the heterozygous ALPS type la  mutations exhibit a dom inant interfering 
phenotype as this observation must be a direct consequence o f  the m olecular 
mechanisms o f Fas-induced apoptosis. This dominant interfering phenotype is 
manifested by the absolute abrogation o f  FasL-induced T cell apoptosis in cell lines 
from patients with heterozygous ALPS type la  mutations (M artin et al., 1999). The 
simplest explanation for this observation is that oligomerisation o f  the Fas receptor (and 
therefore the death domain) following FasL binding is crucial for signal transduction to 
caspase-8.
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1.9 Outline of this thesis
In general, despite much research activity in the field o f death receptor signalling, we 
still do not fully understand how the death fold protein interactions are regulated, 
particularly with respect to DISC formation and the subsequent activation o f caspases 
and other downstream signalling pathways. Therefore, more work is required to 
understand the exact molecular details o f these protein/protein interactions before we 
can uncover the full details o f death receptor activation and signalling regulation. It is 
the aim o f this study to utilise a multidisciplinary approach to probe the interaction 
between the death domains o f  Fas and FADD in an attempt to further the understanding 
o f this binding event in the context o f Fas-dependent apoptosis.
This thesis is divided into a further four chapters as follows.
Chapter 2 outlines technical details o f the materials and methods utilised throughout this 
study. Chapter 3 introduces the use o f structural biology to probe the interaction 
between the Fas and FADD death domains. First, a productive interaction between the 
DDs was established using the yeast two-hybrid assay. Recom binant production o f  the 
individual DDs in bacteria was then used to provide these two proteins in a tractable 
form for nuclear magnetic resonance (NMR) spectroscopy experim ents to probe the 
interaction between these two domains in solution. A significant proportion o f  this 
chapter focuses on the specific problem o f producing the Fas death dom ain (Fas-DD) in 
sufficient quantities for structural studies at physiological pH.
In Chapter 4, both o f the yeast two-hybrid and NMR-based interaction assays were used 
to carry out a mutagenesis study o f the Fas death domain. Here, m utants o f  Fas-DD with 
substitutions o f amino acid residues on solvent-exposed surface regions o f  the domain 
were analysed for their ability to interact with FADD-DD. This study allowed the 
identification o f those regions o f the Fas-DD surface that are im portant for this 
interaction. Having uncovered several significant novel Fas-DD m utants the rem ainder 
o f this chapter focuses on the analysis o f these mutations in the context o f  other death 
fold family protein/protein interactions.
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Chapter 5 outlines the development o f  a functional, cell-based apoptosis assay for Fas 
mutants. Here the Fas receptor, and three Fas death domain mutants, are individually 
expressed in a human cell line that expresses no endogenous Fas. A controllable 
expression system is used to ensure that the cell lines express equal amounts o f  the 
receptor and the cell lines are then tested for their ability to undergo Fas-induced 
apoptosis.
This thesis concludes with a Discussion (Chapter 6) o f the results obtained in the course 
o f this work, and speculates on what these results mean for the mechanism o f Fas 
signalling and DISC formation in the physiological situation, as well as looking forward 
to how else this intriguing system maybe probed by further investigation.
43
Chapter 2
Materials and Methods
2.1 Molecular biology protocols
Chapter two outlines the experimental protocols used to carry out the investigations in 
this study. Reagents were obtained from Sigma or VW R unless otherw ise stated. Cell 
culture plastics were obtained from Orange scientific.
2.1.1 Escherichia coli growth
Liquid cultures o f E. Coli were grown at 37°C in a shaking incubator in autoclaved LB 
media (1% w/v tryptone, 0.5% w/v yeast extract and 0.5% w/v NaCl) (unless otherwise 
stated) containing the relevant antibiotics for plasmid selection. For antibiotic selection 
o f transformed cells, E. coli were grown overnight at 37°C on 10mm plates containing 
LB media supplemented with 1% agar. Antibiotic concentrations, w here used, w ere as 
follows: 100 mg/ml carbenicillin (an analogue o f ampicillin w ith increased stability) or 
100 mg/ml kanamycin.
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2.1.2 Plasmid DNA propagation
Supercoiled plasmid DNA was transformed into the D H 5a strain o f  E. coli as outlined 
in Section 2.1.3. D H 5a is a nuclease deficient (recA' end A') strain o f  E. coli suitable for 
DNA propagation. Single colonies from the resultant plates were grown overnight in 
10ml (or 100ml) o f liquid culture. Pure plasmid DNA was extracted from these cells 
using the Qiagen Miniprep (or Midiprep) kits. The final elution step in these 
purifications -  and in all other Qiagen kit purifications -  was carried out using sterile 
filtered ddF^O.
2.1.3 Preparation of competent E. coli
For the transformation o f supercoiled plasmid DNA E. coli cells were m ade chem ically 
competent using the following protocol:
1) 10 ml o f liquid culture containing the relevant strain o f E. coli w ere grown overnight 
in LB medium containing no antibiotics.
2) Cells were harvested in a centrifuge by spinning for 10 minutes (mins) at 1250 g.
3) The resultant cell pellet was resuspended gently in 25 ml o f  an ice cold solution o f 10 
mM CaCb and left on ice for 20mins.
4) Cells were harvested by spinning at 500 g for 10 mins and the supernatant discarded.
5) Steps 3 and 4 were repeated twice and the competent cells finally resuspended in a 
volume o f 1.5 ml CaCb- These chemically competent cells w ere either used 
immediately for transformations or stored at -80°C after the addition o f  sterile filtered 
glycerol to a final concentration o f 15%.
2.1.4 Transformation of E. coli
Plasmid DNA (50-100 ng in ddFhO) was added to 50pl o f  com petent cells and 
incubated on ice for 30 mins. Cells were heat shocked at 42°C for exactly 45 seconds 
before being returned to the ice for a further 2 mins. Following the heat shock, 300 pi o f  
SOC media (2% w/v tryptone, 0.5% w/v yeast extract, 0.05% w /v NaCl, 2.5 m M  KC1,
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10 mM MgCl, 20 mM glucose, pH 7) pre-warmed to 37°C was added to the cells. After 
incubation at 37°C 1 hour, 150 pi o f the transformed cells were spread onto an agar 
plate containing the antibiotic suitable for selection o f the transformed plasmid.
2.1.5 Agarose gel electrophoresis
Agarose gels were prepared using the RunOne system (EmbiTech). Agarose was 
dissolved in TAE buffer (40 mM Tris-Acetate pH8.4, Im M  EDTA) to a final 
concentration o f 1% or 2% w/v. Gels were cast and set in the apparatus provided. DNA 
samples were prepared by addition o f DNA gel loading buffer (30% v/v glycerol, 0.1% 
w/v bromophenol blue in water). Electrophoresis was carried out in TAE buffer at a 
constant voltage o f 100 V. On all gels molecular weight markers were included as a 
reference. In 1% gels 1 kilobase markers were used and in 2% gels 100 base markers 
were used (New England Biolabs)
Following electrophoresis, gels were stained in a 0.01% solution o f  ethidium brom ide 
for 30 mins, destained in water for 10 mins and photographed under long-wave ultra­
violet (UV) light.
2.1.6 Polymerase chain reaction (PCR)
PCR mixtures were prepared on ice to the following recipe in thin-walled 200 pi PCR 
tubes:
Plasmid DNA template 
dNTP* mix 
5’ primer 
3 ’ primer
Pfu DNA polymerase 
lOx Pfu buffer** 
ddH20
50-100 ng
2 mM 
1 mM 
1 mM
3 units 
10 pi
To a final volume o f 100 pi
* An equimolar mixture o f dATP, dCTP, dTTP and dGTP (Promega)
**Promega
PCR was carried out using a Primus thermocycler (M W G-Biotech). The heating block 
o f the thermocycler was pre-heated to 95°C and the PCR samples added to the block
46
straight from ice (a technique known as “hot start” PCR) to improve the efficiency o f 
the initial primer annealing event.
Samples w ere subjected to 30 rounds o f thermal cycling (95°C for 30 seconds, 55°C for 
30 seconds and 72°C for 90 seconds) to amplify the required stretch o f  DNA.
Following the thermal cycling, PCR products were purified using the Qiagen PCR 
clean-up kit and analysed on 2% agarose gels.
2.1.7 Restriction enzyme digestion of DNA
For subcloning purposes, plasmid DNA and PCR products w ere digested with the 
relevant restriction enzymes. Restriction enzymes were purchased from New England 
Biolabs (NEB) and were supplied with individual buffers. D igests were carried out in 
these buffers as recommended by the manufacturer with 3 pi o f  enzym e (and 1 mM 
BSA where advised) in a total volume o f 60 pi. Where necessary, digests with two 
enzymes were carried out by including 3 pi o f the second enzym e in the same reaction 
mixture. In this case the reaction was carried out in a buffer com patible w ith both
enzymes as advised by the manufacturer. All digests were perform ed at 37°C for 2
hours.
Digested DNA was electrophoresed on agarose gels (1% agarose for digested plasm id 
DNA and 2% agarose for digested PCR products). Gels were stained with ethidium 
bromide and the required bands, as identified by size com parison w ith the m olecular 
weight markers, were excised from the gel under UV light. DNA was purified from the 
excised pieces o f  agarose using the Qiagen gel extraction kit.
2.1.8 DNA ligation
Purified inserts were ligated into digested plasmid vectors using the following protocol:
The ligation mix consisted o f 10-50 ng o f digested plasmid, betw een 0.1-1 pg o f 
digested PCR product , 0.5 pi o f T4 DNA ligase (NEB) and buffer as supplied by the
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manufacturer in a total volume o f 20 pi. This mixture was incubated at 15°C overnight. 
Subsequently, the ligation reaction was heat inactivated at 55°C for 10 mins before 
being transformed into subcloning efficiency supercompetent E. coli D H 5a cells 
(Invitrogen). The heat shock when transforming these particular cells was carried out at 
37°C for 30 seconds as recommended by the manufacturer. Transform ed cells were 
plated onto antibiotic selective agar plates.
2.1.9 Selection of positive clones
Typically 10 colonies from each ligation were suspended in 20 pi o f  sterile ddT^O, 10 pi 
o f which was grown up in 10 ml o f media containing the relevant antibiotics, the 
remaining 10 pi was heated at 95°C for 10 mins. 1 pi o f the heated sample was used as 
the template in a PCR reaction with primers specific for the ligated insert. 10 pi o f this 
PCR reaction was run on a 2% agarose gel to check for the presence o f  a PCR product 
o f the correct size. Plasmid DNA was extracted from those cultures found to contain the 
insert and sent for DNA sequencing.
2.1.10 DNA concentration and purity estimation
Where only small volumes (<100 pi) o f DNA were available, DNA concentrations were 
estimated by comparison to a DNA mass ladder (Invitrogen) on an agarose gel. W hen 
large volumes were available (>100 pi) concentrations were estim ated by optical 
absorbance at 260 nm (A260) using a Biomate-3 UV/visible spectrom eter (Thermo). In 
this case the purity o f the DNA was also estimated by measuring the A 260: A 280 ratio. 
This purity measurement takes into consideration the absorbance at 280 nm from any 
contaminating proteins present in the sample.
2.1.11 Site directed mutagenesis
Point mutations were made in genes o f interest by using the QuickChange site directed 
mutagenesis kit (Stratagene) following the manufacturer’s protocol. All selected clones
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were subjected to DNA sequencing to ensure only the required m utations had been 
introduced.
2.2 Yeast protocols
2.2.1 Saccharomyces cerevisiae growth
S. cerevisiae was grown, when no selection was required, in liquid culture either in 
YPD (1% w/v yeast extract, 2% w/v peptone, 2% glucose, pH 5.8) or on lOmM plates 
containing YPD with 1.5% w/v agar. In both cases yeast was grown at 30°C in an 
incubator.
When auxotrophic selection o f  yeast cells was required, m edia was prepared with 
minimal SD base (Clontech) and DO -trp, -leu, -his supplem ents (Clontech). As 
required, this media was supplemented with 20 mg/L tryptophan, 60 mg/L leucine or 20 
mg/L histidine to create single or double deficient media. For growth on 10 mM plates 
these media were supplemented with 1.5% w/v agar.
2.2.2 Cloning into pOAD and pOBD2 vectors by homologous recombination
Recombination cloning techniques were used to insert the required genes into the pOAD 
and pOBD2 plasmids. A two-step PCR protocol was used to generate DNA w hich had 
sufficient homology at its terminal ends to allow homologous recom bination with 
linearised vector inside the yeast cell.
The first PCR reaction utilised primers designed to specifically am plify the coding 
region o f interest. Additionally, both primers contained “tails” o f  20 nucleotides that 
were homologous to sequences in the pOAD and pOBD 2 plasm ids. The second PCR 
reaction used “re-PCR” primers that were specific for the tails from the first reaction 
and extended the homologous region by a further 50 bases.
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Generalised yeast two-hybrid PCR primer sequences:
First round PCR:
Forward primer: 5 ’ AA TTC CAG CTG ACC AAC ATG xxx xxx xxx xxx xxx xxx 3’
The xxx’s represent the base sequence o f the start o f the coding region o f  interest 
Reverse primer: 5’ xxx xxx xxx xxx xxx xxx *** GTA CCG TTA AGG CGG CCT AG 3’ 
Where the xxx 's represent the base sequence o f end o f the coding region o f  interest and 
*** represents a stop codon.
Re-PCR:
Forward primer: 5’ C TAT CTA TTC GAT GAA GAT ACC CCA CCA AAC CCA AAA 
AAA GAG ATC GAA TTC CAG CTG ACC ACC ATG 3’
Reverse primer: 5’ GTA CCG TTA AGG GCC CCT AGG CAG CTG GAC GTC TCT 
AGA TAC TTA GCA TCT ATG ACT TTT TGG GGC GTT C 3 ’
In order to ensure accurate recombination pOAD and pOBD 2 were linearised by 
digesting with the restriction enzymes PvuII and Ncol.
By transforming the re-PCR products into the yeast cells along with the linearised 
plasmids, homologous recombination would take place inside the yeast cells to result in 
the gene o f interest being incorporated into the plasmids.
2.2.3 Transformation of yeast cells
Yeast cells were made competent and transformed with plasm id DNA using the 
following protocol:
1) 10 ml cultures o f  yeast cells were grown overnight in YPD medium. 1 ml o f  this 
culture was used to inoculate 100 ml o f YPD medium the next day. This 100 ml culture 
was grown for 4 hours before the cells were harvested in a centrifuge by spinning at 
3000g for 5 mins.
2) The harvested cells were washed once with sterile ddF^O before being resuspended 
in 1 ml o f 100 mM lithium acetate (LiAc) and incubated at 30°C for 30 m ins
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3) Cells were pelleted in a microfuge and resuspended in 400 pi o f  100 mM  Li Ac. 50 pi 
aliquots o f these competent cells were used immediately for transformations.
4) The following components were added, in the order listed, to the com petent yeast 
cells for transformation.
240 pi o f 50% w/v PEG-3500
-  36 pi o f 1M Li Ac
♦
-  25 pi o f  2 mg/ml single stranded carrier DNA
-  0.2 pg linearised plasmid DNA (in a volume o f 50 pi in ddELO)
-  0.5 pg re-PCR product DNA
5) The transformation mixture was vortexed and incubated at 30°C for 30 mins.
6) The cells were heat shocked for 20 mins at 42°C before being pelleted in a microfuge 
at 6000 rpm and the supernatant discarded.
7) Pelleted cells were resuspended gently in 0.5 ml ddLLO and 200 pi spread onto 
selective plates.
* ssDNA was prepared from double stranded salmon sperm DNA (Sigma) by heating at 
95°C for 10 mins.
2.2.4 Selection of positive yeast transformants
4 colonies from each successfully transformed plate were individually re-streaked onto 
fresh selective plates. Single colonies from these plates were picked and resuspended in 
20 pi o f spheroblasting solution (1.2M sorbitol, lOOmM NaPCL, 2.5 m g/ml zymolase, 
pH 7.4). These cells were heated in a water bath at 37°C for 30 mins and 1 pi o f  the 
sample used as template in a PCR reaction using the re-PCR prim ers. 10 pi o f  this PCR 
reaction was run on an agarose gel to check for the presence o f  a PCR product o f  the 
correct size.
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2.2.5 3-aminotriazole (3-AT) self-activation assay
Individually transformed colonies were grown on selective plates (his /leu ' or his’/trp )  
containing different concentrations o f 3-AT (0, 0.5, 1, 2, 4 and 8 mM ) for seven days. 
If, after this time, any growth was seen on the plates with 2 mM 3-AT or above then use 
o f that particular construct was discontinued.
2.2.6 Mating of two-hybrid yeast strains
Selected colonies o f  PJ694A (transformed with pOAD) and PJ694a (transform ed with 
POBD2) were grown overnight in 1 ml o f leu' or trp' media respectively. These cells 
were harvested and resuspended in 1 ml YPD. 25 pi o f  the PJ694A strain was mixed 
with 25 pi o f the PJ694a strain and the resultant mixture was left overnight to mate and 
grow in 1 ml YPD.
Cells were plated the next day on leu'/trp' plates to select for m ated yeast containing 
both pOAD and pOBD 2 plasmids. After 3 days these plates were replicated (using 
velvet cloth) onto leu'/trp'/his' plates with 4 mM 3-AT and incubated for 10-14 days.
2.3 Protein expression and purification
2.3.1 Small scale protein expression tests
Plasmid vectors were transformed into the E. coli BL21 Star (Invitrogen) protein 
expression strain. Single colonies were picked from the transform ation plates into 10 ml 
LB with the relevant antibiotics. These cultures were grown until the optical density (as 
measured at 600 nm) (OD6oo) was 0.8 when protein expression was induced by the 
addition o f 0.75 mM isopropyl-(3-D-thiogalactopyranoside (IPTG). Cultures w ere left to 
express protein for 3-6 hrs.
Both before and after the induction o f protein expression a 1 ml sam ple w as taken. The 
post-induction sample was sonicated for three 15 second bursts (w ith 10 second gaps) in
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order to lyse the cells. Sonicated samples were spun in a microfuge for 10 mins at 
13000 rpm, the supernatant retained and the pellet resuspended in 1 ml o f  water. 15 pi 
o f the pre-induction and post-induction soluble and insoluble fractions were run on a 
polyacrylamide gel (see Section 2.3.7) to test for protein expression.
2.3.2 Large scale protein expression
Plasmid vectors were transformed into E. coli BL21 Star cells (Invitrogen). Four single 
colonies were picked from the transformation plates and grown overnight in 20 ml o f 
LB with the relevant antibiotics. The next day these cultures were used to inoculate four 
separate 500 ml LB cultures in 2 L flasks. When the OD6oo o f  the 500ml cultures 
reached 0.8 protein expression was induced with 0.75 mM IPTG. Induced cultures were 
left to express protein for 4-6 hours. Cells were then harvested in a Sorvall RN30 
centrifuge by spinning for 15 mins at 5000 g.
2.3.2.1 Large scale expression of isotope labelled proteins
15N-labelled proteins were expressed in the following manner: Plasm id vectors were 
transformed into the BL21 Star cells. Four single colonies were picked from the 
transformation plates and grown overnight in 20 ml o f LB with the relevant antibiotics. 
The next day the cells were harvested by centrifugation and the cells resuspended into 
100 ml o f 15N-labelled minimal media with antibiotics. This culture was grown until 
A 6oo~0.6 when the cells were harvested again. Finally these harvested cells were 
resuspended into 500 ml 15N-labelled minimal media with antibiotics, grown to 
A 6oo=0.8 and protein expression induced by the addition o f 0.75 mM IPTG. Following 
4-6 hours protein expression, cells were harvested by centrifugation at 5000 g for 15 
mins in a Sorvall RC-B5 centrifuge.
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The composition o f minimal media was as follows:
Per litre:
6 g Na2H P 0 4 
3 g KH2PO4 
0.5 g NaCl
1 g 15N-labelled (NH4)2S04 (Cambridge Isotopes Ltd.) 
The pH o f this solution was adjusted to 7.4 and autoclaved.
The following components were then filtered sterilised and added:
2 ml IM M gC l 
10 pi 1M CaCl2
1 ml 0.01 M F eS 0 4
2 g glucose
1 ml lOOOx Vitamins solution 
1 ml 1 OOOx micronutrient solution
* 1000X Vitamins solution 
Per litre:
0.4 g Choline chloride 
0.5 g Folic acid 
0.5 g Pantothenic acid 
0.5 g Nicotinamide
1.0 g M yo-inositol 
0.5 g Pyridoxal HC1 
0.5 g Thiamine HC1 
0.05 g Riboflavin
1.0 g Biotin
2.3.3 Protein purification
2.3.3.1 Purification of polyhistidine-tagged proteins
Cells harvested from 2 L o f culture were resuspended in 25 ml o f  lysis buffer (100 mM 
Tris-HCl, pH 8, 300 mM NaCl) and lysed by passing three times through a French Press 
(American Instrument Company) at 1000 Psi. Lysed cells were then spun in a Sorvall 
RC-B5 centrifuge at 12000 g in an SS34 rotor for 1 hour to rem ove any insoluble 
particles and general cell debris.
Uncharged His-bind resin (Novagen) was prepared as follows: Resin was w ashed three 
times with 10ml ddH20  then incubated with 10 ml o f  100 mM  N iSQ 4 for 30 m ins to
** lOOOx m icronutnent solution
3 pM  Am m onium  M olybdate
400 pM H 3BO 3
30 pM  C 0 CI2
10 pM  C u S 0 4
80 pM  M nC l2
10 pM  Z n S 0 4
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charge the matrix with nickel (II) ions. The charged resin was then w ashed three times 
with 10 ml ddH20  before being equilibrated in 10 ml o f  lysis buffer for 30 mins and 
finally washed twice with 10 ml o f lysis buffer. Between each w ashing step the resin 
was centrifuged for 3 mins at 1250 g and the supernatant discarded.
The lysed cell supernatant was incubated with equilibrated resin for 1 hour at 4°C to 
allow the six histidine residue (His)-tagged protein to bind to the nickel ions. The resin 
was washed three times with 15 ml o f wash buffer (lysis buffer with 10 mM imidazole) 
to remove contaminating proteins. Purified protein was eluted in three steps with 5 ml 
o f elution buffer (lysis buffer plus imidazole) containing increasing concentrations o f 
imidazole (200 mM, 400mM and 600mM).
At each stage o f the purification process a 15 pi sample was rem oved for later analysis 
by SDS polyacrylamide gel electrophoresis (SDS-PAGE).
Both unlabelled and 15N-labelled proteins were purified in exactly the same manner.
2.3.3.2 Purification of GST-tagged proteins
Glutathione-S-transferase (GST) tagged proteins were purified using glutathione- 
sepharose (GS) resin (Amersham). Cells were resuspended in phosphate buffered saline 
(PBS) and lysed as described in Section 2.3.4.
GS resin was prepared by washing three times with ddH20  and equilibrated with PBS 
for 30 mins. The lysed cell supernatant was incubated with 5 ml o f  equilibrated resin for 
1 hour at 4°C or to allow the GST-tagged protein to bind to the glutathione. The resin 
was then washed three times with 15 ml o f PBS. Purified protein was eluted in three 
washes o f 5 ml o f elution buffer (PBS plus 25 mM reduced glutathione).
As with His-tagged protein purifications, at each stage o f  the process a 15 pi sample 
was removed for later analysis by SDS-PAGE.
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2.3.3.3 Preparative size exclusion chromatography
Size exclusion chromatography was carried out on a Biocad Sprint (Perceptive 
Biosystems) or an AKTA purifier (Amersham) chromatography system. Samples o f no 
more than 2 ml were applied to 120 ml Superdex 75 or Superdex 200 (Amersham) 
columns and eluted with NM R buffer (50 mM phosphate, pH 6.2, 100 mM NaCl, 1 mM 
EDTA, 4 mM DTT) at a flow rate o f 0.5 ml/min. 5 ml fractions were collected and 
analysed by SDS-PAGE. Fractions containing pure protein were pooled for future use 
and stored at 4°C.
2.3.4 Polyacrylamide gel electrophoresis (PAGE)
Protein samples were electrophoresed on one o f two types o f  SDS-PAGE gels. Gels 
were either prepared and run using the Biorad Protean system (as described below), or 
pre-cast Novex (Invitrogen) gels were electrophoresed using the XCell-SureLock 
system.
2.3.4.1 Protean gels
12% or 16% polyacrylamide separating gels were prepared to the following recipe:
-  3 ml (for 12% gels) or 4 ml (for 16% gels) 40% acrylam ide solution
-  2.5 ml separating gel buffer (1.5 M Tris, pH 8.8, 4%  w/v SDS)
-  ddH 2 0  to a final volume o f 10 ml
-  50 pi o f 20% ammonium persulphate (APS)
-  25 pi N,N,N',N '-Tetramethylethylenediamine (TEM ED)
Approximately 4 ml o f this gel mixture was poured between two glass plates in the 
Proteanll apparatus. A small volume o f d d ^ O  was then layered on top o f  this liquid to 
avoid dehydration o f the gel as it set.
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A 6 % stacking gel was prepared to the following recipe:
-  0.5 ml o f 40% acrylamide solution
1.25 ml stacking gel buffer (1.0 M Tris, pH 6.8, 4%  w/v SDS)
-  ddH20 to a final volume o f 5 ml
-  25 pi o f  20% APS 
25 pi TEMED
Once the separating gel had set excess water was poured away and the stacking gel mix 
poured on top to fill the glass plates. A 15-well comb was placed in the top o f  the 
staking gel to create the sample wells.
Protein samples were prepared by boiling for 5 mins in loading buffer (50 mM Tris, pH 
6.8, 100 mM DTT, 2% w/v SDS, 0.1% bromophenol blue, 10% w/v glycerol) before 
being loaded onto the gel. Gels were run at a constant voltage o f  180 V for 45 mins in 
the Proteanll gel tank in SDS-PAGE running buffer (25 mM  Tris, pH 8.3, 250 mM 
glycine, 0.1% w/v SDS).
2.3.4.2 Novex Gels
12-16% Bis-Tris Novex gradient gels were electrophoresed as recom m ended by the 
manufacturer using the XCell-SureLock gel tank using the loading and running buffers 
provided. These gels were run at constant voltage o f  200 V for 30 mins.
All SDS-PAGE gels were stained with coomassie blue stain (45% m ethanol, 10% acetic 
acid, 0.25% coomassie blue R-250) for 20 mins and destained w ith destaining solution 
(20% methanol, 7% acetic acid) until clear protein bands became visible.
2.3.5 Concentration of purified proteins
Pure proteins were concentrated using Vivaspin centrifugal concentrators w ith a 5000 
kDa molecular weight cut-off. Concentrators were washed with 25 m l ddH 20 before 
sample addition and were spun at 3000 g.
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2.3.6 Protein concentration determination
A Biomate-4 spectrometer was used to measure the UV light absorbance o f 
concentrated proteins at 280 nm in a 1 ml quartz cuvette. Each protein concentration 
was measured twice using two different dilutions, both relative to the flowthrough from 
the Vivaspin concentrator used to concentrate that protein. Protein dilutions were 
chosen to give an A 280 measurement between 0.01 and 0.5 to reflect the accurate 
dynamic range o f such a measurement. Protein concentrations were calculated using the 
Beer-Lambert law, stating that A 280 = e.c.l (where 1 is the path length, c the protein 
concentration, and e the extinction co-efficient). Theoretical extinction co-efficients for 
individual proteins were calculated from their primary sequences using the Expasy 
ProtParam tool (Gill and von Hippel, 1989).
2.4 Nuclear magnetic resonance (NMR) spectroscopy
['H-^N J-HSQC experiments were carried out on UCL/Ludwig Institute Varian 
UNITYplus spectrometers (operating at nominal 'H  frequencies o f  500 M Hz and 600 
MHz) equipped with a triple resonance ('H , 13C, 15N) probe including z-axis pulse field 
gradients.
[’H -^N j-H SQC spectra o f protein samples in NM R buffer (50 mM phosphate, pH 6.2, 
100 mM NaCl, 1 mM EDTA, 4 mM DTT) were recorded at 25°C  using gradient 
coherence selection, sensitivity enhancement and a water flip-back pulse (Zhang et a l., 
1994). All spectra were recorded with 1024 complex points in the direct dim ension and 
256 complex points in the indirect dimension. For experiments recorded at 500 M Hz 'H  
frequency sweep widths o f 4000 Hz in the direct, 'H  dim ension and 1650 Hz in the 
indirect, l5N dimension were used. For experiments recorded at 600 M Hz !H frequency 
sweep widths o f 4200 Hz ( !H) and 2000 Hz (15N) were used. The num ber o f  scans 
varied depending on the protein concentration. However, during titration experim ents 
the number o f scans was kept constant for each point in the titration.
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NMR data was processed using the NM RPipe (Delaglio et a l ,  1995) and AZARA 
(Boucher 2002) software packages and images o f  spectra w ere produced using the 
program PLOT2 from the AZARA package.
2.5 Cell culture
The three adherent human carcinoma cell lines, Huh7, A549 and Hep-3b, were grown 
and maintained in D ulbecco’s modified Eagle’s medium (DM EM ) supplem ented with 
10% heat-inactivated foetal bovine serum (HI-FBS) and penicillin/streptom ycin (100 
units/ml penicillin and 0.1 mg/ml streptomycin) in 10 mm tissue-culture dishes. Cells 
were passaged (see Section 5.2.2) when confluent and replated at a density o f  2.5x105 
cells/dish. FBS was heat-inactivated by incubation at 55°C for 30 mins.
The murine B-cell line, A20, was cultured in suspension in 75 cm 2 flasks in RPM I 1640 
medium supplemented with 10% HI-FBS, 2 mM L-Glutamine, penicillin/streptom ycin 
solution and 0.05 mM p-mercaptoethanol. When cells reached a density o f 2 x l0 6 
cells/ml they were harvested by centrifugation at 1100 rpm for 4 m ins and resuspended 
in fresh medium at a concentration o f  2x104 cells/ml.
For experiments, cells were plated in 96 well plates at a density o f  15000 cells/well (or 
50000 cells/well in the case o f  A20 cells) in 100 pi o f  standard m edium  containing 
0.1% HI-FBS.
All cells were grown in humidified incubators at 37°C with 10% carbon dioxide for 
adherent cells lines and 5% carbon dioxide for the A20 cells.
2.5.1 Passage of cultured adherent cells
Cells were washed twice with 5 ml H ank’s balanced salt solution (HBSS) and detached 
with 0.5 ml 0.5 mg/ml bovine trypsin solution (in HBSS supplem ented w ith 0.2 mM 
EDTA). Trypsinisation was allowed to proceed for 2-3 mins at 37°C before being 
stopped by the addition o f  5 ml 10% HI-FBS in DMEM. A 20 pi aliquot o f  cells was
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removed for counting and the remaining cells were harvested by centrifugation at 500g 
for 4 mins.
2.5.2 Cell counts
Cells were counted by addition o f an equal volume o f 0.4% w/v trypan blue dye to a 20 
pi aliquot o f cell suspension. Trypan blue is impermeable to the plasm a membranes o f 
living cells but penetrates and stains dead cells. A haem ocytom eter was used to count 
the number o f viable (unstained) cells in the sample.
2.5.3 MTT assay
25 pi o f 0.5 mg/ml methylthiazoletetrazolium (MTT) in PBS was added per well to cell 
cultures in 96-well plates. Plates were incubated at 37°C for 2 hours before the addition 
o f 100 pi lysis buffer (10% SDS in 50% Dimethylformamide (DMF)) to each well. 
After incubation overnight at 37°C the absorbance o f each well was m easured at 540 nm 
in an Optimax plate reader (Molecular Devices) relative to a blank well containing no 
cells.
2.5.4 Fas-ligand treatment
In order to test the sensitivity o f cell lines to apoptosis through the Fas receptor, cells 
were treated with various concentrations o f recombinant, human, soluble Fas-ligand 
(rhsFasL -  Alexis) plus enhancer (at ten times the concentration o f  the ligand -  as 
recommended by the manufacturer). Cells were incubated overnight at 37°C before 
being analysed.
2.5.5 Western Blotting
Western blots were carried out on whole cell lysates to test for the presence o f  Fas and 
other proteins.
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2.5.5.1 Cell lysate preparation
Adherent cells were washed twice with PBS and scraped from the dish surface using a 
sterile cell-scraper. Cells were lysed by the addition o f 250 pi o f  1 % SDS, pre-heated to 
95°C, to the dish and the resultant lysate was collected into a 1.5 ml centrifuge tube.
A20 cells were harvested by centrifugation at 500g for 5 mins, washed with 5 ml PBS 
and lysed by addition o f 250 pi o f 1 % SDS pre-heated to 95°C.
DNA in the lysates was sheared by passing twice through a 0.6 mm gauge sterile needle 
and they were subsequently centrifuged at 13000 g for 15 mins to remove insoluble 
debris. Clear supernatant was collected and stored at -20°C.
2.5.5.2 Protein concentration determination of cell lysates
The bicinchoninic acid (BCA) assay (Pierce) was used to analyse the total protein 
content in cell lysates. 2 pi o f cell lysate was added to two wells o f  a 96-well plate 
followed by addition o f  100 pi BCA assay reagent (prepared as recom m ended by the 
manufacturer). The reaction was left to proceed in the dark for 15 mins before 
absorbance was measured at 562 nm in an Optimax spectrophotom eter (M olecular 
Devices). The absorbance was compared to that o f a set o f bovine serum  album in (BSA) 
standards -  0, 2, 4, 8, 10 and 20 pg/ml -  as assessed in duplicate on the same plate -  to 
allow accurate determination o f protein concentration in the lysates.
2.5.5.3 Blotting and detection procedures
The appropriate volume o f cell lysates calculated to contain 50 pg o f  total protein was 
electrophoresed on 10 % SDS-PAGE gels (prepared using the Protean system as 
described in Section 2.3.4) at 200 V for 45 mins. Rainbow M arkers (A m ersham ) were 
used for molecular weight comparison. Gels, along with sections o f  blotting paper 
(Biorad) and a section o f  Immobilon-P Polyvinylidene Difluoride (PVDF) m em brane
(Millipore) cut to the size o f the gel, were equilibrated in w estern transfer buffer (50
61
mM Tris, 200 mM glycine, 0.03 % w/v SDS, 20% v/v methanol) for 15 mins. 
Following equilibration proteins were transferred from the gel to the PVDF membrane 
using a semi-dry transfer electrophoresis system (ESA) run for 1 hour at 20 V. 
Membranes were then washed once with 20 ml Tris-buffered saline supplem ented with 
0.1 % Tween20 (TBS-T) before being incubated in 20 ml blocking buffer (TBS-T, 10% 
w/v skimmed milk powder) for 1 hour at 20°C to block the rem aining protein binding 
sites on the membrane.
An indirect detection method was utilised for visualising specific proteins on the 
membrane. Indirect detection uses an unmodified primary antibody (1° ab) to bind to the 
protein o f interest followed by a modified secondary antibody (2° ab) which binds to the 
l°ab. This type o f secondary antibody is readily com mercially available for many 
different species and with several types o f modification for different uses. In this study 
horseradish peroxidase (HRP)-conjugated 2° antibodies w ere used for detection 
allowing sensitive detection since light being emitted from the enzym e can be detected 
using x-ray film (following addition o f a specific substrate).
Membranes were then washed three times with 20 ml TBS-T before incubation with the 
primary antibody overnight at 4°C. Primary antibodies were prepared diluted in 5 ml 
TBS, 5% w/v skimmed milk powder. Specific monoclonal antibodies used in this study 
are outlined in Table 2.1.
Target Species Clone Company W orking Dilution
Fas (IC) mouse 3D5 Alexis 1/500
Fas (EC) mouse 610197 BD Biosciences 1/1000
FADD mouse 610399 BD Biosciences 1/250
Caspase-8 rabbit H-134 Santa Cruz 1/250
Fas Ligand rabbit N-20 Santa Cruz 1/1000
Table 2.1: Primary antibodies used in Western blotting and ICC experiments. All antibodies are 
specific for the human protein but show cross-reactivity with murine isoforms. Optimal working 
concentrations (given as dilutions from the supplied stock solutions) for Western blotting 
analysis are shown in this table. Note that for ICC experiments all antibodies were used at a 
1/50 dilution (see Section 2.5.6)
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Following primary antibody incubation membranes were washed three tim es with 20 ml 
TBS-T before being incubated with a horse-radish peroxidase (HRP) conjugated 
secondary antibody for 1 hour at 20°C (diluted in 15 ml TBS, 5% w/v skimmed milk 
powder). For murine primary antibodies a polyclonal, HRP-conjugated, goat-anti-m ouse 
secondary antibody (Amersham) was used at a 1/1000 dilution and for the lapine 
primary antibodies a polyclonal, HRP-conjugated, goat-anti-rabbit secondary antibody 
(DAKO) was used at a 1/2000 dilution (these concentrations are as recom m ended by the 
manufacturers).
Membranes were then washed three times with 20 ml TBS-T before being incubated 
with 2 ml Lumiglow peroxidase substrate (KPL) for 2 mins at 20°C. Excess liquid was 
drained from the membranes which were analysed by autoradiography by exposure to 
Hyperfilm x-ray film (Amersham) in an autoradiography cassette (Amersham) and 
development in an Optimax x-ray film processor (IGP). Exposure times were varied 
depending on the strength o f  the signal.
During experiments to equalise the expression levels o f Fas m utants, in order to ensure 
that the total amount o f protein in each cell lysate was consistent, blots were probed 
with an anti-(3 tubulin antibody (Santa Cruz) following the detection o f  Fas. The (3 
tubulin protein is expressed at a constant level in any particular cell line (and is 
unaffected by doxycyclin) and hence serves as a good loading control for western 
blotting experiments.
2.5.6 Immunocytochemistry
For immunocytochemistry (ICC) experiments cells were seeded onto eight-well 
chamber slides (Nalge Nunc) at a density o f 15,000 cells per cham ber in the relevant 
medium containing 0.1% FBS and left overnight to recover.
Cells were fixed in 500 pi o f 4%  paraformaldehyde for 10 mins at 20°C, washed tw ice 
with 500 pi PBS and, where required, permeablised by incubation w ith 250 pi, 0.1% 
Triton (in PBS) for 10 mins 20°C. The cells were then washed tw ice w ith 500 pi PBS 
and excess protein-binding sites were blocked with 4% normal goat serum and 1% BSA 
for 1 hour at 20°C. Following blocking were then washed again tw ice w ith 500 pi PBS
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and incubated overnight at 4°C in a humidified chamber with 50 pi o f  prim ary antibody 
diluted in PBS. Following primary antibody incubation, cells were w ashed three times 
with PBS in a Coplin jar, incubated for 1 hour at 20°C with 50 pi o f  biotin conjugated 
secondary antibody diluted in PBS and washed again three times with PBS. Finally the 
cells were incubated for 30 mins at 20°C in the dark with fluorecsein (FITC)- 
streptavidin, washed with PBS and mounted under coverslips using Vectashield 
(Vector) with 4-6-Diamidino-2-phenylindole (DAPI) counterstain. DAPI fluoresces 
when specifically bound to double stranded DNA and this counterstaining procedure 
helps to visualise intact, healthy cell nuclei when labelling cell cultures.
For all ICC experiments the 1° ab was used at a dilution o f  1/50 and the 2° ab used was 
a polyclonal biotin-conjugated goat-anti-mouse ab (DAKO), also used at a 1/50 
dilution.
Fluorescent labelling was visualised and photographed using a N ikon Eclipse E600 
fluorescence microscope using the Lucia G software package (Nikon). FITC was 
detected using with 465-495 nm excitation and 515-555 nm em ission wavelengths. 
DAPI staining was detected using wavelengths 340-380 nm (excitation) and 435-485 
nm (emission).
2.5.7 Transfection of adherent cells
The reagent selected for the transfection o f the three cell lines was Fugene6 (Roche). 
Such lipid-based reagents rely on the formation o f lipid-DNA com plexes formed sim ply 
by incubation with plasmid DNA. The lipid-DNA complex can then be added to a cell 
culture for transfection to take place by fusion o f the lipids with the cell-m em brane and 
subsequent uptake o f  the DNA by endocytosis. However, the efficiency o f  different 
transfection methods can vary greatly according to cell-type, so Fugene6 was 
specifically chosen in this study because it is previously reported to have been 
successfully used to transfect the three cells lines; Huh7, Hep3b and A459 (transfection 
database at http://www.roche-applied-science.com/).
Mammalian cell transfection protocols rely on the use o f pure DNA  in m ulti-m icrogram  
quantities. Plasmids used in this study were produced by propagation in E. coli cells and
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by extraction with the Qiagen Midiprep kit from 100 ml cultures o f  bacteria. DNA 
purity was estimated as described in Section 2.1.10 using an A 26o:A28o absorbance ratio. 
It is generally accepted that an absorbance ratio above 1.7 indicates the DNA is pure 
enough to use for transfection. By eluting DNA from the M idiprep kits in sterile- 
filtered, distilled, deionised water, DNA was generally found to have an absorbance 
ratio o f 1.7-1.9 and was hence pure enough for transfection. The concentration o f 
plasmid samples from this purification method was also in the correct region (between 
0.2-0.5 pig/ptl) to carry out the chosen transfection protocol.
For the transfection o f each cell line with the pTET-on plasm id all six wells o f a six 
well tissue-culture plate were seeded with 2 x l0 5 cells and left overnight to recover. For 
each o f the three cell-lines the six wells (labelled A-F below) were treated as follows:
A) Cell control -  no Fugene6, no DNA
B) Reagent control -  6 pi Fugene6, no DNA
C) DNA control -  no Fugene6, 2 pg DNA
D) 3:1 ratio -  3 pi Fugene6, 1 pg DNA
E) 3:2 ratio -  3 pi Fugene6, 2 pg DNA
F) 6:1 ratio -  6 pi Fugene6, 1 pg DNA
This system allows the toxicity o f both the reagent and the plasm id DNA to be tested as 
well as three reagent:DNA ratios. The reagent:DNA ratio is an im portant variable in 
lipid-based transfection protocols and one that can only be optim ised em pirically since 
it depends both on cell-type and the quality o f the DNA used in the experiment.
At 48 hours post-transfection the cells from each well were split into two 100 mm 
dishes containing standard medium supplemented with 750 pg/m l G418. G418 is a 
soluble analogue o f  neomycin used here to select for cells that had been successfully 
transfected with the pTet-on plasmid. There were no adverse effects noted from the 
reagent and DNA control wells suggesting that Fugene6 is non-toxic to these three cell 
lines and that the plasmid DNA preparation was pure enough not to dam age the cells. 
Antibiotic selection was allowed to proceed for fourteen days, w ith m edium  changes 
every three days.
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The second stable transfection procedure (using pTRE2 plasmids) was carried out in the 
same manner as the pTet-on transfection with the following exceptions: Firstly, for each 
of the five pTRE2 plasmids only one Fugene6 :DNA ratio was used (the 6:1 ratio) for 
transfection as this was found to be the most successful from the previous experiments. 
Secondly, antibiotic selection o f the pTRE2 plasmid was carried out using 75 pg/ml 
hygromycin B as this plasmid contains a hygromycin resistance gene. Finally, the 
double stable transfected cell lines were cultured in standard m edium supplemented 
with 200 pg/ml G418 and 50 pg/ml hygromycin B (double selective medium)
2.5.8 Luminescence Assay
Cells that were transiently transfected with the pTRE2-luciferase plasm id were analysed 
using the Luclite luminescence assay (Perkin Elmer) according to the m anufacturer’s 
protocol. Luminescence was measured in white 96-well plates (Com ing) using a 
Victor2 multilabel plate reader (Perkin Elmer). The Luclite assay works by lysing the 
cells and providing a substrate for firefly luciferase -  the light em itted from this assay 
can be measured in a luminometer and is proportional to the am ount o f  luciferase 
expression in the cells.
2.5.9 DNA fragmentation assays
The fluorescent-detection TUNEL assay used in this study utilises a terminal 
deoxynucleotide transferase (TdT) enzyme to add FITC-labelled nucleotides to the 3 ’ 
termini o f fragmented DNA strands. These nucleotides can be directly observed under a 
fluorescent microscope. For this purpose cells from the four Fas-expressing cell lines 
were seeded on chamber slides, induced with doxycyclin, treated w ith 2 0 0  ng/ml 
rhsFasL and then subjected to the TUNEL assay using the Apoptag Fluorescein Direct 
In Situ Apoptosis Detection Kit (Chemicon) following the m anufacturer’s protocol. 
Control experiments for each cell line were carried out where cells w ere treated with 
500 nM staurosporine (as a positive control for the assay) or left untreated (to test the 
background level o f apoptosis). Also, as a negative control for the TU N EL assay, one 
chamber o f the wild-type Fas expressing cell line was treated with rhsFasL but addition
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of the TdT enzyme was omitted during the assay protocol. Cells were counterstained 
with Hoechst stain by incubation with a 2 mg/ml solution for 10 mins at room 
temperature in the dark, washed twice with PBS and mounted under glass coverslips 
using Vectorshield (Vector). Fluorescence microscopy o f these slides was carried out as 
described in Section 2.5.6.
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Chapter 3
Investigation of the interaction between the 
death domains of Fas and FADD
3.1 In vitro studies of Fas-DD and FADD-DD
HIS chapter will cover the initial approaches taken to study the interaction
between the death domains o f Fas and FADD in vitro. Particular attention is
given to the resolution o f the problem o f expression and purification o f  Fas-DD. This is 
followed by an account o f a series o f NMR-based protein/protein interaction 
experiments.
The aim o f this study is to further the understanding o f the interaction between Fas-DD 
and FADD-DD in vitro in order to improve the understanding o f  how these proteins 
interact to carry out their physiological roles in vivo. Structural biology techniques, such 
as nuclear magnetic resonance (NMR) spectroscopy and X-ray crystallography, provide 
us with the most powerful tools for such in vitro studies o f proteins as, in principle, they 
allow atomic scale resolution o f these biological molecules.
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However, the use o f NMR techniques, in particular, for studying proteins in solution is 
often limited by the requirement for multi-milligram quantities o f protein that is soluble 
in aqueous buffers at millimolar concentrations. Arguably, it is either technically 
impossible or economically unfeasible to produce the m ajority o f  proteins and 
polypeptides in such quantities. Even if  a protein can be expressed in a recom binant 
fashion, at high enough levels, it is often the case that the resultant m olecule is not 
sufficiently stable (with respect to aggregation and precipitation) at the concentrations 
required for structural studies.
As outlined in Chapter 1, the NM R solution structures o f  Fas-DD (Huang et a l., 1996) 
and FADD-DD (Jeong et al., 1999; Berglund et al., 2000) are already available and this 
may lead to the conclusion that the production o f these two dom ains for NM R-based 
interaction studies should be straightforward. Unfortunately this is not the case as these 
two structures were determined with a large difference in one key variable -  the pH o f 
the buffer used for the NM R experiments. It was reported by Huang et al. that Fas-DD 
is prone to aggregation at physiological pH and that this problem  could be overcom e 
using a pH 4 buffer to carry out the NMR experiments. It m ay be presum ed that the 
protonation o f acidic side chains o f Fas-DD helps to stop the intrinsic self-aggregation 
properties o f this protein in solution. In contrast, the FADD-DD structure was solved in 
the Driscoll group laboratory at pH 6.2 (Berglund et al., 2000) and in this case FADD- 
DD presented no reported problems with self-aggregation.
It is clear that in order to carry out a biologically relevant study o f  the interaction 
between these two domains the buffer conditions must be kept as close to physiological 
pH (and salt concentration) as possible. It was therefore necessary to discover a m ethod 
to recombinantly express and purify both o f these domains in such a w ay that they 
would both be soluble enough for NM R experiments at a pH as close to 7.4 as possible. 
In practical terms, this relied on the discovery o f a method to produce Fas-DD in a 
recombinant manner such that it would not aggregate at the required concentrations.
However, before attempting the large scale expression and purification o f  Fas-DD and 
FADD-DD it was first necessary to find an interaction assay to confirm  that the domains 
used for structural studies would productively interact. In this case, the yeast tw o-hybrid 
assay was chosen.
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3.2 Use of the yeast two-hybrid assay system
The yeast-two hybrid assay was chosen as the primary m ethod for studying the 
interaction between Fas-DD and FADD-DD for two main reasons. Firstly this 
experiment would replicate the original study documenting the existence o f a direct 
interaction between these two domains (Chinnaiyan et a l ,  1995). Secondly, this assay 
provides a convenient method o f screening many potential alternative protein 
interactions in parallel.
The potential o f the yeast two-hybrid assay to screen many interactions is important 
when considering the difficulties in production o f recom binant proteins for NMR 
studies. There are several ways to overcome such problems, m any o f  which involve 
altering the genetic construct used for recombinant expression o f  the protein o f interest. 
For example, when working with domains that represent only a fragm ent o f  the intact 
protein, as is the situation with the death domains o f Fas and FADD, it is often the case 
that only slight alterations in the amino-acid sequence selected to define the limits o f 
that domain (i.e. the predicted domain “boundaries”) can lead to dramatic changes in the 
expression levels or solubility o f the resultant protein product. A nother common 
strategy that is adopted to improve the solubility o f a particular protein domain is to 
make point mutations in amino-acid residues known (or predicted) to be on the surface 
o f that domain. Alteration o f  the distribution o f electrostatic charges or the hydrophobic 
character o f the protein surface with point mutations can greatly enhance the intrinsic 
solubility o f the protein target (for example (Eberstadt et a l ,  1998; W aldo et a l ,  1999) 
etc.) Therefore, according to the strategy we were obliged to adopt, if  it proved 
necessary to alter the Fas-DD or FADD-DD constructs in either o f  these ways then the 
yeast two-hybrid assay would provide a facile means to screen m any o f  these alterations 
in parallel in order to check whether the altered domains are still able to interact.
3.2.1 Mechanism of the yeast two-hybrid assay
The yeast two-hybrid assay was developed as a powerful m ethod for studying 
protein/protein interactions in a cellular environment (Fields and Song, 1989). The main 
application o f this non-ubiquitous methodology has becom e the m edium - to high- 
throughput screening o f large numbers o f potential interactions involving the use o f  
whole libraries o f  candidate interacting genes or partial cDNAs, but it rem ains ju st as
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applicable on a smaller scale. The mechanism underlying the yeast two-hybrid assay is 
outlined in Figure 3.1 where it is illustrated how this technique takes advantage o f the 
modular nature o f  the yeast GAL-4 transcriptional activator. GAL-4 has two 
independently functioning domains that can be separated onto different polypeptide 
chains and only need to be brought into close proximity to restore full functionality 
(Keegan et al., 1986). These two domains are named BD for the DNA binding domain 
(residues 1-147 o f GAL-4) and AD for the transcriptional activation domain (residues 
768-881 o f GAL-4). The experimenter arranges that one protein o f interest (the “bait”) 
is genetically fused to BD whilst a potential binding partner (the “prey”) is fused to AD. 
These two proteins, the bait-BD fusion and the prey-AD fusion, are then expressed in 
the same yeast cell. If  the prey protein interacts with the bait protein then BD is brought 
close enough to AD to initiate the transcription o f a reporter gene via recruitm ent o f the 
endogenous RNA polymerase complex. In the illustrated exam ple the reporter gene 
produces a histidine biosynthesis enzyme -  the HIS3 gene product -  the expression o f 
which allows the specifically chosen yeast strain to grow on medium  lacking histidine. 
In the absence o f  the bait-prey interaction, expression o f HIS3 is extrem ely low and the 
yeast will not grow in the absence o f histidine.
There are now many commercial systems available for application o f  the yeast two- 
hybrid assay but the non-commercial system used here -  kindly provided by colleagues 
in the laboratory o f  Professor Peter Piper at University College London -  was very 
similar to that described by the laboratory that originally introduced the assay (Cagney 
et al., 2000). This system uses two plasmid vectors to express the GAL-4 AD and GAL- 
4 BD fusion proteins; these vectors are known as pOAD and pO B D 2 respectively (see 
Appendix 4). The DNA constructs encoding the target bait and prey proteins are 
subcloned into these vectors (to create pOAD-prey and pO BD 2-bait plasm ids) such that 
when transformed into Saccharomyces cerevisiae yeast these plasm ids express the BD- 
bait and AD-prey fusion proteins under the control o f  the constitutive yeast alcohol 
dehydrogenase, ADH, promoter.
71
a)
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Figure 3.1: Mechanism of the yeast two-hybrid assay, a) This panel shows the GAL4- 
BD/bait fusion protein interacting with the GAL4-AD/prey fusion protein. The resultant 
complex is capable of activating transcription of the HIS3 reporter gene, b) This 
mechanism is carried out in yeast cells by initial transformation of the pOAD and pOBD2 
plasmids into separate yeast strains. Mating of these two strains allows the two fusion 
proteins to be expressed in the same cell. Subsequently, mated cells are grown on 
medium lacking histidine to probe the bait-prey protein/protein interaction. If the two 
proteins interact the HIS3 gene product is synthesised allowing the yeast to grow on his 
medium. In contrast, as shown in c), a lack of bait/prey interaction results in no HI S3 
production and these yeast are unable to grow on medium lacking histidine
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Also used in this system are two genetically modified yeast strains, nam ed PJ694A and 
PJ694a. These two strains are genetically identical (their full genotype being: M A Ta/a 
trpl-901 leu2-3,l 12 ura3-52 his3-200 ga/4(deleted) ga/59(deleted) LYS2::GAL1-HIS3  
GAL2-ADE2 met2::GAL7-lacZ) but are capable o f  mating with each other and, having 
had their tr p l , leu2 and his3 genes mutated, both are auxotrophic for leucine, tryptophan 
and histidine.
The pOAD-prey plasmid is transformed into the PJ694A yeast strain and the pOBD2- 
bait plasmid is transformed into PJ694a. The pOAD plasmid expresses the leu2 gene 
product and the pOBD 2 plasmid the trpl gene product allowing yeast cells that have 
been successfully transformed with these plasmids to be selected on growth medium 
lacking leucine or tryptophan respectively. Following transformation with the individual 
plasmids, the two successfully transformed yeast strains are mated with one another. 
During this mating procedure, the total complement o f  the two yeast strains’ genetic 
material is shared so that the resulting progeny contain both o f  the expression plasmids 
(see Figure 3.1b). Successfully mated yeast cells which contain both the pOAD-prey 
and pODB2-bait plasmids can be positively selected by growth medium  lacking both 
leucine and tryptophan.
Following selection o f the successfully mated yeast the resultant cells are transferred to 
growth medium lacking all three o f histidine, leucine and tryptophan. In order for these 
yeast strains to be able to grow on such a medium it is required that the BD-bait and 
AD-prey proteins be expressed and subsequently bind to each other in order to switch 
on the HIS3 reporter gene. If  there is no interaction between bait and prey proteins then 
cell growth and proliferation will be impaired.
Whilst the yeast two-hybrid assay is an extremely well established m eans o f detecting 
protein-protein interactions, one o f the major limitations is the potential for the 
reporting o f false positive indications. This is suspected to occur when either o f  the 
fusion proteins on its own is able individually activate transcription o f  the reporter gene. 
In order to overcome this problem a self-activation assay was used to filter out any bait 
or prey constructs that may give false positive results. This self-activation assay 
(described in Section 2.2.5) involves the use o f 3-aminotriazole (3-AT), a com petitive 
inhibitor o f the HIS3 gene product. It is widely accepted for this system  that if
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transformation o f a particular construct allows the yeast to grow on selective media 
(lacking histidine) in the presence o f greater than 2 mM  3-AT then that construct is 
“self-activating” and must not be used for further experiments.
3.2.2 Investigation of the Fas-DD/FADD-DD interaction with the yeast two- 
hybrid assay
Plasmids encoding the death domains o f Fas and FADD were available in the laboratory 
-  a kind gift from Professor Neil McDonald o f Birkbeck College School o f 
Crystallography -  and were used as templates for the first round o f PCR (using PCR 
primers 1 and 2 or 3 and 4 respectively -  see Appendix 3 for a list o f  all PCR primers 
used in this study) for sub-cloning into the yeast two-hybrid expression plasmids (see 
Section 2.2.2). Initially the amino-acid sequence boundaries o f  these two domains were 
chosen to mimic those found in the respective three dimensional structure papers, as 
these constructs would provide suitable starting points for subsequent large scale protein 
expression tests. Therefore human Fas-DD was defined as encom passing amino-acid 
residues 202-307 (Huang et al., 1996), and human FADD-DD as residues 93-192 
(Berglund et al., 2000).
DNA encoding Fas-DD was sub-cloned into pOAD and transform ed into yeast strain 
PJ694A with successful transformants being selected for by growth on agar plates with 
medium lacking leucine -  leu 'plates (see Section 2.2.3). As a negative control the DNA 
encoding the Fas-DD point mutant D244A was sub-cloned and transform ed into 
PJ694A in the same way -  see Chapter 4 for a more detailed description o f  this point 
mutation. DNA encoding FADD-DD was sub-cloned into pO BD 2 and transform ed into 
yeast strain PJ694a with successful transformants being selected for by growth on trp' 
plates.
Selected clones were tested for self-activation by growth on 3-AT plates (see Section 
2.2.5) and found to be non-self-activating (see Figure 3.2c). W ild-type and m utant Fas- 
DD clones were separately mated with the FADD-DD clone and in each case, following 
mating, the resultant positively selected (on trp'/leu' plates) yeast were transferred onto 
leu'/trp'/his' plates with 4 mM 3-AT.
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C) 3-AT: 0 mM 0.5 1 mM
3-AT: 2 mM 4 mM 8 mM
Bait: FADD-DD FADD-DD
Prey: Fas-DD Fas-DD-D244A
Figure 3.2 Interaction between Fas-DD and FADD-DD shown by the yeast 2-hybrid assay, 
a) re-PCR of DNA constructs encoding: A:FADD-DD, B:Fas-DD, C:Fas-DD-D244A (M: 
DNA size ladder), b) Colony screen of various Fas-DD and FADD-DD transformants 
showing bands of the correct size to confirm accurate transformation of these constructs 
into yeast cells (lanes from positive colonies are indicated by arrows), c) Self-activation 
assay of A:FADD-DD, B:Fas-DD and C:Fas-DD-D244A. Cells are plated in sections onto 
increasing concentrations of 3-AT. No growth is seen above 1 mM indicating no self­
activation (the unlabelled segments correspond to an unrelated experiment), d) Mated cells 
are grown on trp'/leu'/his' plates with 4 mM 3-AT. Proliferation is seen when FADD-DD 
cells are mated with Fas-DD cells but not when FADD-DD cells are mated with Fas-DD- 
D 9 4 4 A  p.e 11c
Cells which contained Fas-DD and FADD-DD were able to grow on these plates 
whereas cells with the Fas-DD-D244A construct did not proliferate (see Figure 3.2d). 
The feint background o f  yeast cells that can be seen in Figure 3.2d in the region 
corresponding to cells containing the Fas-DD-D244A mutant results from cells that 
have been replica-plated from the trp /leu ' plate but are unable to proliferate on the 
medium lacking histidine. These results indicate that there is an interaction between the 
wild-type Fas and FADD death domains that can be disrupted by the single D244A 
point mutation o f Fas-DD.
3.3 Production of Fas-DD and FADD-DD for NMR studies
Since the yeast two-hybrid assay confirmed that a productive interaction between the 
Fas and FADD death domains was formed in this cellular environm ent, attempts were 
made to produce these proteins in sufficient quantities for N M R studies in order to 
provide a detailed analysis o f this binding event.
3.3.1 Production of recombinant FADD-DD
The 3D solution structure o f FADD-DD was previously solved in the Driscoll 
laboratory (Berglund et al., 2000) and hence a robust, high-level expression system for 
this protein was immediately available. This system uses the pET15b (Novagen) 
expression plasmid (see Appendix 4) containing an insert that encodes residues 93-192 
o f human FADD with an N-terminal, six histidine residue (His) purification tag. This 
plasmid, named pET-FADD-DD, was provided and used unaltered throughout this 
project. pET-FADD-DD was freshly transformed into E. coli BL21 Star cells 
(Invitrogen) on each occasion that a batch o f FADD-DD protein was required.
The BL21 Star strain o f E. coli is engineered by integration o f  genes from the modified 
“DE3” bacteriophage into the host chromosome. This modification allows these cells to 
express T7 RNA polymerase (T7pol) under control o f the lac operon (outlined in Figure 
3.3). Under normal conditions o f bacterial cell growth, expression o f  the T7-pol gene is 
suppressed by binding o f  the lac repressor protein to the lac operator sequence in the 
promoter o f the T7-pol gene. Addition o f allolactose (or a stable analogue thereof) to 
the bacterial cell culture results in this sugar binding to the lac repressor. This binding
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event causes the dissociation o f the lac repressor from the lac operator and hence allows 
the T7-pol gene to be transcribed by the endogenous RNA polymerase. The majority o f 
commercially available E. coli protein expression vectors (including those employed in 
this study) place the target gene downstream of a T7 promoter sequence. This promoter 
sequence is not present elsewhere in the E. coli genome so the induction o f T7-pol 
expression leads solely to the expression o f the target gene(s) within the expression 
plasmid. The vectors used in this study also contain the lac repressor gene and the lac 
operator sequence (as part o f the T7 promoter) thus allowing double repression o f target 
protein expression in the absence o f allolactose. Isopropyl-(3-D-thiogalactopyranoside 
(IPTG) is the most commonly used allolactose analogue for induction o f protein 
expression in this system. Since IPTG cannot be broken down by E. coli the addition o f 
this chemical to the bacterial cell culture allows a constant, high level o f  heterologous 
protein expression.
The BL21 Star strain is also specially engineered to be deficient in RNAse E and the 
protease OmpT which results in increased stability o f  both the transcribed RNA the 
translated protein in the E. coli cell.
A reproducibly high level o f expression o f FADD-DD from the pET-FAD D-D D  vector 
was possible using BL21 Star cells. The His-tag present on FADD-DD, w hen expressed 
in this manner, allowed the protein to be easily purified away from unwanted E. coli 
proteins by immobilised metal ion affinity chromatography (IM AC) on nickel (II)- 
charged resin. Nickel (II) binds strongly to the His-tag at pH 8  and retained protein can 
be easily eluted using an increasing concentration o f im idazole w hich competes with 
histidine for the nickel-ion binding sites (see Section 2.3.4).
After IMAC purification, proteins were further purified using preparative scale size- 
exclusion chromatography (SEC) (see section 2.3.6). SEC prim arily separates molecules 
by their hydrodynamic size so can be used to purify small proteins away from other 
contaminating biological macromolecules. SEC is normally carried out under non­
denaturing conditions in aqueous buffers and so this method is ideal for the purification 
o f proteins for structural biology. In this project, all proteins purified in this two-stage 
manner were found to be sufficiently pure for NM R spectroscopy and other solution- 
based experiments (>95% pure as analysed by SDS-PAGE).
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Figure 3.3 : Expression of recombinant protein in E. coli BL21 cells.
a) Before induction, the lac repressor is bound to the lac operator elements thereby 
suppressing expression of the T7 RNA polymerase gene and the target gene, b) IPTG 
added to the cell culture binds to the lac repressor, changing its conformation and 
effecting its dissociation from the lac operator sequences both in the chromosomal DNA 
and on the expression plasmid. This leads to the initiation of expression of theT7 RNA 
polymerase by endogenous E. coli polymerases. The T7 polymerase then binds to the T7 
promoter in the expression vector leading to a high level of expression of the target 
protein.
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Figure 3.3 : Expression of recombinant protein in E. coli BL21 cells.
a) Before induction, the lac repressor is bound to the lac operator elements thereby 
suppressing expression of the T7 RNA polymerase gene and the target gene, b) IPTG 
added to the cell culture binds to the lac repressor, changing its conformation and 
effecting its dissociation from the lac operator sequences both in the chromosomal DNA 
and on the expression plasmid. This leads to the initiation of expression of theT7 RNA 
polymerase by endogenous E. coli polymerases. The T7 polymerase then binds to the T7 
promoter in the expression vector leading to a high level of expression of the target 
protein.
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An example o f the purification o f His-FADD-DD from a 2 litre culture o f  E. coli grown 
in LB media is shown in Figure 3.4.
a) His-FADD-DD
14 kDa
b)
P SN FT W1 W2 W3 M„ E1 E2 E3
00
CM
14 kDa
Mw 16 17 18 19 20 21
160100 120 140
Elution time (mins)
Figure 3.4: His-FADD-DD protein purification.
The two step purification of His6-FADD-DD is shown in a) and b). The initial IMAC 
purification as analysed by 16% SDS-PAGE is shown in a) and the subsequent S200 
preparative-scale size-exclusion chromatography is shown in b). For SEC analysis both 
the elution profile, as monitored by UV absorbance, and SDS-PAGE analysis of the 
chromatographic fractions are shown (the numbers correspond to eluted fractions).
Key: Mw -  molecular weight markers. P -  pellet, SN -  supernatant, FT -  flow through,
W -  wash, E -  elution.
The figures illustrate that His-FADD-DD was produced in high yields and was readily 
purified by a combination o f IMAC and SEC. Then, in order to produce a sample 
suitable for NM R experiments, the eluted fractions from SEC that contained pure
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FADD-DD protein were concentrated to a volume o f ~1 ml (see Section 2.3.8). The 
protein concentration o f this sample was determined (see Section 2.3.9) and found to be
2.2 mM. Since His-FADD-DD has a molecular mass o f 14.5 kDa, this corresponds to a
total o f 40 mg o f protein and hence an expression yield o f 20 mg per litre o f  cells (20
mg/L). The expression yields o f  all recombinantly-expressed proteins were calculated in 
this way.
3.3.2 Production of recombinant Fas-DD
3.3.2.1 His6-tagged Fas-DD
The expression and purification o f Fas-DD was initially attempted using the same 
system as used for His-FADD-DD. PCR primers 7 and 8 were used to amplify DNA 
encoding the death domain (residues 202-307) o f Fas. These prim ers contained the 
necessary restriction sites (Bam H l and Ndel) to sub-clone this piece o f  DNA into the 
pET15b expression vector thereby creating the plasmid pET-Fas-DD. [The PCR cloning 
strategy utilised throughout this study is outlined in sections 2.1.6 -  2.1.9 and involved 
a standard PCR/ restriction-digestion/ ”sticky-end” ligation protocol.] All clones were 
subjected to DNA sequencing before use to ensure the correct expression construct had 
been created.
Small scale expression trials (see Section 2.3.1) using pET-Fas-DD in BL21 Star cells 
showed that only a small proportion o f the expressed protein was in the soluble fraction 
o f the cell lysate. Attempts to purify the soluble fraction o f this protein in a buffer at pH
6.2 on a larger scale resulted in only a relatively small am ount o f  pure protein -  
approximately 2 mg/L. Crucially, attempts to concentrate pure H is-Fas-DD  resulted in 
the formation o f  a viscous, gel-like fluid caused by self-aggregation o f  this protein. This 
observation is perhaps unsurprising as the solution structure o f  this dom ain was solved 
at pH 4 precisely to overcome these aggregation problems (Huang et a l., 1996). The 
combination o f low expression level and self-aggregation m eant that this expression 
strategy was not suitable for producing Fas-DD for NM R-based interaction studies with 
FADD-DD and hence alternative strategies were needed to im prove the expression o f 
this domain.
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3.3.2.2 GST-tagged Fas-DD
One strategy that has been developed to increase the expression levels and solubility o f 
previously insoluble target proteins is the use o f  fusion protein systems. Expression o f a 
target protein fused, at the C-terminus, to a highly expressed, soluble protein has been 
shown to be a successful way o f increasing its expression yield and solubility reviewed 
in (Davis et al., 1999).
Glutathione-S-transferase (GST) one o f the most commonly used fusion partners as it 
has the combined advantage o f  an intrinsically generally high expression level coupled 
with a facile affinity purification system (Smith and Johnson, 1988). GST has a very 
specific and high affinity for glutathione and hence the fusion protein can be easily 
purified using an affinity chromatography system employing a resin chemically 
modified with glutathione.
There are many a commercially available plasmid vectors for the expression o f GST- 
fusion proteins. For this study the plasmid pGEX-2T (see Appendix 4) was chosen to 
express Fas-DD as a GST-fusion protein (GST-Fas-DD). As with all com mercial GST- 
fusion expression vectors, the target gene o f interest m ust be sub-cloned into this 
plasmid using a cloning site that lies immediately downstream o f  the DNA sequence 
that encodes the GST protein. DNA encoding Fas-DD was therefore sub-cloned into the 
pGEX-2T vector (Amersham) -  PCR primers 9 and 10 were used to am plify the 
relevant sequence o f DNA and these primers contained the Bam H I and EcoR I restriction 
enzyme sites required for sticky-end ligation o f the amplified fragment into the multiple 
cloning site o f this vector. The resultant plasmid -  pGEX-Fas-DD -  was used to express 
the GST-Fas-DD fusion protein.
Recombinant protein expression from pGEX-Fas-DD in B121 Star cells resulted in only 
a small amount o f  soluble protein (approximately 2.5 mg/L). The purification o f  this 
protein (GST-Fas-DD 1) is shown in Figure 3.5 a, c and d. As w ith Flis-Fas-DD, 
attempts to concentrate the pure GST-Fas-DD protein resulted in aggregation and also 
precipitation. It was therefore decided to try altering the Fas-DD dom ain itse lf in an 
attempt to improve its expression characteristics.
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Figure 3.5: GST-Fas-DD purification
Analysis of the two-step purification of GST-Fas-DDl (wild type) and GST-Fas-DD- 
D244A. a) and b) show SDS-PAGE analysis of the GST affinity purification step, c), d) 
and e) show the respective S200 size-exclusion chromatograms and subsequent fractional 
analysis by SDS-PAGE from these two protein purifications. There is a clear difference 
in protein yield between wild-type GST-Fas-DD and the D244A mutant.
Key: Mw -  molecular weight markers. P -  pellet, SN -  supernatant, FT -  flow through,
W -  wash, E -  elution.
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It is widely accepted that even small changes in amino-acid sequence can dramatically 
change protein expression levels and solubility characteristics (W aldo, 2003). First, 
therefore, the domain boundaries o f the Fas-DD construct were altered in an attempt to 
alter the expression properties. Seven new constructs were produced by PCR cloning 
(see Table 3.1). The constructs produced had 3-residue N-terminal extensions or a 
longer C-terminus. However, expression and purification o f  these GST-Fas-DD 
constructs gave only a minor increase in yield relative to the initial construct (see Table 
3.1).
It became clear, therefore, that changing the domain boundaries from those o f  the initial 
construct did not greatly alter the expression characteristics o f  Fas-DD. Since the yeast 
two-hybrid assay gave a positive result with the original Fas-DD construct it is unlikely 
that the extended terminal regions play a part in the interaction with FADD-DD and 
hence for the remaining studies the domain boundaries were kept as originally described 
(Fas residues 192-307). Alternative strategies were therefore sought to improve the 
expression and solubility o f GST-Fas-DD.
As was the case with for yeast two-hybrid assay (see Section 3.2.2), the point mutation 
Fas-DD-D244A was produced as a GST-fusion protein to be used as a negative control 
in FADD-DD binding assays. The QuickChange site-directed mutagenesis kit 
(Stratagene) was used (with pGEX-Fas-DD as the template and PCR prim ers 15 and 16) 
to create pGEX-Fas-DD-D244A. It can be seen from Figure 3.5 and Table 3.1 that 
expression o f GST-Fas-DD-D244A in BL21 Star cells resulted in a ten-fold increase in 
the yield o f soluble, purified protein when compared to expression o f  the wild type 
protein. This type o f remarkable result from a single point m utation has been noted 
before in the expression o f death fold protein domains. For exam ple the F25Y mutation 
has a very similar effect on the expression o f the death effector dom ain o f  FADD 
(Eberstadt et al., 1998), allowing the solution structure o f this domain to be solved. It is 
likely that both o f  the D244A and F25Y mutations are disrupting the self-aggregation 
properties o f these proteins by altering the charge distribution or enhancing the polarity 
on the surface o f their respective domains. Adding weight to this argum ent is the 
difference in behaviour o f  wild-type Fas-DD -  which seems to have an aggregated, gel­
like composition when concentrated -  and the GST-Fas-DD-D244A protein which 
remains free in solution at higher concentrations.
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The success o f the D244A mutation suggested that it may be possible to find a point 
mutation that substantially reduced the self-aggregation properties o f  Fas-DD but did 
not disrupt its FADD-DD binding activity -  the D244A m utation only provided a 
solution to the first o f these requirements as it completely abrogates FADD-DD binding 
in the yeast two-hybrid experiment. A reasonably extensive m utational analysis had 
been previously presented in the Fas-DD structure determination publication (Huang et 
al., 1996). Here, both Fas-DD self-aggregation and a FADD-DD binding assays were 
described and applied to several Fas-DD mutants. One point mutation, K247A, was 
described as having significantly reduced Fas-DD self-aggregation properties relative to 
the wild type protein, whilst maintaining FADD-DD binding activity.
Construct Name Fas-DD residue 
Boundaries
5’ PCR 
primer
3 ’ PCR 
prim er
Expression 
yield mg/L
GST-Fas-DD 1 192-307 9 10 2
GST-Fas-DD2 192-319 9 14 2
GST-Fas-DD3 196-307 11 10 3
GST-Fas-DD4 196-319 11 14 3
GST-Fas-DD5 199-307 12 10 3
GST-Fas-DD6 199-319 12 14 3
GST-Fas-DD7 202-307 13 10 3
GST-Fas-DD8 202-319 13 14 3
GST-Fas-DD-D244A 192-307 13 14 25
GST-Fas-DD-K247A 192-307 15 16 25
Table 3.1: GST-Fas-DD constructs, their corresponding PCR cloning primers and expression 
yields of pure protein per litre of bacterial culture grown in LB medium (as described in Section 
3.3.1).
GST-Fas-DD-K247A was therefore produced by site-directed m utagenesis using the 
pGEX-Fas-DD plasmid as the template and the mutagenic PCR prim ers 17 and 18. The 
expression yield o f GST-Fas-DD-K247A in BL21 Star cells was very sim ilar to GST- 
Fas-DD-D244A (-25  mg/L, see Table 3.1) and, as such, both o f  these proteins could be 
expressed, purified and concentrated as necessary for N M R spectroscopy at pH 6.2.
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Although the GST-Fas-DD-K247A construct was well expressed and highly soluble at 
the desired pH, this construct was not ideal for NM R studies o f  Fas-DD for several 
reasons. Firstly, its size makes it difficult to study by NMR. GST is an obligate 
homodimer (Lim et al., 1994) and hence, in solution, GST-Fas-DD-K247A has a 
molecular mass o f 76 kDa. Despite a series o f recent technological improvements 
proteins larger than ~50 kDa are refractory to the application o f  m any o f  the standard 
triple resonance NMR pulse schemes (Kay, 2001). Also, and probably more 
importantly, the fact that this protein has a point mutation means there was a chance that 
it would not interact with FADD-DD in the same manner as w ild-type Fas-DD. These 
issues meant that whilst the K247A mutant was being fully analysed by methods 
including NMR, attempts to produce the wild-type Fas-DD dom ain in a soluble form 
were continued.
3.3.2.3 Gbl-tagged Fas-DD
The problems presented by the use o f GST as the fusion partner for Fas-DD were 
eventually overcome by the utilisation o f a different fusion protein construct. There are 
many fusion partners that are available for protein expression in E. coli (Davis et al., 
1999) but it has turned out that the most appropriate choice in the case o f  wild-type Fas- 
DD was the B1 domain o f protein G (G bl). G bl is an excellent fusion partner for the 
production o f fusion proteins for NMR studies because, as well as potentially enhancing 
expression levels and solubility o f the target protein, it is monom eric in solution and has 
a molecular mass o f only 6 kDa (Zhou et al., 2001). It is w orthy o f  note that this fusion 
partner has been used successfully with another member o f the death fold protein family 
-  the solution structure o f the NALP1 PYRIN domain was solved using NM R 
spectroscopy as an intact Gbl fusion protein (Hiller et al., 2003).
A modified form o f the pET30a vector that expresses the G bl dom ain as an N-terminal 
tag was a provided by Professor Gerhard Wagner o f the Harvard M edical School (see 
Appendix 4). DNA encoding Fas-DD was sub-cloned into the single B am H I site in this 
vector to create the plasmid pETGbl-Fas-DD. This plasmid was used as the tem plate in 
two separate site-directed mutagenesis reactions to create two further plasm ids encoding 
point mutant forms o f Fas-DD, pETGbl-Fas-DD-D244A and pETG bl-Fas-D D -K 247A .
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These three plasmids were subsequently used to express wild-type and m utant G bl-Fas- 
DD fusion proteins in BL21 Star cells.
As well as the addition o f an N-terminal Gbl tag, expression o f  protein from the 
pETGbl-Fas-DD vectors results in the addition o f  a C-terminal polyhistidine tag to 
allow the target proteins to be purified using Ni (II) IMAC. All three G bl-Fas-D D  
proteins, importantly including the wild type Fas death domain fusion, were solubly 
expressed at high levels -  the yield o f all three o f these proteins was approxim ately 40 
mg/L -  and successfully purified using IMAC and SEC. It was found that the pure wild- 
type G bl-Fas-DD  protein was soluble up to 0.7 mM and the two Fas-DD mutants were 
soluble to at least 1.5 mM in a pH 6.2 phosphate buffer. An exam ple o f  the two-stage 
purification o f wild type G bl-Fas-DD  is shown in Figure 3.6.
The rationalisation o f  the success o f this G bl-fusion expression strategy remains 
unclear. Presumably the G bl fusion partner suppresses the self-aggregation properties 
of Fas-DD allowing a high level o f soluble protein expression. Quite why this is the 
case remains a mystery.
3.3.3 Protein expression summary
The reproducible expression o f His-FADD-DD was well established giving a high level 
o f soluble protein as expressed in E. coli BL21 Star cells. This protein is soluble up to at 
least 2.5 mM in the pH 6.2 phosphate buffer in which the solution N M R structure was 
solved (Berglund et al., 2000).
Previously it had not been possible to express Fas-DD in a soluble form such that it was 
suitable for NMR spectroscopy at physiological pH. In the process o f  trying to solve 
this problem two separate solutions were discovered. First, it was established that 
expression o f wild-type Fas-DD as a G bl-Fas-DD  fusion protein enhances its 
expression level and promotes its solubility in the optimal FADD -DD  N M R buffer. 
Second, it was found that the self-aggregation properties o f Fas-DD  could be overcome 
by mutation o f certain charged residues on the protein’s surface.
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Both the K247A and D244A mutations, when made as either GST or G bl fusion 
proteins, are well expressed and highly soluble. Interestingly, these mutations have 
similar effects on the expression and solubility characteristics o f  Fas-DD even though 
they remove oppositely charged residues from surface o f the protein -  the K247A 
substitution removes a positively charged amino group and the D244A substitution a 
negatively charged carboxylate group. It is therefore possible that both residues are 
implicated in the self-aggregation o f this death domain.
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Figure 3.6: Gbl-Fas-DD purification
Both the IMAC purification (a) -  utilising this protein’s C-terminal polyhistidine tag -  and 
the SEC purification (b) stages are shown as analysed by SDS page.
Key: Mw -  molecular weight markers. P -  pellet, SN -  supernatant, FT -  flow through, W 
-  wash, E -  elution.
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The combination o f these highly soluble protein constructs allowed the detailed study o f 
the Fas-DD/FADD-DD interaction using NMR spectroscopy -  the subject o f  the next 
section. Fas-DD has been engineered in such a way that for first time it can be 
expressed as a wild-type domain that is stable as a monomer at physiological pFf The 
GST-Fas-DD-K247A construct allows us to observe whether there is any impact o f the 
effective dimerisation o f Fas-DD on the interaction with FADD-DD. Finally, the Fas- 
DD-D244A mutant is an excellent negative control for FADD-DD binding experiments 
as it has been shown to dramatically knock down the FADD-DD binding activity o f  
Fas-DD.
3.4 NMR studies of Fas-DD/FADD-DD interactions
The next section o f this chapter will cover the use o f NM R spectroscopy as applied to 
the study Fas-DD and FADD-DD in solution.
3.4.1 NMR as a tool for studying protein/protein interactions
High resolution solution state NMR spectroscopy is a highly versatile m eans to measure 
analytes (in the most general sense) and to probe the structure and dynamics o f 
molecules, notably in broad fields o f organic and synthetic chem istry and m ore recently 
molecular and structural biology. NMR spectroscopy is most usefully applied to the 
investigation o f nuclei with magnetic spin quantum number Vi (so-called spin-half 
nuclei) and results from the fact that these nuclei, when placed in a magnetic field 
interact productively with high power radiofrequency (RF) radiation to provide highly 
resolved ID spectra with sharp signals. Each line in the spectrum (or resonance) may 
originate from a single nucleus. The frequency (chemical shift), linewidth and nuclear 
relaxation rates o f each resonance may reveal some aspect o f  the physical state o f  the 
target molecule. In proteins, the only spin-half nuclei o f reasonable natural abundance is 
the ]H proton (-100% ); 13C carbon is present at about 1.1% but this is presently not so
useful. ID ]H spectra o f proteins can have sharp lines (particularly for small proteins),
but are more often than not highly overlapped, m aking analysis less than 
straightforward. Partly inspired by this difficulty, as well as by the extraordinarily rich
physics o f interacting spin-half nuclei, NMR spectroscopists have invested a great deal 
of effort in the development o f multi-dimensional NM R spectroscopy that provides 
information concerning the connectivities embedded within networks o f  spin-half 
nuclei, or ‘spin systems’. This field o f research is necessarily large and intrinsically 
complex and, as such a full theoretical description o f this technique is beyond the scope 
of this thesis. However, the following provides a cursory description o f  the particular 
NMR method used routinely in this work, namely 2D [^N -'H J-H SQ C  spectroscopy.
3.4.2 Heteronuclear single quantum coherence (HSQC) spectroscopy
In general, multi-dimensional NMR spectroscopy o f macromolecules provides spectral 
information in the form o f chemical shift correlations, or cross-peaks, that connect 
resonances either because the corresponding nuclei are coupled ‘through bonds’ (i.e. via 
scalar couplings) or ‘through space’ (i.e. through dipole-dipole interactions). Here the 
discussion is only concerned with the former type o f nuclear coupling. For unlabelled 
proteins, observable scalar couplings between protons are typically o f  the order o f  <18 
Hz, and the correlated spectroscopy -  COSY-type spectra that exploit these connections 
are rather insensitive and tend to be highly overlapped. W hilst m uch can be 
accomplished using two-dimensional homonuclear JH spectroscopy, particularly for 
very small proteins, the majority o f multi-dimensional NM R experim ents in common 
use today exploit 15N and/or 13C-isotope labelling because o f  the relatively large one- 
bond scalar couplings (typically > 40Hz). The larger scalar couplings that can then be 
exploited in heteronuclear experiments provide for relative high sensitivity, and the fact 
the spectra produced have non-identical frequency axes, which dram atically reduces 
spectral complexity.
One heteronuclear NMR experiment in particular has come to be particularly useful for 
the characterisation and monitoring o f the chemical state o f protein molecules: the 15N, 
'H-COSY experiment, which is most often referred to as [^N -'H ]-heteronuclear single 
quantum coherence (HSQC) spectroscopy. In the pulse sequence w hich delivers the 
HSQC spectrum (illustrated in highly schematic form in Figure 3.7), !H nuclear 
polarisation is first transferred from the NH proton onto the N H  n itrogen-15 atom 
(providing for an increase in sensitivity for the low gyromagnetic ratio nucleus). At the 
end o f this so-called INEPT transfer, the magnetisation com ponents on the 15N  atom are
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in antiphase with respect to the attached proton. A period o f  free precession (ti) allows 
this “coherence” to be labelled with the resonance frequency (chemical shift) o f  the 15N- 
atom and then combined 90 degree RF pulses applied to both N and NH atoms convert 
this magnetisation into antiphase magnetisation o f the NH proton. Following a period 
for refocusing o f this 'H  magnetisation into an in-phase transverse magnetisation, the 
signal is detected (as a function o f time t2) whilst the 15N atoms are decoupled using a 
train o f low power 15N pulse. The signal recorded for each NH group is a collapsed 
doublet (singlet) with the 15N-*H coupling removed.
A full description o f  the theory and practice o f pulse sequence design is rather beyond 
the scope o f this thesis. However, it is important to note that the 2D Fourier 
transformation o f the dataset provided by the HQSC pulse sequence provides a 2D 
spectrum that correlates each 15N nucleus to its attached proton(s). Therefore the [15N- 
]H]-HSQC spectrum o f a typical protein contains only slightly m ore signals than the 
number o f amino acid residues -  one signal for each backbone amide NH group, and 
several more corresponding to side chain NeH (Arg, Trp) and N H 2 (Asn, Gin, Arg) 
groups. Experience shows that the dispersion o f chemical shifts in this type o f  spectrum 
is characteristic for the folding status o f the protein. M oreover the spectrum provides an 
extremely convenient way to monitor the effects o f external perturbations to the protein, 
e.g. the addition o f binding partners, or a change in the buffer or tem perature conditions. 
Because the chemical shift o f both the NH group 15N and *H atoms is sensitive to the 
local chemical environment, changes to these parameters are interpreted to indicate that 
the NH is close to the site o f interaction with the ligand, or point to a local change in the 
protein conformation in each o f these circumstances. To that end the [^N -'H J-H SQ C  
spectrum is referred to as providing a snapshot ‘fingerprint’ for the protein. This is now 
the NMR experiment o f choice for monitoring the binding and conform ational state o f 
the target protein in a number o f experimental situations. Here 15N isotope labelling and 
[^N -'H j-H SQ C spectroscopy has been used to monitor the interaction o f  the Fas and 
FADD death domains, as well as the folding o f various m utant forms o f  the Fas-DD 
protein.
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Figure 3.7: The ['H-l5N]-HSQC experiment, a) Shows a highly simplistic representation 
of the coherence transfers utilised in this experiment where the red line corresponds to the 
“path” of coherence as it is transferred from 'H nuclei to l5N nuclei and back before being 
detected, tj is the time delay that is varied to produce a two dimensional data set. b) 
Shows the theoretical effect of this experiment on a fully l5N-labelled polypeptide chain. 
A signal is produced from each amide group in the chain and where these groups lie in 
different chemical environments (as is the case for a fully folded protein domain) each 
generated signal will have a different chemical shift value. An example o f a [1H-l5N]- 
HSQC spectrum of a fully l5N-labelled sample of His-FADD-DD is shown in (c).
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3.4.3 NMR studies of FADD-DD
15N-labelled His-FADD-DD (15N-FADD-DD) was expressed from the pET-FADD-DD 
vector in E. coli BL21 Star cells grown in minimal media containing 15N H4C1 as the 
sole nitrogen source (described in Section 2.3.2.1). This protein was purified in the 
same manner as unlabelled His-FADD-DD. The resultant sample o f  pure protein was 
concentrated to approximately 2 mM and, following the addition o f  10% v/v D20 , used 
for NMR experiments. The addition o f 10% D20  is a requirement for N M R samples to 
provide a reference signal for the spectrometer field-frequency lock system.
Figure 3.7c shows a ['H -^N j-H SQ C  spectrum recorded for a 2 m M  sample o f 15N- 
FADD-DD at 25°C and at 600 MHz 'H  frequency. The num ber o f  cross peaks 
(approximately 120) and the pattern o f chemical shifts are exactly as reported by 
Bergland et al. 2000. The cross peaks in this spectrum are well resolved and well 
dispersed over a wide range o f chemical shifts as expected o f  a pure, fully folded 
sample o f a protein o f this size.
3.4.4 NMR titrations with 1SN labelled FADD-DD
One o f the most common ways to study protein-protein interactions by N M R is to titrate 
a sample o f one unlabelled binding partner into an isotope-labelled sample o f  the other. 
By following this titration by HSQC spectroscopy it is possible to selectively track the 
effects o f the addition o f the first protein upon individual residues o f  the second, 
labelled protein through analysis o f any changes in the chemical shifts and intensities o f 
individual cross peak signals o f the isotope-labelled component o f  the mixture. This 
technique, known as “chemical shift mapping” can be a very powerful tool for, for 
example, determining the individual amino-acid residues that are involved in a specific 
protein-protein interaction. In particular, perturbations in the chem ical shifts are 
presumed to occur when the chemical environment o f the nucleus in question is altered, 
reflecting a change in the immediate nature and arrangement o f  the atoms in the 
vicinity. Where these effects are o f sufficient magnitude, they are often interpreted as 
defining the scope o f  the binding surface (van Nuland et al., 1993; Zuiderweg, 2002).
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One limitation o f this approach is that, in order to extract the greatest amount o f 
information possible from such experiments, knowledge is required o f  which cross peak 
in the HSQC spectrum corresponds to which individual amino-acid residue in the 
protein’s primary structure. Generally, the assignment o f these cross peaks to their 
corresponding residues can only be reliably accomplished by the recording and analysis 
of a set o f three-dimensional heteronuclear NMR experiments. However, since the full 
three-dimensional structure o f FADD-DD had been solved in the same laboratory a full 
set o f resonance assignments o f the FADD-DD spectrum were already available for this 
project. Hence, titrations o f G bl-Fas-DD or GST-Fas-DD-K247A into a sample o f 15N- 
FADD-DD were carried out in order to probe the Fas-DD/FADD-DD interaction.
3.4.4.1 15N-FADD-DD/ Gbl-Fas-DD titrations
An unlabelled sample o f Gbl-Fas-DD  was prepared and concentrated to 0.7 mM. 
Although the ideal concentration for an NMR protein sample is above 1 mM, in practice 
this is often unachievable. The G bl-Fas-DD sample, for example, began to precipitate 
at concentrations higher than 0.75 mM. This unlabelled protein sample was used in a 
titration with a sample o f 15N-FADD-DD.
When carrying out any titration it is essential to avoid any dilution effects that can occur 
from the addition the two samples. This dilution effect can often be overcome, 
especially when titrating small molecules, by using a stock solution o f  one component 
o f the titration at a much higher concentration than is required in the final mixture. 
When added to the larger volume o f the first component, the small incremental volume 
associated with the addition o f the highly concentrated sample can be considered 
insignificant. This approach, however, breaks down when the two samples to be titrated 
are limited by their maximum concentration -  as is often the case when studying 
proteins by NMR. For example, the addition a 0.7 mM sample o f  G bl-Fas-D D  to a 1 
mM sample o f  15N-FADD-DD would lead to a two-and-a-half-fold volum e change by 
the time stoichiometric equivalence (a 1:1 molar ratio) is reached.
In order to avoid this problem, an alternative titration strategy was used. Here, two 600 
pi NMR samples were initially produced, one containing 0.5 m M  15N-FADD-DD 
(sample A) and one containing 0.5 mM 15N-FADD-DD mixed w ith 0.5 m M  G bl-Fas- 
DD (sample B). These two samples effectively correspond to the start (A) and end (B)
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points o f the required titration. HSQC spectra were recorded for both samples, A and B, 
using exactly the same NMR parameters. Then, by simultaneously swapping a small 
volume aliquot out o f sample A and adding it to sample B, and vice versa, and recording 
spectra for these new mixtures, two more points in the titration could be recorded. By 
repeating this series o f swapping volume aliquots between the A and B samples and 
recording HSQC spectra a whole titration series can be filled in.
Figure 3.8 shows the titration o f Gbl-Fas-DD into 15N-FADD-DD. Here, the initial 15N- 
FADD-DD HSQC is the same as the spectrum shown in Figure 3.7c and corresponds to 
the pure FADD-DD protein. However, as increasing amounts o f  G bl-Fas-D D  were 
added to the 15N-FADD-DD sample it was observed that the m ajority o f  the 15N-FADD- 
DD cross peaks exhibited a fall in intensity. As one molar equivalence is reached the 
majority o f the 15N-FADD-DD cross peaks are no longer visible. The positions o f few 
remaining cross peaks in the spectrum were compared to the available FADD-DD 
resonance assignments (Berglund et al., 2000). All such rem aining cross peaks were 
found to correspond to residues from the flexible N- and C- termini o f  FADD-DD.
In order to quantitatively analyse the results from the Fas-DD/FADD-DD titration the 
ANSIG software package (Helgstrand et al., 2000) was used to extract peak intensity 
values from each o f  the HSQC spectra recorded at different titration points. All cross 
peaks from the initial 15N-FADD-DD spectrum were selected and their intensities 
determined as a function o f the relative concentration o f G bl-Fas-D D . Figure 3.8b 
shows the mean peak intensity values from these spectra, relative to the initial spectrum 
of pure 15N-FADD-DD, plotted against the molar ratio o f G bl-Fas-D D  to 1 ^ -F A D D - 
DD. It can be seen from this graph that there is a monotonic loss o f  signal from the 15N- 
FADD-DD protein upon titration o f Gbl-Fas-DD. It would appear from the graph in 
Figure 3.8b that the 15N-FADD-DD signals decay essentially to zero at a concentration 
o f Gbl-Fas-DD  that is less than the FADD-DD concentration.
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Figure 3.8: NMR titration of Gbl-Fas-DD into ,5N-FADD-DD. a) HSQC spectra of 15N- 
FADD-DD following the addition of increasing concentrations of unlabelled Gbl-Fas- 
DD. b) A graph of mean cross peak intensities from HSQC spectra recorded during the 
titration. Values are calculated relative to the mean intensity of the peaks from the initial 
15N-FADD-DD spectrum.
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However, due to the nature o f  the NM R experiments, the point at w hich the signal 
intensity reaches equilibrium is not properly accessible (as there are some signal losses 
caused by relaxation processes during the pulse sequence). Also the protein 
concentration measurements here are necessarily approxim ate and hence it is difficult to 
be precise about the stoichiometry o f the binding reaction.
Whilst this outcome does not reveal a situation in which the chem ical shift o f a subset 
group o f  FADD-DD cross peaks are selectively perturbed by the presence o f  the G b l- 
Fas-DD protein, in the paradigm o f  a “chemical shift m apping” exercise the fact that the 
FADD-DD spectrum is globally diminished in intensity does indicated that the G b l- 
Fas-DD protein does im pact the behaviour o f the FADD-DD protein in solution. It can 
therefore be concluded that FADD-DD and G bl-Fas-D D  do, by some means or other 
interact in vitro.
In order to establish w hether this result was due to the interaction betw een the two death 
domains or if  the observations were due to an artefact o f the experiment, for example an 
interaction between FADD-DD and the G bl domain o f the G bl-Fas-D D  protein, a 
titration was carried out using the G bl-Fas-D D -D244A  mutant in place o f  the wild type 
G bl-Fas-DD  protein. This mutation was previously shown to knock out the interaction 
with FADD-DD in the yeast two-hybrid assay and was readily expressed and purified 
for NMR experiments. Figures 3.9a, b and e show the titration o f  unlabelled G bl-Fas- 
DD-D244A with 15N-FADD-DD. In dramatic contrast to the behaviour o f  the wild-type 
protein, it can be seen from this data that the addition o f G bl-Fas-D D -D 244A  had 
essentially no effect on the spectrum o f 15N-FADD-DD.
A titration o f G bl-Fas-D D -K 247A  into 15N-FADD-DD was also carried out in order to 
establish the effect o f  this particular mutation on the behaviour o f  Fas-DD. The results 
from this titration are presented in Figure 3.9c, d and e and indicate that the G bl-Fas- 
DD-K247A protein behaves, in this assay, in a very similar m anner to the wild-type 
G bl-Fas-DD  protein.
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Figure 3.9: NMR titrations of Gbl-Fas-DD constructs into 15N-FADD-DD. HSQC 
spectra of a) and c) FADD-DD alone and with a 1:1 molar ratio of unlabelled b) G bl- 
Fas-DD-K247A and d) Gbl-Fas-DD-D244A. The full titration data are summarised in 
graph e).
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These results provide good evidence that there is a specific interaction between the two 
wild-type death domains o f Fas and FADD that results in the loss o f  intensity o f the 
majority o f the FADD-DD cross peaks. Moreover, this behaviour is insensitive to the 
mutation o f Lys 247 to Ala in Fas-DD, but can be abrogated by the “knockout 
mutation” Asp 244 to Ala.
3.4.4.2 15N-FADD-DD/GST-Fas-DD titrations
Since the experiments with the G bl-Fas-DD  constructs had established that, in terms o f 
its FADD-DD interaction properties, the K247A mutant behaved in an essentially 
equivalent manner to the wild-type Fas-DD, and that wild-type GST-Fas-DD protein 
was intractable in terms o f production yield and solubility for N M R studies, a titration 
was carried out between GST-Fas-DD-K247A and 15N-FADD-DD in order to test the 
effect o f dimerisation on the interaction between Fas-DD and FADD-DD.
The GST-Fas-DD-K247A protein could only be concentrated to a m axim um  o f 0.5 mM 
so this experiment did not exactly mimic the G bl-Fas-D D  titration: the final 
concentrations o f GST-Fas-DD-K247A and 15N-FADD-DD in the titration endpoint 
sample were each 0.3 mM. However, as can be seen from Figures 3.10a, b and e, the 
result o f this experiment was, again, a monotonic loss o f  the 15N-FADD-DD signals 
upon addition o f the GST-Fas-DD-K247A construct. Again, as a negative control, a 
titration was carried out with the equivalent D244A construct (GST-Fas-DD-D244A) 
and no effect was seen on the 15N-FADD-DD spectrum (see Figures 3.10c, d and e).
These experiments have established that the production o f  Fas-DD either as a 
monomeric G bl fusion or as a dimeric GST fusion results in sim ilar outcom e in terms 
o f the characteristic response encoded in the 15N-HSQC spectrum o f  FADD-DD. The 
fact that essentially identical sets o f results were obtained for the wild-type, and K247A 
and D244A mutants is a strong suggestion that the fusion partner to Fas-DD (G bl or 
GST) does not play a significant role in the interaction between FAD D-DD and the Fas- 
DD proteins.
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Figure 3.10: NMR Titrations of GST-Fas-DD constructs into 15N-FADD-DD. HSQC 
spectra of a) and c) FADD-DD alone and with a 1:1 molar ratio of unlabelled b) GST-Fas- 
DD-K247A and d) GST-Fas-DD-D244A. The full titration data are summarised in graph e).
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3.4.5 NMR studies of Fas-DD
Thus far the interaction between Fas-DD and FADD-DD proteins has been monitored 
by observation o f the [1H -15N]-HSQC of the isotope-labelled FADD-DD protein. 
Carrying out similar NMR titrations but swapping the 15N -labelling to the Fas-DD 
component would probe the behaviour o f the Fas-DD fusion proteins in these titrations 
and would allow for further NMR studies o f the death domain o f Fas itself. Therefore 
15N-labelled samples o f G bl-Fas-DD, Gbl-Fas-DD-D244A  and GST-Fas-DD-K247A 
were expressed and purified. The Gbl-Fas-DD  fusion proteins gave very similar yields 
when expressed in minimal media compared to their expression in the rich LB media 
used for unlabelled expression. However, as is more often the case with the expression 
o f isotope-labelled proteins, GST-Fas-DD-K247A expressed at a lower level than in LB 
(giving approximately half the yield o f the corresponding unlabelled preparation) -  
although this expression level still allowed us to obtain a suitable quantity for NM R 
studies.
The two dimensional ['H -^N l-H SQ C  spectra o f G bl-Fas-D D , G bl-Fas-D D -D 244A  
and GST-Fas-DD-K247A are shown in Figure 3.11. There are several points to note 
about these spectra:
Firstly, the spectra o f G bl-Fas-D D  and Gbl-Fas-DD -D 244A  are almost identical. The 
similarity o f these two spectra indicates that the D244A substitution does not disrupt the 
structure o f the Fas-DD. The vast majority o f the cross peaks in both spectra have 
essentially the same chemical shift values, implying that the amino-acid residues must 
be in essentially the same chemical environments and hence the m utation has had little 
or no effect on the overall fold and structure o f the protein. This observation 
substantiates the presumption that the effect o f the D244A m utation on the interaction 
o f Fas-DD with FADD-DD is a consequence solely o f a local change in the protein- 
protein interface and not a result o f a “structural” disruption o f the Fas-DD fold.
The outstanding feature o f the 15N-GST-Fas-DD-K247A HSQC spectrum  is that only 
approximately 120 cross peaks are observed. The GST component o f  the fusion protein 
has 218 residues and Fas-DD 105 residues so, naively, the expected num ber o f cross 
peaks in this spectrum is o f the order o f 320. It was initially assum ed that the cross
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peaks in this spectrum corresponded only to signals from Fas-DD residues and this idea 
was subsequently confirmed by the superposition o f 15N-GST-Fas-D D-K 247A  and 15N- 
Gbl-Fas-DD spectra (see Figure 3.1 Id). The vast majority o f  the cross peaks from the 
15N-GST-Fas-DD-K247A spectra precisely align with cross peaks in the 15N -G bl-Fas- 
DD spectrum. This overlap would only occur if  both o f these sets o f  cross peaks were 
from the same folded protein domain in the fusion -  in this case Fas-DD. The fact that 
few signals from the GST protein are observed is an interesting phenom enon which can 
be explained by the modular composition and hydrodynamic properties o f  the GST-Fas- 
DD fusion protein. W hen expressing a protein from the pGEX-2T vector a flexible, 
protease cleavable, eight-residue linker between GST and the target protein is encoded. 
This linker does not appear to affect the ability o f GST to enhance the solubility o f  the 
fusion partner. However, apparently it does allow the two individual domains o f  the 
whole fusion protein to behave independently in a hydrodynamic sense. There is 
presumably a low activation barrier to conformational averaging o f  the backbone d>, 'F 
torsion angles in this linker region, permitting the Fas-DD dom ain to rotate essentially 
independently from the heavier GST. In terms o f NM R experiments, this free rotation 
means that the two domains will have the potential to display nuclear relaxation 
parameters.
Relaxation is the process by which nuclei return to their resting state after excitation. 
The relaxation rate o f a specific nucleus is key to the determination o f  the linewidth the 
associated NMR signal. In a compact protein domain m ost nuclei will have similar 
transverse relaxation rates that are determined by the overall rotational correlation time 
o f that domain. Generally, smaller proteins (or protein domains) tum ble in solution with 
faster correlation times and hence their transverse nuclear relaxation rates are slower 
than those o f larger proteins. Slower relaxation rates lead to more N M R resonances with 
narrower linewidths and greater intensities in multidimensional heteronuclear NM R 
spectra.
In the case o f the GST-Fas-DD-K247A molecule, therefore, it seems that the dimeric, 
54 kDa GST moiety tumbles sufficiently slowly such that the HSQC experim ent is not 
sensitive enough to detect it under the conditions o f  the experim ents recorded in this 
study (i.e. at 25°C and 600 MHz *H frequency). The Fas-DD dom ain, however, is
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behaving like an essentially independent, fast rotating, monom eric 12 kDa moiety that 
gives rise to typically narrow lines and relatively intense HSQC cross peaks.
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Figure 3.11: 2D HSQC spectra of 15N-labelled Fas-DD constructs. Spectra of 15N-Gbl- 
Fas-DD, 15N-Gbl-Fas-DD-D244A and 15N-GST-Fas-DD-K247A are shown in (a), (b) and 
(c) respectively, d) shows a superposition of spectrum (c) in blue on spectrum (a) in black.
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This transverse relaxation “contrast” phenomenon is also observed with the G bl-Fas- 
1 > sitsion proteins. Here, the G bl moiety is again linked to Fas-DD through a flexible 
peptide linker allowing the two domains to rotate in solution effectively independently. 
In this case, however, because the Gbl domain is smaller than the Fas-DD moiety (6 
kDa compare I '2  kDa), signals from the Gbl residues are detected and indeed have 
narrower line-widths and greater intensities than those from the Fas-DD domain.
3.4.5.1 Titrations with ,SN-Fas-DD constructs
A titration o f unlabelled FADD-DD into l3N -Gbl-Fas-D D  is presented in Figures 3.12a, 
b and e. The results demonstrate that there is a monotonic loss o f  signal intensity from 
the cross peaks that correspond to Fas-DD residues within the fusion protein. Addition 
of FADD-DD to 15N~Gbl~Fas~DD~D244A is shown in Figure 3.12c, d and e, and, in 
this case, there is no reduction in signal intensities from the labelled protein.
Interestingly, it can be seen from Figure 3.12b that the cross peaks from the G bl 
domain o f the 15N -Gbl-Fas-D D fusion protein remained unaffected by the addition o f 
I'ADD-DD even whilst the Fas-DD signals were being dim inished in strength. The Fas- 
DD cross peaks were identified by overlapping the GST-Fas-DD-K247A and G bl-Fas- 
DD spectra (see Figure 3.1 Id) and selecting only those cross peaks from G bl-Fas-D D  
that exactly matched cross peaks in the GST-Fas-DD-K247 spectrum. The remaining 
cross peaks were identified as signals from Gbl domain residues and all these signals 
remained invariable upon addition o f FADD-DD suggesting that the G bl m oiety is not 
involved in the observed interaction between Fas-DD and FADD-DD.
Figure 3.13 illustrates this point by showing the superposed spectra o f  !>N -G bl-Fas- 
DD, 15N-Gbl-Fas-DD with FADD-DD, and 15N-GST-Fas-DD-K247A. This figure 
emphasises the presence o f two distinct sets o f cross peaks in the 15N -G bl -Fas-DD 
spectrum, one set corresponding to Gbl residues (that remain visible upon addition o f 
FADD-DD), and a second set corresponding to Fas-DD residues (that overlap with the 
signals from 15N-GST-Fas-DD-K247A and are lost upon addition o f  FADD-DD).
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Figure 3.12: NMR titrations of FADD-DD into different forms of 15N-Gbl-Fas-DD. HSQC 
spectra of a) Gbl-Fas-DD alone and b) with a 1:1 molar ratio of unlabelled FADD-DD. 
Spectra of (c) Gbl-Fas-DD-D244A alone and d) with a 1:1 molar ratio of unlabelled 
FADD-DD. The full titration data are summarised in graph (e).
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Once the Fas-DD cross peaks had been specifically identified, the graph shown in 
Figure 3.12e was produced as an analysis o f the intensity o f  the Fas-DD residues in the 
15N-Gbl-Fas-DD spectrum during the titration with FADD-DD. Direct comparison 
between this result and the 15N-FADD-DD/Gbl-Fas-DD titration in Figure 3.8b shows 
great similarity between these two sets o f data indicating the com plem entarity o f these 
experiments and highlighting the overall similarity o f the nature o f  the perturbations to 
the Fas-DD and FADD-DD NMR spectra upon complexation.
Due to the expression difficulties with 15N-GST-Fas-DD-K247A insufficient protein 
could be produced to carry out a full NM R titration. However, as shown in Figure 3.14, 
when unlabelled FADD-DD was added, in an equimolar concentration, to a sample o f 
this protein, most o f the signals are lost from the HSQC spectrum. This result indicates 
the observation o f a general effect similar to that seen when unlabelled GST-Fas-DD- 
K247A was titrated into 15N-FADD-DD. Once again, this highlights the common 
outcome o f these experiments and indicates that the K247A m utant has a very similar 
behaviour in solution to wild-type Fas-DD in terms o f its FADD-DD interaction 
properties.
3.4.6 Ionic strength dependence of Fas-DD/FADD interaction
Since the interaction between Fas-DD and FADD-DD can be disrupted by the removal 
o f a single charge from the surface o f Fas-DD -  as seen with the attempts to observe an 
interaction between FADD-DD and the point mutant Fas-DD-D244A -  it was 
postulated that this interaction may be dominated by electrostatic forces between 
specific charged residues on the surfaces o f each domain. This hypothesis is reinforced 
by the results o f  an experiment by (Bang et al., 2000) who showed, using surface 
plasmon resonance techniques, that an interaction between hum an Fas-DD and the full- 
length, murine FADD protein could be disrupted by increasing salt concentrations in the 
buffer. In order to discover whether the same effect could be seen in our N M R 
experiments, a titration with NaCl was carried out
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Figure 3.13: Superposition of 2D ['H-15N]-HSQC spectra of 15N-Gbl-Fas-DD, 15N- 
GST-Fas-DD-K247A and 15N-GB1-Fas-DD+FADD-DD. a) HSQC spectrum of 15N- 
Gbl-Fas-DD alone, b) superimposed HSQC spectra of 15N-GST-Fas-DD-K247A and 
15N-GB1-Fas-DD+FADD-DD. If visualised in black and white the figure (b) is seen 
to be highly similar to spectrum in (a), allowing the identification of two sets of cross­
peaks in the [1H-15N]-HSQC spectrum, one set corresponding to signals from Gbl 
residues and the other to signals from Fas-DD residues. Note that coloured names 
correspond to the colour of the respective HSQC spectra.
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Figure 3.13 continued: c) Superposition of HSQC spectra of 15N-Gbl-Fas-DD and 15N- 
GST-Fas-DD-K247A. All of the cross peaks from the GST-Fas-DD-K247A spectrum 
essentially overlap with cross peaks from the Gbl-Fas-DD spectrum highlighting the 
lack of signals from the GST moiety in the GST-Fas-DD spectrum as well allowing the 
identification of Fas-DD cross peaks in the Gbl-Fas-DD spectrum. Moreover this 
figure indicates that the K247A mutant does not disrupt the Fas-DD structure. A 
superposition of HSQC spectra of 15N-Gbl-Fas-DD and 15N-GB1-Fas-DD+FADD-DD 
is shown in (d). This figure highlights the loss of Fas-DD signals upon addition of 
FADD-DD to Gbl-Fas-DD and that the chemical shifts of the Gbl signals are 
unperturbed, indicating that the Gbl moiety is not involved in the DD/DD interaction.
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Figure 3.13 continued: e) superimposed HSQC spectra of 15N-Gbl-Fas-DD, 15N-GST- 
Fas-DD-K247A and ,5N-GB1-Fas-DD+FADD-DD. Essentially all cross peaks from the 
Gbl-Fas-DD spectrum overlap with cross peaks from either the GST-Fas-DD-K247A or 
the GBl-Fas-DD+FADD-DD spectrum allowing straightforward identification of signals 
corresponding to either Fas-DD or Gbl residues.
Here, two equimolar mixtures o f GST-Fas-DD-K247A and l5N-FADD-DD was 
prepared, one in the same phosphate buffer as used previously (NM R buffer -  see 
Section 2.3.6), and one in NMR buffer containing 1M NaCl. These two samples were 
used to carry out an ionic strength titration using the same m ixing strategy as previously 
described. HSQC spectra were recorded, using a common set o f  NM R param eters, at 
each point in the titration in order to follow the effect o f the addition o f  N aCl to the Fas- 
DD/FADD-DD complex.
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Figure 3.14 Addition of FADD-DD to 15N-GST-Fas-DD-K247A. The spectrum of 15N- 
GST-Fas-DD-K247A (a) is notable for the general absence of cross peaks deriving from 
the GST moiety. A spectrum taken after addition of FADD-DD is shown in b).
The results o f the ionic strength titration can be seen in Figure 3.15. The HSQC 
spectrum from the FADD-DD/Fas-DD mixture at low salt concentration is essentially 
identical to that previously described, showing only about 10 cross peaks corresponding 
to the flexible, terminal residues o f FADD-DD. However, upon addition o f  NaCl, the 
remaining FADD-DD cross peaks were fully recovered. This result shows that the 
observed interaction between the two domains can be fully disrupted by an increase in 
the ionic strength o f the buffer and hence would appear to be dom inated by electrostatic 
interactions, presumably between the many charged residues on the surfaces o f  these 
two death domains.
It is worth noting that the chemical shift values o f the FADD-DD residue cross peaks 
changed slightly during the salt titration. This is because the addition o f  salt to the 
sample changes the chemical environment o f the amide groups in FADD-DD 
sufficiently to give a small but significant alteration in amide group chemical shifts. 
However these shift changes are unrelated to the interaction between the two domains.
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Figure 3.15 Ionic strength titration of the Fas-DD/FADD-DD complex. A 1:1 molar ratio 
mixture of ,5N-FADD-DD and GST-Fas-DD-K247A was titrated with NaCl from 100 
mM to 1 M. a) -  d) show spectra of several points from this titration indicating that as the 
salt concentration is increased signals from 15N-FADD-DD are recovered, suggesting 
disruption of the complex formed between these two proteins.
3.4.7 Analysis of the effect of pH on the Fas-DD/FADD-DD interaction
All the experiments described previously in this study were carried out at pH 6.2 using a 
buffer identical to that in the three dimensional structure determ ination o f  FADD-DD 
(Berglund et al., 2000). However, in order to test the physiological relevance o f the 
previous titration results, it was felt that the observations should be tested at 
physiological pH (=7.4). Two experiments were therefore carried out. In the first
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experiment a 1:1 mixture o f 0.5 mM 15N-FADD-DD and G bl-Fas-D D  in NM R buffer 
(pH 6.2) was prepared, titrated to pH 7.4 using 10 M NaOH and analysed by HSQC 
spectroscopy. In a separate experiment the pH o f two separate samples o f  ‘^ -F A D D - 
DD and Gbl-Fas-DD were individually titrated to pH 7.4 before being mixed and 
analysed.
It can be seen from the HSQC spectra in Figure 3.16 that changing the pH from 6.2 to
7.4 has little or no effect on the FADD-DD construct by itself or on the observed 
interaction with Fas-DD. As a control experiment 500 mM NaCl was added to a sample 
of a 15N-FADD-DD/Gbl-Fas-DD mixture at pH 7.4 to show that the interaction can still 
be disrupted at this pH and that the FADD-DD [15N-*H]'-spectrum is fully recoverable at 
high ionic strength (see Figure 3.16c).
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Figure 3.16 Studies of the FADD-DD/Gbl-Fas-DD complex at pH 7.4. HSQC spectra 
of: a) a sample of 15N-FADD-DD + Gbl-Fas-DD mixed in a 1:1 ratio and adjusted to 
pH7.4. b) Samples of 15N-FADD-DD and Gbl-Fas-DD separately adjusted to pH 7.4 
before being mixed together. Spectrum (c) shows an HSQC spectrum of sample (a) 
after addition of 500 mM NaCl.
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3.5 Conclusions from NMR titrations
To our knowledge this chapter has described the first time that N M R spectroscopy has 
been successfully used to study the interaction between the death dom ains o f  Fas and 
FADD. It has been shown how several different strategies were used to overcome the 
difficulties o f producing suitable quantities o f recombinant proteins that are sufficiently 
soluble for NMR studies. In particular, the production o f  Fas-DD was initially limited 
by its intrinsic self-aggregation properties. However it was found that by producing this 
domain as a G bl fusion protein or by mutating amino acid residues on its surface 
(specifically residues D244 and K247), the poor expression yields and, to some extent, 
the poor solubility o f Fas-DD could be overcome allowing N M R studies to be carried 
out at physiologically relevant pH values.
The outcome o f NMR-based titration experiments in which one o f  G bl-Fas-D D  or 
FADD-DD was titrated into a 15N-labelled sample o f the other protein indicated a direct 
interaction between these two domains. The result o f these titrations was a monotonic 
loss o f the NMR signals from the 15N-labelled death domain upon titration o f the 
unlabelled domain which is consistent with the formation o f a complex between the two 
death domains. It would appear, however, that the complex formed in these titrations 
has the hydrodynamic properties such that it is beyond the range that can be detected 
with NMR experiments.
There remains the possibility that line-broadening was observed during the death 
domain titration experiments due to chemical exchange between the bound and unbound 
state o f the individual labelled domain. It is possible that, if  such chem ical exchange 
was occurring at an intermediate rate, then the signal intensities o f  the labelled protein 
may have broadened to zero upon saturation with the unlabelled domain. This 
observation is also consistent with the selective nature o f the line-broadening observed 
in experiments with 15N-Gbl-Fas-DD, since only signals from regions o f  this protein 
involved in FADD-DD interaction would be expected to broaden upon interaction. 
However, if  intermediate exchange was occurring then, associated w ith this process, 
would be chemical shift changes o f those broadening signals. Since no chemical shift 
changes were observed in the titration experiments in ths study it is unlikely that 
exchange processes were responsible for the effects detected by these titrations.
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Curiously, mobile elements within the complex are still observed in the spectrum 
indicating that the interacting proteins remain in solution and that these elements retain 
a substantial degree o f rotational independence from the interacting death domains. 
Indeed, the solubility o f this complex was also shown indirectly by its disruption with 
increased ionic strength buffers which led to the recovery o f  signals from the labelled 
death domain component. Importantly, the observed interaction between Fas-DD and 
FADD-DD could be entirely disrupted by m utation o f  the Fas-DD aspartate 244 residue 
to alanine. These in vitro data obtained by NM R are consistent with both the results o f 
the yeast two-hybrid assay presented at the start o f  this chapter and the prior knowledge 
o f this residue as a mutational hotspot in the disease ALPS which is known to be caused 
by a disruption o f Fas-DD/FADD interactions. Also, the titration o f  FADD-DD into a 
15N-labelled sample o f G bl-Fas-DD  indicated that the interaction did not affect residues 
from the Gbl domain since the loss o f NM R signals was only observed from Fas-DD 
residue cross peaks. The nature o f this observed interaction, therefore, despite lacking 
in any real molecular detail at this stage, does appear to be highly specific.
Speculation as to the exact size o f the complex formed between Fas-DD and FADD-DD 
in this study is, at this stage, at best, tentative. The observation that the intensity o f  the 
majority o f cross peaks for the isotope-labelled death domain m onotonically diminish 
upon titration with the unlabelled death domain implies that, in all probability, the 
hydrodynamic radius o f the complex is in the order of, or greater than, other proteins 
that do not give rise to significant cross peak intensity under the conditions o f the NM R 
experiments used here. A lower limit for this size might be provided by the molecular 
weight o f the GST homodimer (58 kDa) which is essentially not visible in the spectra o f 
the 15N-GST-Fas-DD fusion proteins recorded in this study (for exam ple see Figure 
3.9d). Also, since the predicted size o f  a simple 1:1 FA D D -D D /G bl-Fas-D D  
heterodimer is lower than 35 kDa, it is reasonable to suggest that it w ould have been 
possible to record tractable NMR spectra o f  such a complex had it been formed. This 
prediction, combined with extensive experience o f  biom olecular N M R w ithin the local 
protein NM R community suggests that the complex is larger than 35 kD a indicating that 
a heterodimeric, low molecular weight complex is not formed.
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In an attempt to charaterise the exact size o f such a complex, several preliminary 
biophysical and biochemical measurements were made by a variety o f  techniques. 
Dynamic light scattering carried out on a complex between GST-Fas-DD-K247A and 
FADD-DD indicated that this species may be very much larger than 30 kDa and 
possibly in the megadalton range. Attempts to analyse this complex by analytical size 
exclusion chromatography proved to be unproductive since the protein mixture would 
not enter a size exclusion (S200) column -  although this data is, in itself, indicative o f a 
large complex further investigation must be carried for confirmation. Finally, chemical 
crosslinking with either gluteraldehyde (a non-specific protein crosslinking reagent) or 
1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (a homobifunctional 
amide-amide crosslinking reagent) was attempted using samples o f  FADD-DD and 
Gbl-Fas-DD. Using these reagents, however, it was not possible to specifically 
crosslink the two death domains to each other. Therefore, although some o f the data 
obtained in attempts to characterise the exact size o f  the Fas-DD/FADD-DD complex 
formed in solution is suggestive o f a large, mulitmeric complex (and, as such, is in 
disagreement with the suggestion that chemical exchange processes m ay be involved in 
the observations from the NMR titrations), such data is too prelim inary to present in this 
thesis and hence more work is required to establish the veracity o f  such indications.
The next chapter describes the extension o f the use o f  the Fas-DD/FADD-DD 
interaction assays developed in this section, to investigate the effects o f  a range o f Fas- 
DD mutations on FADD-DD binding.
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Chapter 4
Mutational analysis of the Fas death domain
4.1 Mutations in Fas-DD
HE focus o f Chapter four is on the mutational analysis o f  the Fas death domain
and the implications o f these mutations for Fas-DD/FADD-DD signalling. The 
aim o f the analysis presented in this chapter is to identify am ino-acid residues in Fas- 
DD that may be crucial in mediating Fas-DD/FADD-DD interactions. The identification 
o f these residues will help to further the understanding o f  the mechanism o f this 
interaction by providing insight into how the complex between these two domains is
The methods used in this chapter echo those described in Chapter 3. Since the yeast 
two-hybrid assay is capable o f screening a large number o f protein/protein interactions 
in parallel and in a cellular context, it was used here to test m any m utant forms o f  Fas- 
DD simultaneously for their ability to bind FADD-DD. N M R spectroscopy then 
provides an attractive means to further analyse these mutants and the death domain 
interactions in vitro.
formed.
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4.1.1 Previous reports of mutational analysis of Fas-DD
There have been several previous studies o f mutations o f FasL, Fas and FADD; this is 
unsurprising since mutations in the Fas signalling pathway lead to the onset o f  the 
autoimmune disease ALPS, as discussed in Chapter 1. The symptoms o f ALPS type la  
are attributed to failure o f the FasL-induced apoptotic signalling pathways specifically 
resulting from mutations in Fas. Interestingly, it has been observed that the death 
domain o f Fas is particularly disposed to mutation since more patients presenting with 
the symptoms o f ALPS have mutations in the death domain than in any other region o f 
Fas (Martin et a l ,  1999). Such Fas-DD mutations apparently lead to a disruption o f  the 
Fas/FADD interaction and abrogate Fas-induced apoptosis leading to the ALPS 
phenotype (Vaishnaw et al., 1999).
The strong link between Fas and disease allows the acquisition o f  data on Fas-DD 
mutations from both clinical (Fisher et al., 1995; Bettinardi et al., 1997; Sneller et al., 
1997; Jackson et al., 1999; Martin et al., 1999; Rieux-Laucat et al., 1999; Vaishnaw et 
al., 1999; Peters et al., 1999; Siegel et al., 2000; Straus et al., 2001; van den Berg et al., 
2002; Rieux-Laucat et al., 2003b) as well as biochemical studies (Huang et al., 1996; 
Eberstadt et al., 1997)). Table 4.1 outlines the known naturally occurring and artificially 
engineered Fas-DD mutations and their effects. Since this study is solely interested in 
finding individual amino-acid residues that affect FADD binding, only missense 
mutations are listed (i.e. nonsense, deletion and insertion m utants are not directly 
relevant to this study and are not included in Table 4.1).
Missense mutations in Fas-DD have also been found in examples o f other conditions 
such as non-Hodgkin’s lymphoma (Gronbaek et al., 1998), gastric cancer (Park et al., 
2001), non-small cell lung cancer (Lee et al., 1999) and squamous cell carcinoma (Lee 
et al., 2000). However the role o f Fas mutations in these diseases remains unclear and 
hence, unlike many o f the ALPS-related mutations, they cannot be presumed to affect 
FADD binding.
The mutation data from Table 4.1 is summarised in Figure 4.1 in the form o f  a linear 
map o f the structure o f  Fas-DD indicating the positions o f  individual mutation sites. It 
can be seen from this figure that there is no obvious clustering o f  these m utation sites in
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any specific region o f the death domain and hence there is no clear indication o f how 
this data fits with FADD binding. One problem with the analysis o f  the mutations 
presented in Table 4.1 is that the majority o f these mutants have not been analysed at 
the molecular level. Without such molecular analysis it remains unknown as to whether 
these mutations affect the overall structure o f Fas-DD. This aspect is the subject o f the 
next section.
4.1.2 Structural mutations
Before drawing any conclusions about the residues outlined in Table/Figure 4.1 in terms 
of their relevance for FADD interaction, it is imperative to understand the effects o f 
these mutations on the three-dimensional structure o f Fas-DD. Since the biological 
function o f a protein is intrinsically linked to its 3D structure, any disruption to its 
structure resulting from amino acid substitutions o f critical residues will almost 
certainly cause the loss o f that function.
It is quite possible for a single amino-acid change to disrupt the whole, or key parts of, a 
protein’s structure. Therefore, one must distinguish between mutations that disrupt 
Fas/FADD interactions by altering the surface characteristics o f Fas-DD without a 
major impact on the polypeptide fold (and are therefore o f interest to this study) and 
those mutations that knock out the function o f Fas-DD through global or partial 
disruption o f its 3D structure. An example o f one such “structural m utation” is the lprcg 
mutation. Originally lprcg was discovered as a point mutation in murine Fas-DD that 
causes an ALPS-like syndrome including lymphoproliferation and splenomegaly 
(Matsuzawa et al., 1990). This mutation was later mapped to residue 1246 in murine 
Fas-DD (which is mutated to asparagine in the lprcg mouse). The solution structure o f 
human Fas-DD with the equivalent mutation -  Fas-DD-V238N -  was later investigated 
by NMR spectroscopy (Eberstadt et al., 1997) and this structure reveals a unfolded and 
disordered region o f the polypeptide chain corresponding to the a3  helix. This result 
suggests that the buried V238 side chain, part o f  the loop that connects a l  and a3 , is 
important in maintaining the regular structure o f the a3 helix and suggests that the side 
chains projecting from a3  may play a significant role in the interaction with FADD.
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Mutation Effects Reference
Y216C ALPS type la, reduced FasL-induced apoptosis A
T225P ALPS type la, no FADD binding, reduced FasL-induced apoptosis, 
death domain unfolded
B, C
T225K ALPS type la D
G231A ALPS type la, no FADD binding, reduced FasL-induced apoptosis, 
death domain unfolded
B
V233F ALPS type la K
V233L ALPS type la K
R234A Reduced FADD binding E
R234Q ALPS type la, no FADD binding, reduced FasL-induced apoptosis B, F
R234P ALPS type la, no FADD binding, reduced FasL-induced apoptosis, 
death domain unfolded
G
G237D ALPS type la K
G237S ALPS type la K
V238N Human equivalent of the murine lprcg mutation. Murine Fas-I246N 
mutation has ALPS-like phenotype, death domain partially unfolded, 
knocks out FADD binding,
H
E240A Reduces FADD binding E
A241D ALPS type la, abrogated FasL-induced apoptosis, B
A241V ALPS type la, no FADD binding, abrogated FasL-induced apoptosis G
I243R ALPS K
I243T ALPS K
D244A No FADD binding E
D244V ALPS type la, no FADD binding, abrogated FasL-induced apoptosis B
D244Y ALPS type la, no FADD binding, reduced FasL-induced apoptosis, 
death domain unfolded
G
D244G ALPS type la, no FADD binding, abrogated FasL-induced apoptosis G
E245A Reduced FADD binding E
K247A No Fas-DD self-aggregation E
T254I ALPS type la G, C
T254K ALPS type la K
E256G ALPS type la C ,I
W265C ALPS type 1 a K
L268P ALPS type 1 a K
D276A No reported effect E
K283A Reduced FADD binding E
I294S ALPS type la, no FADD binding, reduced FasL-induced apoptosis, 
death domain unfolded
B, J
L299A No reported effect E
Table 4.1: Human Fas-DD missense mutations reported in the literature and their effects in 
relation to FADD binding and disease.
Reference key: A: (Bettinardi et al., 1997); B: (Martin et al., 1999); C: (Straus et al.,
2001); D: (Jackson et al., 1999); E: (Huang et a l, 1996); F: (van den Berg 
A. et al., 2002); G: (Vaishnaw et al., 1999); H: (Eberstadt et al., 1997); I: 
(Peters et al., 1999); J: (Sneller et al., 1997); K: (Rieux-Laucat et al., 
2003b)
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R234 E240 D244 T254
Y216 T225 G231 V238 A241 E245 E256i i n u u n i K283 I294I I
l l  l l  l l !
V233 G237 I243 K247 W265 L268 D276
I
L299
Figure 4.1: Sites of previously reported missense point mutations in Fas-DD mapped 
onto a linear representation of the domain. Residues reported to be disrupt FADD 
binding when mutated are shown by red arrows. Those residues that, when mutated, 
have no effect on FADD binding are indicated by black arrows. a l-a 6  denote the six a- 
helices of Fas-DD.
However, because the helix is completely disrupted in this mutant, it is not possible to 
precisely identify which o f  the a3  side chains are important in the interaction o f the 
wild-type protein with FADD.
A convenient method to establish whether a particular mutant alters the overall structure 
of a protein is to use NM R spectroscopy. Comparison o f the [!H -15N]-HSQC spectrum 
of the wild-type protein to that o f a mutant variants o f  the same protein is an excellent 
way to identify and characterise the nature and extent o f a structural mutation. Any 
change in the overall structure o f a protein will lead to gross changes in its HSQC 
spectrum -  such as loss o f chemical shift dispersion and/or cross-peak intensity. This 
technique was employed by (Martin et al., 1999) in an excellent study on the molecular 
basis o f ALPS. Here six Fas-DD missense mutations derived from patients with ALPS 
were analysed not only for their ability to induce apoptosis, but also for the structural 
integrity o f the death domain by 2D [15N-'H]-HSQC spectroscopy. In this paper three 
out o f the six point mutations analysed (T225P, G231A and I294S) were shown to 
disrupt the structure o f Fas-DD. However, three other single residue mutations also 
derived from ALPS patients (R234Q, A241D and D244V) were shown to give HSQC 
spectra very similar to the wild-type domain and so these three side-chains can be 
presumed to be important in FADD-binding.
Previous studies on Fas-DD mutations have concluded that the region around a-helices 
2 and 3 is the most important region for FADD binding because this region seems to
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have the highest proportion o f mutations that disrupt the Fas/FADD interaction (see 
Table 4.1 and Figure 4.1). However these studies generally did not take into 
consideration whether or not these are structural mutations. It is the intention o f this 
study, therefore, to attempt to analyse several new Fas-DD mutants at sites distributed 
across the entire death domain as well as to consider, in the context o f  direct tests o f 
FADD-DD interactions, the relevance o f several previously described point mutations. 
Such analysis will be accompanied by NMR studies to test whether mutant forms o f the 
domain are still correctly folded.
4.2 Fas-DD mutations chosen for analysis
Several criteria were used in the selection o f sites in Fas-DD to mutate for this study. 
First, in an attempt to preserve the overall 3D structure o f the protein, and because we it 
can be presumed that only solvent-exposed residues can interact with FADD, only 
residues from the surface o f the protein were chosen for mutation. The program 
“NACCESS” (Hubbard et al., 1991) was used to determine the solvent accessibility o f 
all o f the Fas-DD side-chains based on the NM R solution structure o f  this domain 
(Huang et a l,  1996), PDB entry lddf. The NACCESS algorithm simulates the rolling o f 
a probe over the van der Waals surface o f a protein structure and subsequently 
calculates the percentage surface exposure o f each residue relative to a fully exposed 
side chain (relative surface exposure -  RSE). The NACCESS output data for Fas-DD is 
shown in Table 4.2. The utility o f this approach is reflected in the data for the mostly 
exposed R234, A241 and D244 side chains and for the highly buried V238 side chain 
(the lprcg mutation site) -  the RSE value for this residue is 0.2%. It is straightforward to 
understand from this information how mutation o f the hydrophobic valine side chain to 
the more polar asparagine could lead to a local unfolding o f the Fas-DD structure. 
Observation o f the Fas-DD 3D structure -  using Swiss-PDB Viewer -  was also used to 
confirm that the side-chains o f the residues selected for mutation are on the surface o f 
the protein. Secondly, due to the evidence that the Fas-DD/FADD-DD interaction is 
almost certainly dominated by electrostatic forces (Bang et al., 2000), it was decided to 
focus on the charged residues. It was also decided to select residues from several 
different surface regions o f the protein in order to test whether areas other than the a2 - 
a3  region are important in the FADD-DD interaction. Finally, several previously
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reported substitutions were also selected to help validate the assays used in this study, as 
well as, in some cases, to check whether these alterations correspond to structural 
mutations.
Residue No. RSE Residue No. RSE Residue No. RSE
GLU 202 72.2 GLY 237 71.5 LYS 272 84.8
THR 203 77.8 VAL 238 0.20 GLU 273 63.1
VAL 204 89.0 ASN 239 60.7 ALA 274 4.30
ALA 205 61.7 GLU 240 59.7 TYR 275 13.2
ILE 206 57.7 ALA 241 75.7 ASP 276 43.2
ASN 207 95.8 LYS 242 51.6 THR 277 22.4
■  LEU 208 29.5 ILE 243 0.50 LEU 278 0.00
SER 209 80.5 ASP 244 60.3 ILE 279 16.4
ASP 210 86.2 GLU 245 78.2 LYS 280 67.1
VAL 211 9.60 ILE 246 12.4 ASP 281 16.2
ASP 212 71.1 LYS 247 40.5 LEU 282 0.00
LEU 213 6.60 ASN 248 84.1 LYS 283 57.4
SER 214 53.5 ASP 249 66.6 LYS 284 82.4
LYS 215 86.0 ASN 250 19.5 ALA 285 4.70
TYR 216 12.4 VAL 251 64.9 ASN 286 100
ILE 217 0.20 GLN 252 98.0 LEU 287 16.7
THR 218 53.9 ASP 253 35.2 CYS 288 57.7
THR 219 52.0 THR 254 49.6 THR 289 47.3
ILE 220 0.00 ALA 255 71.2 LEU 290 1.30
ALA 221 0.00 GLU 256 62.9 ALA 291 3.70
GLY 222 61.8 GLN 257 4.20 GLU 292 66.1
VAL 223 46.9 LYS 258 15.0 LYS 293 37.8
MET 224 1.90 VAL 259 18.3 ILE 294 0.00
THR 225 48.3 GLN 260 48.3 GLN 295 51.2
LEU 226 9.70 LEU 261 0.10 THR 296 55.6
SER 227 71.6 LEU 262 0.00 ILE 297 17.8
GLN 228 38.0 ARG 263 59.3 ILE 298 3.10
VAL 229 0.00 ASN 264 25.6 LEU 299 61.0
LYS 230 18.3 TRP 265 0.30 LYS 300 42.4
GLY 231 33.5 HIS 266 19.6 ASP 301 54.0
PHE 232 0.00 GLN 267 81.5 ILE 302 58.5
VAL 233 0.00 LEU 268 37.6 THR 303 55.7
ARG 234 29.8 HIS 269 54.5 SER 304 12.9
LYS 235 58.8 GLY 270 42.0 ASP 305 45.4
ASN 236 17.0 LYS 271 89.8 SER 306 92.4
GLU 307 71.3
Table 4.2: NACCESS data from Fas-DD (PDB file lddf). RSE -  relative solvent exposure -  is 
the calculated percentage exposure of individual residues in the structure relative to a fully 
exposed side-chain. Residues with an RSE value of less than 30 % have been shaded in grey and 
were not considered as candidates for mutation in this study. The lprcg mutation site V238 is 
highlighted in yellow.
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Tables 4.3 and 4.4 present a list o f the Fas-DD mutations as chosen for analysis together 
with a rationale for each selection. Table 4.3 describes previously reported mutants that 
are further characterised in this study and Table 4.4 describes the novel mutants 
designed and characterised in this work. PCR primers (see Appendix 3) were designed 
and used to introduce the mutations into the G bl-Fas-D D -H is construct using the 
QuickChange site directed mutagenesis kit (Stratagene). All mutant constructs were 
confirmed by DNA sequencing.
Table 4.3: Previously reported Fas-DD mutations also analysed in this study
Substitution Rationale Reference
D244A Already characterised, this ALPS mutation is an excellent 
negative control for the assays used in this study.
(Huang et al., 1996)
K247A This mutation was used in previously reported NMR 
studies but has not yet been tested by yeast two-hybrid 
analysis.
(Huang et al., 1996)
A241D Corresponds to a naturally occurring ALPS mutation and a 
surface exposed residue. Requires confirmation as a non- 
structural mutation.
(Martin et al., 1999)
R234A R234 is a common ALPS mutation site that has also been 
characterised in vitro but is not confirmed as a non- 
structural mutation.
(Huang et al., 1996)
E240A Characterised in vitro as a non-FADD-DD binding 
mutant, but not characterised at the structural level.
(Huang etal., 1996)
D267N Mutation o f this residue is reported to have no effect on 
FADD binding. This mutation therefore provides another 
control for this study.
(Huang et al., 1996)
4.3 Yeast two-hybrid analysis of Fas-DD mutations
The wild-type and the twenty different mutant Fas-DD constructs listed in Tables 4.3 
and 4.4 were tested for FADD-DD interaction using the yeast two-hybrid assay in 
exactly the same way as described in Section 3.2.2. Each mutant pOAD-Fas-DD 
construct was individually tested for self-activation by growth on medium lacking 
leucine and histidine with a range o f 3-AT concentrations. None o f  the mutant Fas-DD 
constructs showed any growth on plates with medium containing more than 2 mM 3-AT 
indicating that they were all suitable for interaction analysis with pOBD 2-FADD-DD. 
The yeast strains containing each Fas-DD construct was individually mated with the 
strain transformed with the pOBD 2-FADD-DD construct and the resulting cells were
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tested for their ability to grow on leu'/trpThis' plates. Mating experiments were repeated 
twice using two separate colonies o f each Fas-DD mutant to ensure reproducibility. 
Cells expressing w ild-type or mutant forms o f Fas-DD that were able to interact with 
FADD-DD showed signs o f proliferation within seven days. Cells containing Fas-DD 
mutants that were unable to productively interact with FADD-DD showed no sign o f 
proliferation after two weeks incubation at 30°C.
Table 4.4: Novel mutations in Fas-DD designed and analysed in this study
Substitution Rationale
S227A S227 is a solvent-exposed polar residue on helix 2. This mutation should give an 
idea of how sensitive the Fas-DD/FADD-DD interaction is to small alterations in 
polarity at the protein surface.
N239Q This mutation, in the putatively important helix 3 will test the sensitivity of the 
interaction to slight increases in steric bulk through the introduction of an extra 
methylene group.
E240Q This mutant is very similar to, but more conservative than the E240A mutation as 
only the charged group is blocked -  it is less likely to be a structural mutation.
K242A K242 is a charged, solvent exposed residue on helix 3. Mutation of this residue to 
alanine will test the importance of this side chain in a region of Fas-DD thought 
to be associated with FADD-DD binding.
N248D This mutant will test the effect of the introduction of a charged group in the 
putatively important helix 3 region of Fas-DD.
V251Q Mutation of this hydrophobic surface residue to glutamine will test the effect of 
subtle changes in the exposed hydrophobic surface of the Fas-DD domain.
Q252A This mutation will test the importance of residue 252, sited in helix 4, by 
removing the large, solvent-exposed glutamine side-chain.
E256Q E256 is a charged, surface exposed residue that, when mutated to glycine, causes 
ALPS. This mutation simply removes the negative charge and should keep the 
domain structurally intact.
R263A R263 is a charged, surface exposed residue sited in helix 4, a region of Fas-DD 
not previously thought to be important in FADD binding
Q267E Residue 267 is sited very close to R263 (on the same surface of helix 4) and is 
also highly solvent exposed. This mutation will test the introduction of an extra 
negative charge to this region of the protein surface.
K272A K272 is a charged, solvent exposed residue sited in the loop between helices 4 
and 5 of Fas-DD, a region not previously thought to be important in FADD 
binding.
K280A Mutation of residue K280 will test the effect o f removing a positive charge from 
the surface of helix 5, a region of Fas-DD not previously thought to be important 
in FADD binding.
K284Q K284 is on the surface of helix 5, a region not previously thought to be important 
in FADD binding. Glutamine was chosen as the replacement residue in order to 
remove the charge from the side chain whilst conserving the structural integrity of 
the domain.
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The results from one o f these mating experiments are shown in Figure 4.2 and the 
overall results from this yeast two-hybrid experiment are sum m arised in Table 4.5. The 
second experiment gave essentially the same results as the experim ent shown in Figure
4.2 except in the case o f the R234A mutation w hich exhibited positive FADD-DD 
interaction properties in one experiment but not in the other and hence had to be further 
analysed in vitro by NMR (see Section 4.4).
To facilitate discussion o f the results o f the yeast tw o-hybrid experiment, the set o f Fas- 
DD constructs employed is divided into three sets o f  mutations in Table 4.5. Those 
mutations that resulted in no yeast growth in the tw o-hybrid assay are defined as 
“knock-out” mutations. Those mutations that resulted in some growth, but lower growth 
than wild-type Fas-DD, are defined as “reduced interaction” . It is probable -  but it 
requires confirmation by other methods -  that the reduced interaction behaviour 
corresponds to a death domain that can still interact w ith FADD-DD but with a weaker 
affinity than the wild-type protein. Finally there are six Fas-DD mutants that show no 
change in the amount o f yeast growth relative to w ild-type Fas-DD. This last group is 
listed in Table 4.4 as “no effect” mutations.
“Knock-out”
mutations
Reduced
interaction
No effect
N239Q V251Q S227A
E240A K280A K 247A
E240Q N286K R263A
A241D Q267E
K242A
D244A
N248D
Q252A
E256Q
K272A
K284Q
R234A*
D276N
Table 4.5: Summary of the effects of Fas-DD mutations on FADD-DD binding based on yeast 
two-hybrid assay data. R234A appears in the knock-out mutation column only after further 
NMR analysis (see Section 4.4).
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A 241DD 244A
E240A
N 248D
Figure 4.2 Analysis of Fas-DD mutations using yeast two-hybrid assay. The assay was 
carried out using FADD-DD as the bait protein and wild-type or mutant Fas-DD as the 
prey. The plates photographed here contain trp'/leu'/his' medium and hence growth on 
these plates indicates a positive bait/prey interaction. For this experiment plates were 
photographed after ten days incubation at 30°C.
The plates shown here are representative of two independent experiments -  with the 
exception of the R234A mutant (see text for details).
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4.4 NMR studies of Fas-DD mutants
Yeast two-hybrid analysis o f the mutant Fas-DD constructs indicated that eleven o f the 
mutants (including seven o f  the novel mutation set) completely abrogate the ability o f 
this death domain to interact with the death domain o f FADD. It is important to assess 
whether these knock-out mutants represent structural mutations or whether the 
individually substituted side chains are significant in terms o f the FADD-DD 
interaction. This issue was assessed by NMR analysis o f Fas-DD mutants expressed in 
the form o f His-tagged G bl-Fas-D D  fusion proteins, similar to the analysis o f the wild- 
type protein described in Chapter 3. To that end, mutations corresponding to those used 
in the yeast two-hybrid analysis were introduced into the pETG bl -Fas-DD expression 
plasmid using the QuickChange site directed mutagenesis kit (Stratagene).
15N-labelled NM R samples o f the eleven non-FADD-DD-binding G bl-Fas-D D  mutants 
were produced to compare their structure to that o f the wild-type protein. All o f these 
proteins were expressed in good yield and sufficient quantities o f  each protein were 
produced for a 500 pi sample o f greater than 0.4 mM. Two dimensional [’H -^N l-H SQ C 
experiments were run on each o f  the twelve mutant Fas-DD samples and the spectra 
from these experiments are shown in Figure 4.3.
The HSQC spectra o f the eleven Fas-DD mutants that knock-out FADD-DD binding are 
very similar to the wild-type protein and so it can be assumed that the overall fold of 
these mutated proteins is the same as the wild-type domain. Since the HSQC spectra in 
Figure 4.3 are spectra o f the G bl-Fas-D D  fusion proteins they contain cross peaks from 
both the Gbl and Fas-DD moieties. For clarity, then, three cross-peaks arising from Fas- 
DD residues with highly characteristic chemical shifts (selected from the analysis o f the 
wild-type G bl-Fas-DD spectrum presented in Chapter 3) have been highlighted in each 
spectrum in Figure 4.3. The presence o f these cross peaks in the mutant spectra, where 
they have essentially the same chemical shifts as in the wild-type spectrum, helps to 
indicate that Fas-DD has the same fold in these mutant constructs as in the wild-type 
domain. An important conclusion from these observations is that each o f  these 
mutations must disrupt the Fas-DD/FADD-DD interaction in the yeast two-hybrid assay 
by altering the surface o f  the Fas-DD domain in such a way that FADD-DD can no- 
longer bind.
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The remaining Fas-DD mutants that retain FADD-DD binding in the yeast two-hybrid 
assay were then compared to the wild-type protein in an NM R-based binding assay. 
These experiments were carried out for two reasons, first to assess the validity o f the 
yeast two-hybrid assay and second to test the theory that the subset o f m utant forms o f 
Fas-DD that appeared to show a reduced affinity in the yeast two-hybrid assay might 
show a correspondingly weaker interaction with FADD-DD in the in vitro NMR 
experiments.
Unlabelled protein samples o f the six Fas-DD mutants that showed binding activity 
close to wild-type levels in the yeast two-hybrid assay and the three reduced interaction 
mutants were produced as G bl-Fas-DD  constructs. All but one o f  these proteins were 
well expressed and could be concentrated to at least 0.4 mM w ithout showing signs o f 
precipitation. The G bl-Fas-DD -Q267E construct gave a lower yield o f soluble 
expressed protein (~10 mg/L o f culture compared to >20 mg/L for the other mutants) 
and showed signs o f  precipitation at concentrations above 0.25 mM. A 15N-labelled 
sample o f this protein was produced to examine whether the protein was becoming 
aggregated as the concentration was increased.
Figure 4.3n shows an HSQC spectrum o f a ~0.2mM  sample o f  Gbl-Fas-DD-Q267E 
which shows many overlapping peaks and poor resolution compared to the spectrum of 
the wild-type protein. The most prominent peaks appear to derive from the G bl part o f 
the fusion protein. These spectral features are indicative o f an aggregated protein and 
so, although giving a positive yeast two-hybrid result, this mutant was not further 
analysed in vitro. It is not clear whether the aggregation also operates at the 
concentrations o f protein relevant inside the nucleus o f a yeast cell, so this result may 
represent artifactual behaviour that is a result o f the high concentration required for 
NMR spectroscopy.
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Figure 4.3: ['H-^Nl-HSQC spectra o f  wild-type (a) and mutant (b-k) 15N-G bl-Fas-DD  
proteins. In all spectra the horizontal axis represents H frequency (in ppm) and the vertical 
axis the 15N frequency (in ppm). All mutated Fas-DD proteins that have no FADD-DD binding 
capacity (b-j) show essentially the same chemical shift dispersion as the wild-type domain. 
Red arrows indicate three examples o f  cross peaks from Fas-DD residues.
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Figure 4.3 continued.
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Figure 4.3 continued. Note that the HSQC spectrum of 15N-Gbl-Fas-DD-Q267E (n) is 
show characteristics typical of an aggregated protein.
To further analyse in the interaction between Fas-DD and FADD-DD, in vitro titrations 
o f a subset o f G bl-Fas-DD  mutants with 15N-FADD-DD was performed and monitored 
using two-dimensional [^N -'HJ-H SQC NMR spectroscopy as described in Section 
3.4.4 for the wild-type proteins. For each o f the titrations an unlabelled G bl-Fas-D D  
mutant protein sample was titrated into a l5N-labelled FADD-DD sample using the 
same mixing strategy that keeps the concentration o f FADD-DD constant throughout 
the titration (see Section 3.4.4.1). The amount o f data recorded in these titration 
experiments is large and it is not sensible to reproduce the NM R spectra here. Rather,
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for simplicity, I state here the general conclusions deriving from these N M R titrations 
and then expound upon select details from the results (however this data may be 
accessed through Professor Paul Driscoll at University College London).
Initially the endpoint sample for each titration was made using a 1:1 ratio o f  G bl-Fas- 
DD to FADD-DD. However, for several o f the mutants (N286K, V251Q, K280A, 
D267N and R234A), this proportion o f Fas-DD was insufficient to result in the same 
loss o f  FADD-DD signal intensity as the equivalent amount o f  wild-type protein. 
Attempts were made, therefore, to produce samples with an increased concentration o f 
Gbl-Fas-DD mutant in order to probe the excess quantity o f these mutants required to 
“saturate” the binding interaction. These attempts were limited by two factors. First, the 
concentrations o f several G bl-Fas-D D  mutants could not be taken above ca. 1.2 mM 
before precipitation occurred. Second, when the concentration o f  15N-FADD-DD was 
taken below about 0.30 mM, the HSQC spectrum gave insufficient signal-to-noise ratio 
to ensure that titration could be performed on a reasonable timescale with reasonable 
sensitivity. Such limitations meant that the highest possible concentrations achievable 
with these mutants were as follows (shown here with the equivalent maximal Fas- 
DD/FADD-DD ratio):
Gbl-Fas-DD-R234A:FADD-DD 1.2 mM: 0.30 mM 4:1
Gb 1 -Fas-DD-V251 Q:F ADD-DD 1.0 mM: 0.33 mM 3:1
Gb 1 -Fas-DD-D276N :F ADD-DD 1.0 mM: 0.33 mM 3:1
Gbl-Fas-DD-N286K:F ADD-DD 1.0 mM: 0.33 mM 3:1
Gbl-Fas-DD-K280A:FADD-DD 1.2 mM: 0.30 mM 4:1
(Higher ratios were possible for the R234A and K280A mutants as these two proteins 
could be concentrated to a maximum o f roughly 1.4 mM)
Figure 4.4 shows combined results o f the titrations o f the seven G bl-Fas-D D  mutants 
that were shown by yeast two-hybrid analysis to still interact with FADD-DD and that 
were tractable for NM R studies (the wild-type G bl-Fas-D D  and the Gbl-Fas-DD- 
D244A mutant titrations are also presented for comparison). None o f  the mutants 
exhibited an alternate behaviour in which increasing concentrations o f  Fas-DD gave rise 
to selective chemical shift changes o f the FADD-DD cross peaks without the loss o f 
signal intensity. It can be seen that the K247A and R263A G bl-Fas-D D  mutants behave 
in essentially the same way as the wild-type G bl-Fas-DD  protein providing further 
evidence that the corresponding substitutions have no bearing on the interaction o f Fas-
131
DD with FADD-DD. The D267N mutation, although observed to have a sim ilar level o f  
interaction to wild-type Fas-DD in the yeast two-hybrid assay was shown to slightly 
attenuate the FADD-DD interaction in the NMR assay. However, such an attenuation 
was seen to a much greater extent by the three Fas-DD mutants, V251Q, N286K and 
K280A all o f which required approximately five-times as much protein as the wild-type 
G bl-Fas-DD to produce an equivalent diminution o f the FADD-DD signal intensity. 
This behaviour in the NMR titrations may be associated with a lower FADD-DD 
binding activity and this data correlates well with the yeast two-hybrid results for the 
same three mutants which were described as having a “reduced activity” relative to 
wild-type Fas-DD.
Titrations of Fas-DD mutations
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Figure 4.4 NM R titrations o f  Fas-DD mutants. Titrations o f  various G bl-Fas-D D  
constructs into ,5N -F A D D -D D  follow ed by the measurement o f  the relative aggregate 
FADD-DD cross peak intensities from HSQC experiments.
Overall, therefore, there is a very high degree o f correlation between the results from the 
yeast two-hybrid assay and those from the assessment o f protein-protein interaction by 
NMR spectroscopy. All but one o f the Fas-DD mutants show agreement between the 
two assays. The R234A mutant gave inconsistent results in the yeast-two hybrid assay, 
although, as it is a previously described naturally occurring ALPS mutation it represents 
a form o f Fas-DD that is not expected to bind FADD-DD, and indeed, when analysed
132
by NMR, no binding activity could be seen. It remains unclear how this particular 
mutation gave rise to a false positive result in one instance o f  the yeast two-hybrid trials.
4.5 Conclusions from mutational analysis of the Fas death domain
Several conclusions can be drawn from this mutational study o f  Fas-DD. Firstly yeast 
two-hybrid analysis o f a bank o f 20 Fas-DD mutants gave reproducible results and 
showed that most o f the mutations either significantly reduced or effectively eliminated 
the interaction with FADD-DD. Those side chain substitutions that knocked out the 
FADD-DD interaction were tested for their effect on 3D structure o f Fas-DD by [!H- 
15N]-HSQC spectroscopy. Comparison with the wild-type spectrum showed that none o f 
these mutant proteins that we analysed yielded evidence o f  any gross structural changes 
within the domain. Those Fas-DD mutations that exhibited FADD-binding activity in 
the yeast two-hybrid assay were analysed by NMR-based titration experiments. Each o f 
these mutant G bl-Fas-D D  proteins, except R234A, were shown to interact with FADD- 
DD in the NMR assay and those mutants that showed reduced FADD-DD binding 
activity did so in both yeast two-hybrid and NM R protein/protein interaction assays. 
Therefore the correlation between yeast two-hybrid experiments and the NM R based 
analysis provides direct and incontrovertible evidence for the presence and apparently, 
to some degree, the strength o f the interaction. Although the yeast two-hybrid assay 
runs the risk o f both false positive and false negative results, the combination o f this 
type o f data with the in vitro NM R analysis provides a powerful method for studying 
the effects o f Fas-DD mutations on its interaction with FADD-DD.
The results from NM R-based titrations showed that each mutant G bl-Fas-D D  protein 
(apart from Gbl-Fas-DD -D244A ) titrated into 15N-FADD-DD exhibited the same type 
o f behaviour as the wild-type domain in producing an overall loss o f signal intensity 
from the FADD-DD ['H-'^NJ-HSQC spectrum. As the simplest interpretation o f this 
behaviour, we equate this progressive loss o f signal with the formation o f a 
hydrodynamically large complex between the two domains. Importantly, in each 
titration, several sharp FADD-DD signals -  corresponding to side chains and residues 
from the flexible tails o f the domain -  were still observed, indicating that FADD-DD, 
and therefore the complex between the two death domains, remained in solution
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throughout the titrations. Some differences are seen, however, betw een the relative 
concentrations o f the mutant proteins that are required to reduce the FADD-DD signal 
intensity by an equivalent amount. The D276N, V251Q, K280A and N286K  Fas-DD 
mutants required relatively higher protein concentrations to effect com plete diminution 
o f the FADD-DD signals. Presumably this behaviour can be attributed to these mutants 
possessing a reduced FADD-DD interaction affinity and, in the case o f  3 out o f 4 o f 
these mutations (V251Q, K280A and N286K), is correlated with the decreased, but not 
abolished, interaction strength suggested by the results o f  the corresponding yeast two- 
hybrid assay trials.
From this mutational analysis several Fas-DD residues have been identified, that, when 
substituted, appear to knock out the FADD-DD interaction. This set o f  residues includes 
four previously described in the literature -  D244A, R234A, A241D and E240A -  
which have all been shown to disrupt the interaction either in vivo or in vitro (see Table 
4.1), but which have been analysed to varying levels. O f these four, only A241D has 
been previously fully described as a non-structural, ALPS-causing m utation (Martin et 
al., 1999). Two others, R234A and D244A, had been described as FADD-DD knockout 
mutants in a biochemical (ELISA-based) study (Huang et al., 1996) but had not been 
confirmed as non-structural mutations (although two very similar ALPS-causing 
mutations, R234Q and D244V had been shown to maintain the fold o f  Fas-DD (Martin 
et al., 1999)). The present study has now confirmed that the R234A and D244A mutants 
have a native death domain fold. This result is especially important in the case of 
D244A mutation as this mutant was used previously as a negative control for FADD- 
DD binding (see Chapter 3). Finally the E240A mutant o f Fas-DD had been shown in a 
biochemical study to knock out FADD interaction (Huang et al., 1996) but in this work 
the protein has been proven to be a non-structural mutant. This study has therefore 
confirmed information about the D244A, R234A, A241D and E240A mutants and 
extended the knowledge o f D244A, R234A and E240A as these proteins had not 
previously been structurally analysed.
O f the set o f mutant Fas-DD proteins examined in this study, there are eight remaining, 
previously uncharacterised, Fas-DD mutations that have been shown by this work to 
knock out FADD-DD interaction in the yeast two-hybrid assay and yet to maintain the 
Fas-DD death domain structure as determined by NM R spectroscopy. These eight
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mutants are as follows: N239Q, E240Q, K242A, N248D, Q252A, E256Q, K272A and 
K284Q. The E240Q mutation, perhaps unsurprisingly, has the same affect as the E240A 
mutation and it was chosen for analysis as a more conservative m utation in case the 
E240A mutation gave rise to structural perturbations. E256Q is a novel Fas-DD mutant 
but was chosen to test the importance o f this residue that, when mutated to glycine, is 
reported to cause ALPS.
V251
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Figure 4.5: Sites of those point mutations in Fas-DD used in this study mapped onto a linear 
representation of the death domain. Residues that disrupt FADD-DD binding when mutated are 
indicated by red arrows. Blue arrows denote mutation sites that partially disrupt FADD binding. 
Those residues that, when mutated, have no effect on FADD binding are indicated by black 
arrows.
Taken as a whole this set o f  data represents the novel identification o f six residues on 
the surface o f Fas-DD that are apparently important for FADD-DD binding: N239, 
K242, N248, Q252, K272 and K284. Moreover, the importance o f  several other Fas-DD 
surface residues that have been previously described through their role in ALPS have 
been confirmed as being vital for FADD-DD binding: R234, E240, A241, D244, and 
E256. Four other Fas-DD residues -  V251, D276, K280 and N286 -  are shown to 
contribute to FADD-DD interaction as, when any o f these residues is mutated, Fas-DD 
exhibits significantly reduced FADD-DD binding activity. Another interesting point is 
that two uncharged residues have been discovered, N239 and Q252, that, when mutated 
to other uncharged amino acids (glutamine and alanine respectively), abrogate the 
FADD-DD binding. This observation shows that, despite the observation that the Fas- 
DD/FADD-DD interaction appears to rely heavily on electrostatic interactions, there is 
almost certainly a hydrophobic and/or shape recognition component as well. This is an 
important observation since previous studies o f the interactions between these domains 
have focussed purely on the charged residues. Finally, o f the 20 residues analysed, only
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four show no apparent effect on FADD-DD binding upon mutation: mutations o f Fas- 
DD-S227, -K247, -R263 and -Q267 gave rise to behaviour indistinguishable from the 
wild-type protein in our binding assays.
The mutation data is summarised in Figure 4.5. Here we can see that there are residues 
from Fas-DD a-helices 2, 3, 4, 5 and 6 that appear to be im portant for FADD-DD 
interaction. This is perhaps unexpected as previous studies have focussed on helices 2 
and 3 as being the most important region in terms o f Fas-DD/FADD interaction. 
However, it is interesting to note that a recent mutational study o f  the death domain o f 
FADD has suggested a role for several surface regions o f FADD-DD in the interaction 
with Fas (Hill et al., 2004). In that report non-structural point mutations in all six a -  
helices o f FADD-DD were found that disrupt the interaction with the cytoplasmic 
domain o f Fas when analysed by a combination o f in vitro GST-pull down and cell- 
based, functional, biological assays.
Figure 4.6 summarises the Fas-DD and FADD-DD mutagenesis data from the present 
study together with that o f  Hill et al. 2004. This figure indicates that there are expansive 
surfaces on both o f these death domains that are implicated by the various mutagenesis 
and assay data in the interaction between the two proteins. It is important to note that we 
can only draw conclusions for those residues that have been mutated but there are many 
other residues on the surface o f  these proteins that remain to be thoroughly examined 
and that may also play a role in this interaction. However, we can see that the two sets 
o f data presented in Figure 4.6 are sufficient to allow for further analysis o f this 
interaction in the context o f other death-fold interactions.
4.6 A m odel fo r Fas-DD/FADD-DD in teraction?
We have seen from the mutagenesis data that both the Fas and FADD death domains 
appear to utilise multiple surface regions in their mutual interaction. This observation is 
consistent with the data from Chapter 3 that illustrated the formation o f an apparently 
hydrodynamically large, stable but reversible complex between the two death domains 
in solution.
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a) Fas-DD
b) FADD-DD
Figure 4.6 Backbone and surface representations of the Fas and FADD death domains in 
the same orientations indicating sites of non-structural point mutations that disrupt their 
mutual interaction. Backbone images (created with MolScript) are coloured by helices -  
a l :  orange, a2: red, a3 yellow, a4: cyan, a5: green, a6 blue -  and mutations sites are 
indicated with ball-and-stick representations. Surface images (generated with Swiss 
PDBViewer) are oriented exactly as the backbone image above and have mutation sites 
coloured blue (Fas-DD) and crimson (FADD-DD). Images on the right are rotated 180° 
about the y-axis relative to those on the left.
The surface representations show the expansive regions involved in the interaction 
between these two domains.
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However, whilst we are clearly able to detect the formation o f  the Fas-DD/FADD-DD 
complex, we still have little precise information about its organisation at the three 
dimensional level. If  only a single defined surface region o f  each domain had been 
highlighted in the respective mutagenesis studies then it would be straightforward to 
conclude that the complex formed is a binary 1:1 Fas-DD/F ADD-DD complex and one 
could reliably embark upon a three dimensional modelling exercise in an attempt to 
rationalise the mutagenesis data. We do not know which surface regions o f Fas-DD 
interact with which surfaces o f FADD-DD and we do not know the stoichiometry o f the 
interaction. W ithout further experimental data that expose these details we are limited to 
speculation based upon pre-existing information from other death-fold domain 
interactions to further our understanding o f the Fas-DD/F ADD-DD interaction.
However, it is possible to compare the sites o f important residues in other death-fold 
interactions with those apparently involved in the Fas-DD/F ADD-DD interaction. From 
this comparison it should be possible to discern any conservation there might be 
between members o f  this superfamily o f domains and how they interact with their 
respective partners.
It has been well established that the death-fold domains vary extensively in relation to 
their primary amino-acid sequences but all have a relatively highly conserved structural 
m otif consisting o f six a-helices. This helical structure is defined by several key, 
conserved hydrophobic residues that constitute the core o f  the domain and hence are 
almost entirely inaccessible to solvent. It is assumed that the folding o f  these domains is 
driven by interactions between the buried hydrophobic core residues. Since the structure 
of these domains is defined by such a small number o f key residues it is relatively 
straightforward to imagine how divergent evolution processes have created such variety 
amongst the remaining residue positions o f these domains (assuming a common 
ancestor for all members o f the death fold superfamily). The evolution process has 
created a family o f protein domains each with unique surface characteristics, the 
specific nature o f which governs how they interact specifically with their respective 
partners (or sets o f partners).
Unfortunately this diversity makes accurate primary sequence alignment o f these 
domains extremely difficult, especially when comparing members from different
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subfamilies. However, in order to test whether there is any conservation o f  residues in 
the interactions between these domains it is first necessary to create such an alignment. 
Fortunately, computer-based tools are now available that generate the alignment o f 
protein sequences based on their three-dimensional structures. Such a tool is ideal for 
this particular situation. The program DALI (http://www.ebi.ac.uk/dali/) was therefore 
used to generate structural alignments between FADD-DD and eight other members o f 
the death-fold superfamily -  including at least one member o f  each subfamily -  for 
which structures were available: Fas-DD (Huang et al., 1996), TNFR1-DD (Sukits et 
al., 2001), Tube-DD and Pelle-DD (Xiao et al., 1999), FADD-DED (Eberstadt et al., 
1998), APAF-1 CARD and Caspase-9 CARD (Qin et al., 1999) and ASC pyrin 
(Liepinsh et al., 2003). The structural alignment was repeated using Fas-DD as the 
template in place o f FADD-DD to generate a total o f 15 structural alignments. This 
alternation o f the template structure was carried out to remove any bias generated by 
using a single structure as the alignment platform. Once the alignments had been 
generated they were collated using the program BioEdit (Hall, 1999) to produce an 
overall structure-based sequence alignment between the nine family members -  see 
Figure 4.7. In order to test the accuracy o f this essentially automatically derived 
structure-based alignment, and to observe if  the core residues are conserved between 
subfamilies, primary sequence alignments from the PFAM database (Bateman et al., 
2004) were used to extract the conserved core residues for each o f  the four death-fold 
sub-families -  DD, DED, CARD and pyrin. The positions o f  these conserved 
hydrophobic core residues for each sub-family were mapped back onto the full 
structural alignment and are shaded in grey in Figure 4.7.
The sequence alignment in Figure 4.7 reveals several points. First, it is interesting to 
note that there is excellent conservation o f the positions o f  the hydrophobic core 
residues throughout the death-fold family (across all four sub-families). Although some 
residues have altered through evolution as the family has diverged into four separate 
subfamilies, the structural distribution and hydrophobicity o f  these residues remains 
consistent. From preliminary observation o f the primary sequences this level o f 
conservation was not immediately apparent.
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Figure 4.7: Structural alignment o f  members o f  the death fold family o f  proteins. The conserved 
hydrophobic residues (shaded in grey) were extracted from the PFAM database sequence 
alignments for each death fold sub-family and are mapped back onto this structural alignment. 
The a-helices are boxed and the residues shown to be important for domain/domain interactions 
are highlighted in red. There is a 26 residue insert in the Tube death domain which has been 
omitted for clarity -  indicated by ***.
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However, analysis o f the structural alignment indicates that these core residues are 
positionally conserved throughout all six helices o f  the death fold and across all four 
sequence sub-families. The presence o f the death domains from Drosophila 
melongaster proteins Pelle and Tube in this alignment alongside the other seven human 
proteins also indicates a cross-species conservation o f the death-fold structure.
It is clear then, that the structure o f these domains is generally conserved and is 
maintained by the preservation o f a set o f hydrophobic core residues. However, 
observation o f  the amino-acid sequences that lie outside the core regions shows that 
there is very little conservation in any other elements o f  these domains. This is true 
when comparing members both across and within sub-families. Naively, it would be 
predicted therefore, that there is not likely to be any similarities between the surface 
properties o f  these individual domains. Indeed, as we have seen from Figure 1.9 the 
charge distributions on the surfaces o f those death fold domains with known structures 
do appear to be remarkably diverse. Such diversity suggests that there is no particular 
reason why there should be a common interaction surface shared by members o f this 
family o f domains.
The availability o f  the three dimensional structures the complexes between the death 
domains o f  Pelle and Tube (Xiao et al., 1999) and the CARD domains o f caspase-9 and 
APAF-1 (Qin et al., 1999) allows for the further analysis o f death-fold protein 
interactions. The residues involved in the interaction surfaces o f  these two complexes 
were identified from their PDB files (ld2z and 3ygs respectively) using the program 
CNS (Brunger et al., 1998). A residues was defined as an “interface residue” if  the side 
chain (3-carbon atom was within 8 A o f the p-carbon atom o f any residue from the other 
chain in the complex. This information was mapped onto the sequence alignment in 
Figure 4.7. Residues at the interfaces o f these two complexes are highlighted in red for 
comparison with the positions o f  characterised mutations in Fas-DD, FADD-DD and 
TNFR1-DD (Telliez et al., 2000). The data for TNFR-1 is from a study to identify 
mutants o f this domain that are important for the interaction with the death domain o f 
the adapter protein TNF-receptor associated death domain protein (TRADD). It is 
important to note that the information from the TNFR1-DD mutations does not 
demonstrate whether these are structural mutants, however all the residues chosen in the 
study were highly solvent exposed on the domain. Hence it is reasonable to presume
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that the substitutions do not disrupt the TNFR1-DD structure and that at least a 
proportion o f these residues are directly involved in intermolecular contacts with 
TRADD-DD.
Comparison o f the positions o f  the red-shaded residues in Figure 4.7 shows no obvious 
conservation o f regions that may be important in the respective death-fold domain 
interactions. However, more information about the Fas-DD/F ADD-DD interaction 
could potentially be gained by modelling these two domains onto the structures o f the 
two known binary death-fold complexes -  Pelle-DD/Tube-DD and caspase-9- 
CARD/APAF-1-CARD. Comparison o f  the mutagenesis data from the Fas and FADD 
death domains with the residues at the protein-protein interfaces o f these modelled 
complexes should permit the detection o f any potential relationship between the Fas- 
DD/F ADD-DD interaction and the other, known death fold interactions.
Four structural models were built in order to test this hypothesis. The NM R solution 
structures o f Fas-DD and FADD-DD were modelled onto the DDs o f Pelle and Tube 
and onto the CARD domains o f  caspase-9 and APAF-1. For clarity, these four models 
have been numbered as show below:
Model 1: Fas-DD -> Tube-DD / FADD-DD ->  Pelle-DD
Model 2: Fas-DD —► Pelle-DD / FADD-DD-* Tube-DD
Model 3: Fas-DD —> Caspase-9 CARD / FADD-DD —> APAF-1 CARD
Model 4: Fas-DD -> APAF-1 CARD / FADD-DD Caspase-9 CARD
Each model was produced by adopting the same procedure outlined below using Model 
1 as an example. In order to create Model 1 the Fas-DD and FADD-DD structures (PDB 
files ld d f and le3y  respectively) were first structurally aligned to Tube-DD and Pelle- 
DD (extracted from the PDB file ld2z) respectively using the program SSAP (Orengo 
and Taylor, 1990). The program PROFIT (Martin, A.C.R., 
http://www.bioinf.org.uk/software/profit/) was then used to fit the Fas-DD and FADD- 
DD structures onto the Pelle-DD/Tube-DD heterodimer (chains A and B from the PDB
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file ld2z*) using the previously created structural alignments as templates. The PROFIT 
program outputs a new PDB format file containing the atomic coordinates o f  the new 
three dimensional model.
Figure 4.8 shows Models 1-4, represented by their polypeptide ribbon structures, both 
individually and superimposed onto their respective templates. It can be seen that the 
models are all reasonably well aligned to the templates in respect o f their regular 
secondary structure elements. Once these models had been created it was then possible 
to generate information about the inter-domain interfacial surfaces that are formed by 
these hypothetical complexes. The residues at the interfaces o f  these four models were 
detected using an objective pairwise distance search coded in CNS exactly as described 
above for the analysis o f crystal structure interfaces. The output o f  this analysis data is 
shown in Table 4.6.
From Table 4.6 it is possible to see that whilst three o f the models include a subset o f 
residues in the knockout mutation list no single model can wholly account for all o f 
them. Model 1 is the least interesting o f the four as it shares no common interface 
residues with the mutagenesis data. Model 2 suggests that there may exist a shared 
binding interface between FADD-DD and Tube-DD However, it is clear that this 
surface does not account for the full interaction between FADD-DD and Fas-DD as 
several other surface regions are also involved, particularly in the case o f Fas-DD.
Similar observations apply to Models 3 and 4, where, in each case, there is a significant 
degree o f overlap between the interface residues from one partner in the model and their 
knockout mutations but where each model fails to accommodate all o f the mutagenesis 
observations. Interestingly, in both Models 3 and 4, the surface region corresponding to
*
A note about the crystal structure of the Pelle-DD/Tube-DD complex: Four molecules are shown in the 
asymmetric unit o f the structure in a linear Pelle-Tube-Pelle-Tube arrangement and hence this 
arrangement provides three distinct Tube-DD/Pelle-DD interfaces. Whilst two o f these interaction sites 
are almost identical, the second (middle) interface is dissimilar and is almost certainly an artefact o f  
crystal packing (N. Gay, personal communication) -  an observation that is backed up by the presence of a 
HEPES molecule from the buffer buried at this interface. For the present study, therefore, only the 
conserved interface was chosen for comparison with the Fas-DD/F ADD-DD data. For this purpose a new 
atomic coordinate file was created consisting of only one pair of Tube-DD/Pelle-DD molecules (chains A 
and B from the original ld2z file) as a template for the modelling exercise.
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the caspase-9 CARD interaction site is the one that yields the highest concordance with 
knockout mutation sites. However, in these cases the partner domain appears to be in a 
largely inconsistent orientation as it shares only one contact residue with the mutation 
list.
“Knockout Interface residues Interface residues
mutations” Model 1 Model 2 Model 3 Model 4
Fas-DD
Fas-DD FADD-DD Fas-DD FADD-DD Fas-DD FADD-DD FADD-DD Fas-DD FADD-DD
—* Tube — Pelle -  Pelle —» Tube APAF-1 —» Casp-9 —► Casp-9 — APAF-1
R234 D106 T219 1147 V238 Q169 T217 R113 R234 R132
N239 R113 V223 N150 N239 M170 T218 R114 K235 Y133
E240 R117 K293 T151 A241 N171 A255 A116 N239 N136
A241 D123 T296 K153 K242 L172 Q256 R117 E240 T138
D244 K125 I297 E154 R263 V173 V259 Q118 A241 E139
N248 R142 K300 N155 N264 A174 Q260 K120 I243 R140
V251 R146 T303 T157 W265 N175 L262 S122 D244 R142
Q252 R166 T304 R189 H266 L176 R263 D123 E143
E256 L172 S306 S190 Q267 Q178 N264 T124
K272 D175 E307 L268 Q179 K125
D276 H269 Q181 C168
K280 K271 Q182 Q169
K284 K272
N286 A274
Table 4.6: List of interface resides from the four generated models of the Fas-DD/F ADD-DD 
complex models. The “knockout mutations” are defined from this study and the study of (Hill et 
a l, 2004) as the sites of residues which, when mutated, lead to an apparent total loss of 
respective Fas-DD/FADD-DD binding without perturbing the overall three dimensional fold of 
the respective death domain. Yellow highlights indicate model interface residues that also 
appear in the list of knockout mutation sites.
Overall we can see from these models that the Fas-DD/FADD-DD interaction cannot be 
readily explained by the current observations o f  death-fold domain interactions. This 
failure stems from the fact that the surface regions involved in the interaction appear to 
be extended over a greater surface area than those interactions o f  the known death-fold 
family interactions. It may be possible to conclude that the Tube-DD and caspase-9 
CARD interactions use similar interacting surface regions (in complexes with Pelle and 
APAF-1) to the Fas and FADD death domains. However, the fact that we see such 
highly dispersed interaction surfaces for these two domains, in an interaction that our 
NMR data suggest is almost certainly not as simple as 1:1 heterodimer formation, 
suggests that there is no genuine similarity between the Fas-DD/FADD-DD and other 
death fold interactions.
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a) Model 1
b) Model 2
c) Model 3
d) Model 4
/
Figure 4.8: Models of Fas-DD/FADD-DD interactions based on the Pelle-DD/Tube-DD 
complex and the caspase-9 CARD/APAF-1 CARD complex. On the left are the four 
individual heterodimer models and on the right as shown superimposed with their 
template structures. Fas-DD is coloured red, FADD-DD yellow, the Pelle/Tube complex 
blue and the caspase-9/APAF-l complex green.
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4.7 Discussion
In this chapter I have presented a detailed mutagenesis study o f  the Fas death domain 
using the yeast two-hybrid system and an NMR-based interaction assay. This study 
identified several novel residues in Fas-DD that are important for FADD-DD binding, 
and we have also seen the significant utility o f using NM R through its ability to 
distinguish between structural and non-structural mutant types in this context. The 
identification o f  residues on several disparate parts o f the solvent-exposed surface o f 
Fas-DD that are vital for FADD-DD interactions fits both with the observations o f 
Chapter 3 that suggest the formation o f  a large complex in solution, and with the data o f 
Hill et al. who recently reported an “extended binding surface o f  FADD-DD” that is 
essential o f Fas-DD binding (Hill et al., 2004). Attempts to use all these data and the 
information from other death-fold domain complex structures to build a model o f the 
Fas-DD/FADD-DD interaction produced results o f apparently limited value as this 
interaction would appear to be more complex than the Pelle-DD/Tube-DD and APAF- 
l/caspase-9 interactions which consist o f straightforward 1:1 heterodimers. The results 
from NMR-based interaction experiments between the wild-type Fas and FADD death 
domains outlined in Chapter 3 are inconsistent with the 1:1 heterodimerisation o f these 
two species in solution as these experiments strongly suggested the formation o f a 
larger, macroscopic complex.
Although the combination o f  the two sets o f results presented in Chapters 3 and 4 have 
not produced sufficient information about the interaction between Fas-DD and FADD- 
DD to build an accurate model at this time, there are several explanations that can be 
attributed to the observed behaviour. The NMR-based titration studies carried out with 
the wild-type death domains indicated the formation o f a hydrodynamically large, 
soluble complex. There is, however, no knowledge o f the size o f this complex and 
stoichiometry o f the interaction. The mutagenesis data, both from this work and the 
work presented by Hill et a l  2004, informs us o f two important facts. First the 
interaction can be essentially abrogated with a series o f single point mutations either in 
Fas-DD or FADD-DD, and second that such “knockout” mutations result from side- 
chain substitutions on multiple surface regions o f each domain.
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The combination o f these observations leads to a num ber o f  conclusions. Firstly this 
interaction is not a simple 1:1 heterodimerisation bu t instead probably involves the co­
aggregation o f these domains into higher-order hetero-oligom ers. W hether this co­
aggregation event results in a homogenous, m onodisperse complex, in the experiments 
carried out here, is unknown. However, the fact that this large complex, involving 
multiple surface regions o f  each domain can be disrupted by single point mutations on 
those surface regions indicates that the formation o f  this complex probably involves a 
co-operative binding event. Such a co-operative binding event must be initiated by the 
interaction between Fas-DD and FADD-DD but the subsequent formation o f  the higher- 
order complex may be driven by pairwise interactions o f Fas-DD:Fas-DD, FADD- 
DD.FADD-DD or Fas-DD/FADD-DD:Fas-DD/FADD-DD death domain interactions. 
Taking into consideration the limited utility o f the com plex-modelling exercise based on 
known death fold domain interactions and w ithout further work to analyse the 
hydrodynamic properties o f this complex in solution it is impractical to conclude 
anything more about the molecular details o f the Fas-DD/FADD-DD interaction at this 
stage.
Future work to characterise the Fas-DD/FADD-DD complex formed in solution should 
involve the biophysical characterisation o f its homogeneity and hydrodynamic size. If 
found to be homogenous, attempts could be m ade to use electron microscopy to 
visualise the gross m orphology o f  the complex or to co-crystallise the two proteins for 
structural analysis. There is also scope for further mutagenesis work o f  both death 
domains. Although FADD-DD mutants have been studied by other groups in different 
Fas/FADD interaction assays, it would be useful to investigate the effects o f several 
FADD-DD mutations, particularly those utilised by Hill et al., in the NMR-based assay 
developed in this study. Also, in order to further analyse the effects o f  altering the Fas- 
DD charge distribution it may be useful to create second-site mutants in the Fas-DD- 
K247A background. This type o f experiment would directly address the issue whether 
one could detect discrete Fas-DD/FADD-DD complexes lacking the characteristic o f 
apparent higher-order association witnessed in the study presented here.
In the final chapter o f this thesis I describe the development o f  a cell-based, functional 
assay that was provides essential corroboration o f the mutagenesis data presented in this 
chapter.
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Chapter 5
A functional assay for the Fas-DD/FADD-DD 
interaction
5.1 The importance of a biological assay
IN the preceding chapters the interaction between the death domains o f the Fas receptor and the adaptor protein FADD has been studied both in vitro (in an NMR- 
based assay) and in a heterologous cellular environment (in the yeast two-hybrid assay). 
However, neither o f these methods allows this interaction to be studied in the context o f 
the normal physiological roles o f these two proteins. This problem is particularly 
relevant to the extensively studied Fas-DD mutants. In order to draw conclusions about 
Fas signalling from the mutational studies o f its death domain is was important to 
correlate the behaviour o f these mutants in the NMR assay and their behaviour in a 
cellular environment.
To address this issue an assay was developed to investigate the biological effects o f 
several o f these mutants.
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5.2 FasL-induced apoptosis as an assay for Fas/FADD interaction
The study o f apoptotic pathways has the advantage o f providing an obvious biological 
readout -  cell death. The death receptor-induced apoptotic pathways have the added 
advantage o f being highly specific and inducible by the application o f  external ligands 
to the cells being studied. It has been extensively shown that the induction o f apoptosis 
through the Fas receptor in cell culture is possible simply by the addition o f FasL to the 
medium (Suda et al., 1994) and that this apoptosis is absolutely dependent on the ability 
o f Fas to bind FADD (Newton et al., 1998; Yeh et al., 1998). These facts allow the 
development o f a Fas-DD/FADD-DD interaction assay based on the ability o f FasL to 
induce apoptosis in a cell line that is artificially induced to expressing the Fas receptor 
so long as those cells also express the remaining components o f  the Fas-dependent 
apoptosis signalling pathway. Once developed, this assay could then be used to test the 
effects o f mutations in Fas-DD on FADD-DD binding in a biological context.
5.3 Development of a functional cell-based assay
The basic concept o f  the biological assay o f Fas function was as follows: wild-type and 
mutant forms o f the Fas receptor were to be expressed in individual human cell lines 
and these cell lines then would be tested for their ability to undergo apoptosis upon 
addition o f FasL. Such an assay would provide a direct biological readout o f the effect 
o f the Fas mutants on their ability to induce apoptosis and this data could then be 
directly compared with the NM R and yeast two-hybrid results for the same mutants.
There were several important factors to be considered in the development o f the assay. 
A cell line had to be selected that fulfilled a number o f  defined criteria. First, since 
human Fas and FADD proteins have been used throughout this study, the cell line 
chosen was o f human origin. Second, the cell line must not endogenously express the 
Fas receptor. Recombinant Fas, and importantly, mutants o f  Fas, could therefore be 
expressed by transfection o f an appropriate plasmid, in these cells without any 
background interference from endogenous, wild-type Fas already present in the cells. 
Quantitative measurements on the effects o f the Fas-DD mutations would then be 
possible. Finally, it was important that the chosen cell line functionally expressed the
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remaining components o f the apoptotic machinery such that when the Fas receptor was 
expressed the cells could undergo apoptosis through the canonical death receptor 
pathway.
Also o f importance in the development o f this assay was the system used to 
recombinantly express Fas in the chosen cell line. The most important factor in this case 
was to ensure that the level o f expression o f the receptor was essentially equal for the 
wild-type and each mutant chosen for analysis. W ithout consistent expression levels it 
would be difficult to quantitatively compare the effects o f  any Fas mutations. 
Traditional methods o f recombinant expression in mammalian cells rely on the use o f 
constitutively active promoters, such as the cytomegalovius (CMV) promoter, to drive 
the expression o f a protein o f  interest from a plasmid that is transfected into the cells. 
However, this method cannot guarantee that equal amounts o f protein will be expressed 
from one experiment to the next. For this reason it was decided to use a more 
controllable method o f  protein expression that takes advantage o f  an inducible promoter 
system to express the protein o f interest. In this case the “Tet-on” system (BD 
Biosciences) was selected to create cell lines that express Fas (or Fas mutants) under the 
control o f a titratable promoter system. The Tet-on system allows the amount o f protein 
expression to be directly controlled by the addition o f tetracycline (or its analogue, 
doxycyclin) to the cell culture medium. Subsequent experiments with these cell lines 
would then give more accurate, quantitative data for the effects o f  the expression of 
wild-type and mutant forms o f  Fas.
The molecular basis o f  the tetracycline-regulated expression system is outlined in 
Figure 5.1. Here it can be seen how the use o f doxycyclin (an analogue o f tetracycline) 
is used to initiate the transcription o f a target gene -  in this case encoding for the Fas 
receptor. The system relies on the use o f the tetracycline responsive transcriptional 
activator (rtRA) protein that binds specifically to the tet-response element (TRE), a 
promoter region o f DNA, encoded so as to initiate the expression o f the target gene. The 
level o f expression o f the target gene is directly proportional to the concentration o f 
doxycyclin present in the culture medium allowing the expression o f wild-type and 
mutant forms o f Fas in individual stable cell lines to be titrated to similar levels. The 
two plasmids required for these experiments -  pTet-on and pTRE2-hyg (Clontech) (see 
Appendix 4) -  contain ampicillin resistance genes to allow their propagation in E. coli.
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Each plasmid also contains a second antibiotic resistance gene (neomycin in the case o f 
pTet-on and hygromycin (hyg) in the case o f pTRE2-hyg) to allow separate and 
combined selection o f successfully transfected mammalian cells.
pCMV
rtTA
Constitutive expression of 
Tet-responsive protein 
(rtTA) from a CMV promoter
Integrated copy of 
pTet-on plasmid
Addition of
.-----  Doxycyclin to
(dox^) ce|| culture 
medium
Activation of rtTA by 
doxycyclin
TRE TRE
Integrated copy of 
pTRE2 plasmid 
containing the Fas gene
Fas gene expression is only 
initiated by active rtTA binding to 
the tet-response element (TRE)
Figure 5.1: The Tet-on mammalian expression system as used to express the Fas receptor. 
Here the Fas gene has been cloned into the pTRE2 plasmid and both the pTet-on and 
pTRE2-Fas plasmids have been stably transfected into a mammalian cell line. The 
constitutively expressed tet-responsive transcriptional activator protein (rtTA) is activated 
by doxycyclin. Once active, the rtTA protein binds to the tet-response element (TRE) to 
initiate expression of the target gene (in this case, Fas).
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5.4 Choice of cell line
Initially three human cell lines were found that potentially fulfilled the criteria outlined 
in Section 5.3. These cell lines were A549, Hep3B and Huh7 (kind gifts from Henning 
Walczak o f the University o f Heidelberg, Germany). A549 and Huh7 represent human 
lung carcinoma cell lines and Hep3B is a human lung carcinoma cell line. These cell 
lines are all reportedly resistant to FasL-induced apoptosis and express little or no Fas 
receptor (H. W alczak, personal communication, (Muller et al., 1997), (Nambu et al.,
1998)). As these three cell lines are transformed (from carcinomas), they have the added 
advantage o f being relatively facile to culture and unlikely to senesce. However, despite 
the promise o f these three cell lines, several important features had to be checked before 
one was selected for further experiments.
First, it was important to confirm the resistance o f  the cells to FasL-induced apoptosis, 
particularly since previously published evidence suggests variability o f different cell 
lines in their responses to different inducers o f Fas (outlined in (Holler et al., 2003) and 
(Algeciras-Schimnich et al., 2003)). It should be noted that both the cross-linking o f Fas 
receptors with either an anti-Fas antibody or using aggregated forms o f  soluble FasL 
can both induce apoptosis in cells expressing the Fas receptor. For the present study the 
use o f FasL was preferred, in order to reflect the natural events o f apoptosis through 
Fas. Specifically, the reagent chosen was a recombinant, human, soluble FasL (rhsFasL 
-  Alexis). It is well established that the trimeric FasL alone is inefficient at promoting 
apoptosis, but when cross-linked to form higher order oligomers, FasL becomes a much 
more potent reagent (Holler et al., 2003). For this reason rhsFasL is epitope tagged 
(with a FLAG-tag -  a sequence o f  26 amino-acids at the N-terminus) and is supplied 
with a cross-linking anti-FLAG antibody (the “enhancer”). Combining rhsFasL with the 
enhancer results in potent and highly specific induction o f apoptosis through the Fas 
receptor.
5.4.1 The MTT assay
An assay using the compound methylthiazoletetrazolium (MTT) in order to test the 
effect o f rhsFasL on cell survival was adopted. In live cells, MTT is metabolised to a
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purple formazan compound by the metabolic enzyme succinate dehydrogenase (SDH), 
while in dead cells the SDH substrate remains yellow (Hansen et al., 1989). Following 
incubation with MTT, cells were lysed with a solution containing SDS detergent (along 
with DMF to solublise the dye) and the absorbance o f the resulting solution was 
measured at 540 nm (see Section 2.5.3). Because the amount o f  dye turned over is 
proportional to the number o f M TT-metabolising cells, this assay provided an accurate 
measure o f the number o f living cells in a culture. The combination o f rhsFasL 
treatment followed by the MTT assay therefore provided a simple method to 
quantitatively assess Fas-dependent cell death in our cultures.
The three cell lines were tested for their response to FasL by incubation with increasing 
concentrations o f rhsFasL (up to 50 ng/ml, see Section 2.5.4). Two different controls 
were carried out in parallel: first, in order to confirm the function o f the FasL reagent, 
the cell line A20 was tested alongside the other cell lines. A20 is a murine B-lymphoma 
cell line that is especially susceptible to apoptosis through Fas and hence provides a 
useful positive control for this part o f  the assay. The use o f  a murine cell line for this 
purpose is possible since human FasL is known to activate murine Fas. Second all four 
cell lines were treated with a high dose o f staurosporine -  a general protein kinase 
inhibitor that is known to initiate caspase-dependent apoptosis independent o f Fas 
(Kabir et al., 2002). The application o f staurosporine here serves as a useful control for 
the MTT assay as well as confirming the integrity o f the apoptotic machinery 
downstream o f caspase activation. As illustrated in Figure 5.2, all four cell lines showed 
significant death in response to treatment with 0.5 pM  staurosporine, whereas only the 
A20 cell line showed a response to rhsFasL. As little as 2 ng/ml rhsFasL resulted in a 
40 % reduction in A20 viability but doses up to 50 ng/ml had essentially no effect on 
the A549, Huh7 and Hep3B cell lines.
Having established that all three human cell lines were resistant to Fas ligand it was 
necessary to check for their expression o f Fas, FADD, caspase-8 and FasL. The 
expression o f the Fas machinery was investigated by Western blotting and the 
expression o f FADD by immunocytochemistry as outlined below.
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Figure 5.2: A549, Huh7 and Hep3B cell lines are not responsive to Fas-ligand. Treatment of 
these three cell lines followed by the MTT assay to count the numbers of remaining, viable 
cells showed no significant reduction in cell number. The A20 cell did respond to FasL at a 
concentration of 2 ng/ml and all four lines showed a significant decrease in cell number in 
response to treatment with 0.5 pM staurosporine. Note that the A20 cell line was only treated 
with a single concentration of FasL (2 ng/ml). Data is displayed as the mean of three 
independent experiments with error bars showing ± one standard deviation from the mean.
5.4.2 Western blotting and immunocytochemistry
Western blotting and “ICC” are two complementary techniques that are used to probe 
cells or cell-lysates for the presence o f particular macromolecules. Each technique 
requires the application o f specific antibodies raised against the protein(s) o f interest. In 
each case a secondary antibody system is used to amplify the signal and provide a 
quantitative readout (see Section 2.5.5).
Cell lysates were prepared from the three cell lines, Huh7, Hep3B and A549, as well as 
from the A20 cells as a control, and Western blotting analysis was carried out as 
described in Section 2.5.5. Initial results o f these analyses are shown in Figure 5.3. 
These images are produced by digitally scanning the x-ray films used to detect antibody 
binding. Fas was only detectable in the A20 cell line, but importantly not in the three 
human cell lines. In contrast, caspase-8 was detected in all three human cell lines, while 
FasL was present in all but the Hep3B cell line. It is unclear why no caspase-8 was 
detected in the A20 cell-line. This may be due to a lower binding affinity o f this
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antibody with murine caspase-8 compared to human caspase-8 (although the 
manufacturer does claim that this antibody does cross-react with the murine isoforms) 
or it may be that the A20 cells express caspase-8 in relatively lower amounts than the 
human cell lines and was hence not detectable in this experiment. Attempts to determine 
FADD expression by Western blotting using the murine anti-FADD antibody (610399) 
proved to be unsuccessful, presumably due to this antibody requiring a native structured 
antigen. Time constraints on the project meant that this specific experiment could not be 
optimised or attempted using alternative reagents and hence ICC was used as an 
alternative to western blotting to test for the presence o f FADD in each o f the three cell 
lines. Huh7, Hep3B and A549 were cultured in two chambers o f a chamber slide and 
the ICC protocol, outlined in Section 2.5.6, was then used with the anti-FADD antibody 
to label any FADD in these cell cultures. As a negative control, for each cell line one o f 
the chambers in these experiments was incubated without primary antibody. This was to 
ensure that any background staining from the secondary antibody could be detected and 
accounted for.
Caspase 8 (55 kDa)
Fas (43 kDa)
FasL (38 kDa)
Figure 5.3: Western blotting analysis of cell lysates probed for the presence of Fas,
FasL and caspase-8. Results shown here originate from three separate blots.
Figure 5.4 shows images o f labelled cells from the three cell lines taken at 60x 
magnification. To create such two-colour images the same microscope field was 
digitally captured twice, once with a FITC-filter and once with a DAPI-filter, and the 
two resulting images overlaid to show healthy DAPI-stained nuclei surrounded by the 
green FITC fluorescent-labelled cytoplasm, indicating the presence o f FADD protein. 
FADD staining was confirmed for all three cell lines and fluorescence was absent from 
all negative-control wells.
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Figure 5.4. Immunocytochemistry analysis of FADD in the three cell lines Hep3B, Huh7 and 
A549. FADD is detected with FITC and appears as green fluorescence in these cells. Nuclei 
are stained blue with DAPI. Images were taken at 60x magnification.
These initial experiments confirm that all three human cell lines were resistant to FasL 
and this was probably due to the absence o f Fas receptor expression. It was also clear 
that the three cell lines expressed caspase-8 and FADD, the key downstream molecules 
in the formation o f the apoptotic DISC. Consequently, all three cell lines were carried 
forward for further analysis.
5.5 Creation of a Tet-responsive cell-line
In order to create stable cell lines expressing wild-type and mutant variants o f  Fas and 
using the Tet-on system several experimental procedures had to be performed as 
outlined below.
1) Stable transfection o f the pTet-on plasmid into the cell line o f  interest.
2) Selection o f the transfected clone that gives the best response to doxycyclin.
3) Cloning o f the target genes o f interest into the pTRE2-hyg vector.
4) Stable transfection o f the pTRE2 plasmids into the selected Tet-on cell line.
5) Selection o f clones that show expression o f the target gene.
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The three mutant forms o f Fas, D244A, K280A and K247A w ere selected for their 
contrasting effects observed in the NMR and yeast two-hybrid FADD-DD binding 
assays. There was particular relevance in testing the D244A and K247A mutants as 
these had been used extensively in the initial NM R experiments, as described in Chapter 
3. The validity o f  the structural data would be greatly enhanced if  it could be shown that 
the D244A Fas mutant was unable to induce apoptosis and if  the K247A mutant was 
shown to have similar activity to the wild-type Fas receptor in a biological system.
As a first step to achieving this goal, the pTet-on plasmid was transfected into the three 
cell-lines, Huh7, Hep3B and A549 with the aim o f creating a stable, doxycyclin 
responsive cell line.
5.5.1 Stable mammalian cell transfection
The transfection o f  mammalian cells with plasmid, or other types o f  DNA constructs, is 
now a well established technology that has become routine in many cell biology 
experiments. However, unlike transformation o f DNA into bacterial cells, stable 
expression o f recom binant proteins in a mammalian cell relies on the integration o f 
target genes into a suitable position in genome o f that cell. In general, this process o f 
integration cannot be precisely controlled and hence transfection can be inefficient. 
Furthermore, as is the case with the Tet-on system, it is not only to the target genes, but 
also the antibiotic resistance gene(s) that must be integrated in order to allow for the 
selection o f successful transformants in medium containing those antibiotics. Therefore, 
following transfection (and after antibiotic selection has occurred) several clones must 
be tested for expression o f  the protein(s) o f interest.
For the present experiment, transfection with the pTet-on plasm id was carried out in the 
6 well plates as directed by the manufacturer’s protocol outlined in Section 2.5.7. For all 
three candidate cell-lines a greater percentage o f cell survival was observed on the 
plates originating from well F, suggesting that the 6:1 transfection reagent:DNA ratio 
was optimal in these experiments.
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The surviving cells were cultured for a further ten days in medium  with a reduced 
concentration o f G418 (200 pg/ml). A fter ten days individual colonies o f  cells began to 
grow. Fifteen such colonies from each cell-line these were picked from the 100 mm 
culture plates using a sterile pipette tip and transferred to an individual well o f a half­
area 96-well tissue culture plate. In this way, individual clones were selected and 
separated from the rest o f the cells for further culturing. This process o f  clonal selection 
enables the detection o f successfully transfected clones that have integrated the plasmid 
genes successfully into their genome.
5.6.1 Tet-on clone selection
After transfection with the pTet-on plasm id the clone that gave the best response to 
induction o f target gene expression with doxycyclin was selected. This was achieved by 
transiently transfecting the individual clones with the pTRE2-Luc plasmid (Clontech). 
The pTRE2-Luc plasmid is a modified form o f the pTRE2-hyg plasmid that is 
engineered to produce the firefly luciferase enzyme under control o f the Tet response 
element.
Each o f the 13 Tet-on clones was seeded into three wells o f a 96-well plate. Two o f the 
three wells o f each cell line were transfected with 40 ng o f  pTRE2-Luc plasmid DNA 
using 0.25 pi o f the transfection reagent Fugene6. Doxycyclin was added to one o f the 
two transfected wells to a final concentration o f 2.5 pg/ml. After 48 hours the cells were 
subjected to the Luclite luminescence assay to measure the activity o f any expressed 
luciferase. By comparing the amount o f luciferase expression in the pTRE2-Luc 
transfected cells with and without the addition o f doxycyclin the most responsive Tet-on 
clone could be selected.
Figure 5.5 shows the data from the luminescence assay as carried out on the 13 
available clones. This data is presented as figures corrected by subtraction o f the 
background luciferase activity (measured for the untransfected cells) from the raw 
luminescence values. It is worth noting, however, that the background luminescence 
was always below the essentially insignificant level o f 100 counts per second (CPS). It 
can be seen from these results that the Huh7 cell line provided the most strongly
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inducible clones (namely Huh7-3 and Huh7-4). These two clones represented the only 
derived cell lines that showed an increase in luciferase expression in response to the 
addition o f doxycyclin and were selected for further use. The remaining clones (and the 
two cell lines A549 and Hep3B) were excluded from further experiments.
During attempts to culture the two Tet-responsive clones Huh7-3 and Huh7-4, it became 
clear that Huh7-3 grew more slowly than Huh7-4. For this reason the Huh7-3 clone was 
also excluded from the remaining experiments.
Luciferase assay
25000
■ - doxcycyclin 
□ + doxycyclinr? 20000
*  15000
g 10000
-J 5000
C lone Name
Figure 5.5 Selection of a single Tet-responsive clone using the luciferase assay. Light 
emitted from the luciferase enzyme expressed in Tet-responsive clones transiently 
transfected with the pTRE2-Luc plasmid was detected as luminescence and recorded as 
counts per second (CPS).
5.7 Creation of Tet-responsive Fas-expressing cell lines
Once the Tet-responsive cell line had been created, a second round o f  transfections was 
necessary in order to create cells that would express Fas (and the chosen mutants o f Fas) 
in a controllable fashion. Therefore, DNA encoding the full length human Fas receptor 
(a kind gift from Jtirg Tschopp, University o f  Lausanne, Switzerland) was subcloned 
between the M lul and N o tl restriction sites in the pTRE2-hyg plasmid, using PCR 
primers 57 and 58, to create the plasmid pTRE2-Fas. The pTRE2-Fas plasmid was used
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as a template to create the three chosen single residue mutants, D244A, K247A and 
K280A with the QuickChange site directed mutagenesis kit (Stratagene) and the 
resulting four plasmids were used for stable transfection into the Huh7-4 cell line. A 
fifth plasmid, the pTRE2-Luc plasmid, was also transfected into this cell line as a 
negative control for the apoptosis experiments.
Two stable clones were produced for each o f the five transfected pTRE2 plasmids 
(containing DNA encoding wild-type Fas, the three Fas mutants and firefly luciferase). 
In order to check for expression o f Fas in these clones, cell lysates were prepared 
following incubation o f the cells for 24 hours in double selective medium supplemented 
with 1 pg/ml doxycyclin. The cell lysates were separated by SDS-PAGE and Western 
blots were carried out to probe for the presence o f the Fas protein. Figure 5.6 shows 
examples o f several o f these lysates from double transfected cells probed with the anti- 
Fas antibody 3D5. From this figure it can be seen that individual clones were found to 
express wild-type or mutant forms o f the Fas receptor and that the luciferase clone, 
along with the untransfected Huh7 cell line, showed no detectable levels o f Fas 
expression. O f the clones tested, some (including the clone named K280A2 shown in 
Figure 5.6) did not express Fas, highlighting the need to test several clones o f each 
stable cell line created in this type o f experiment.
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Figure 5.6: Selection o f  Tet-inducible Fas-expressing cell-lines. Lysates prepared from 
individual double-stable clones, A 20 and untransfected Huh7 cells were probed with anti- 
Fas antibody (3D 5).
From the full set o f  stable, doubly transfected clones, five were chosen that separately 
expressed the different genes o f interest: Wild-type Fas (named Huh7T-Fas), Fas- 
D244A (Huh7T-FasD244A), Fas-K247A (Huh7T-Fas-K247A), Fas-K280A (Huh7T-
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FasK280A) and Luciferase (Huh7T-Luc). The remaining experiments were carried out 
with these five cell lines.
5.8 Equalisation of Fas expression
Next, it was next necessary to normalise the levels o f  expression in the four Fas- 
expressing cell lines before carrying out further experiments by finding conditions 
where equivalent levels o f the target gene was expressed. This normalisation was 
achieved by incubating each cell line with a range o f  concentrations o f doxycyclin 
(between 1 and 5 pg/m l) for a period o f 24 hours, before carrying out Western blotting 
experiments to quantify the level o f Fas protein expression.
The precise concentration o f  doxycyclin used to induce comparable levels o f Fas (or Fas 
mutant) protein expression varied for each o f the four cell lines. In each case, the 
appropriate level o f  doxycyclin was established empirically using Western blotting with 
the anti-Fas monoclonal antibody to quantify the expression level. Using this laborious 
procedure we settled upon the following doxycyclin concentrations for the set o f doubly 
transfected Huh7 clones (see Figure 5.7):
Huh7T-Fas: 1 pg/ml
Huh7T-Fas-K247A: 4 pg/ml
Huh7T-Fas-K280A: 4 pg/ml
Huh7T-Fas-D244A: 5 pg/ml
The expression o f  Fas in the stable doubly transfected cell lines was also confirmed 
using ICC. Visualisation o f the expression Fas on the surface o f the four Fas-expressing 
cell lines was possible by carrying out ICC experiments without permeablising the cells 
before probing with anti-Fas antibody. This experiment required the use o f a second 
anti-Fas antibody as the antibody used in previous experiments (monoclonal antibody 
3D5) was raised against the cytoplasmic domain o f Fas. In this case it was necessary to 
use an antibody raised against the extracellular domain o f Fas, hence a monoclonal, 
mouse anti-human Fas antibody from BD Biosciences (#610197) was selected.
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Figure 5.7 Equalisation o f  Fas expression levels in double-stable Tet-responsive cell lines. 
Cells were incubated for 24 hours with the indicated doxycyclin  (dox) concentrations.
Cell lysates were then probed for Fas expression and for (3-tubulin as a loading control. A:
A20, B:Huh7, C: Huh7-Luc, D:Huh7T-Fas, E: Huh7T-Fas-K280A, F:Huh7T-Fas-K247A, 
G:Huh7T-Fas-D244A. B y using these specific dox concentrations the level o f  Fas 
expression was the same in the four Tet-inducible Fas-expressing cell lines. In contrast, no 
Fas expression w as seen in the luciferase-expressing cell line, after incubation with the 
highest used dox concentration, or in the untransfected Huh7 cells.
ICC experiments on the five double-stable cell lines were carried out in the same 
manner as outlined in Section 2.5.6 but omitting the detergent permeablistion step. 
Sample images obtained from two replicate experiments are shown in Figure 5.8. These 
results indicate that there is surface expression o f the Fas receptor in all four Fas- 
expressing cell lines but not in the cell line expressing firefly luciferase.
Following these procedures, I was in the position where stable cell lines had been 
created that express either wild-type Fas or one o f three Fas mutants (D244A, K247A or 
K280) under control o f  the Tet-on expression system, which permits Fas expression to 
be titrated to the same level in all four cell lines. A fifth cell stable cell line, expressing 
firefly luciferase under control o f the same Tet-inducible promoter, had also been 
created to be used as a negative control in the remaining experiments. In the final set o f 
experiments these cell lines were tested for their ability to undergo Fas-induced 
apoptosis.
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b) Huh7T-Fas
c) Huh7T-Fas-D244A
d) Huh7-Fas-K247A
e) Huh7T-Fas-K280A
Figure 5.8 ICC experiments carried out on unpermeablised double-stable cell lines. C ells were 
probed with an antibody raised against the extracellular domain (E C D ) o f  Fas and a FITC- 
labelled secondary antibody. C ells were counterstained with DAPI (blue). FITC staining 
(green) was only observed in cells shown to expressing Fas by W estern blotting and only in 
the presence o f  the anti-Fas antibody. This data indicates the surface expression o f  
recombinant wild-type or mutant Fas receptors in the Tet-responsive cell lines. Images were 
taken at 60x magnification
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5.9 Cell death experiments
In the final series o f experiments I investigated the ability o f  the five double-stable cell 
lines to undergo cell death in response to the administration o f  FasL to the medium. 
Since it was important to confirm that cell death recorded in these experiments was due 
to apoptosis and not to other cell death pathways, two further experiments were carried 
out. First, a specific caspase-8 inhibitor was used to investigate whether death was 
occurring via the expected Fas-FADD-caspase-8 pathway. Second, a TdT-mediated, 
dUTP nick-end labelling (TUNEL) assay (Gavrieli et al., 1992) was performed to 
specifically label cells containing fragmented chromosomal DNA.
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Figure 5.9: The response o f  cell lines expressing Fas, Fas mutants or luciferase to rhsFasL. 
This data shows the percentage o f  living (actively m etabolising) cells -  as measured by the 
MTT assay -  after incubation o f  the five double-stable cell lines with increasing doses o f  
rhsFasL. Cells expressing wild-type Fas or the K247A mutant die with similar, dose-dependent 
kinetics. Cells expressing Fas-D 244A  or luciferase are com pletely resistant to rhsFasL and 
cells expressing Fas-K 280A die with reduced kinetics relative to the w ild-type protein.
Each o f the five transfected Huh7 cell lines was incubated with increasing 
concentrations o f rhsFasL for a period o f 24 hours after which cell survival was 
measured using the MTT assay. It can be seen from Figure 5.9 that the cell line 
expressing wild-type Fas underwent FasL-dependent cell death in a dose-response 
manner. When incubated with rhsFasL at a concentration o f 200 ng/ml the cells are 
almost 100% dead. In contrast, the luciferase-expressing cell line was completely
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resistant to rhsFasL at the concentrations tested. This data suggested that the 
reconstituted Fas receptor was able to function correctly, to bind FasL and induce cell 
death in the Huh7T-Fas cell line. In contrast to the situation for transfected wild-type 
Fas, the mutant Fas receptor, Fas-D244A, was unable to respond to rhsFasL. The cell- 
line expressing Fas-K247A showed a very similar response to the cells expressing wild- 
type Fas and the cell line expressing Fas-K280A showed some response to rhsFasL but 
this response was greatly attenuated relative to that o f  w ild-type Fas.
5.9.1 Caspase-8 inhibition assay
The specific caspase-8 inhibitor A-benzyloxycarbonyl-Ile-Glu-Thr-Asp- 
fluoromethylketone (z-IETD-fmk) (Martin et al., 1998) was used to ensure that the cell 
death induced by rhsFasL was proceeding through the expected Fas-FADD-caspase-8 
pathway. The synthetic z-IETD-ffnk peptide is designed to mimic the optimal peptide 
sequence recognized by caspase-8 and works by irreversibly binding to the enzyme’s 
active site (Watt et al., 1999). For this experiment cells expressing Fas or firefly 
luciferase were incubated with 50 pM z-IETD-fmk, or vehicle (DMSO), for 1 hour 
before addition o f 200 ng/ml rhsFasL or 500 nM staurosporine. Figure 5.10 shows that 
cells expressing wild-type Fas, Fas-K247A or Fas-K280A were partially protected from 
cell death induced by rhsFasL when treated with the caspase-8 inhibitor. In contrast, 
cells expressing wild-type Fas were not protected from cell death induced by 
staurosporine. This data suggests that cell death induced by rhsFasL in these cells is 
dependent on the action o f  caspase-8.
5.9.2 TUNEL assay
To investigate whether that the caspase-8 dependent cell death induced by rhsFasL was 
apoptosis, the TUNEL assay was used to detect DNA fragmentation in the dying cells. 
DNA fragmentation is one o f the hallmark events o f apoptotic cell death (Saraste and 
Pulkki, 2000) occurring downstream of the caspase cascade. If  it could be shown that 
the cell death induced by rhsFasL in the Fas-expressing cell lines involved DNA 
fragmentation then this data, along with the caspase-8 dependence shown above, would 
constitute compelling evidence that these cells are undergoing Fas-induced apoptosis.
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Caspase-8 Inhibition Assay
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Figure 5.10: Inhibition o f  rhsFasL-induced cell death with the caspase-8 inhibitor z-IETD- 
fmk. C ells were incubated with or without z-IETD-fm k for 1 hour before being treated with 
200 ng/ml rhsFasL. C ells expressing wild-type Fas, Fas-K 247A  or Fas-K 280A  could be 
partially protected by this inhibitor from cell death induced with FasL. Death o f  cells 
expressing wild-type Fas induced by staurosporine (ssp) could not be inhibited.
Each o f the five transfected Huh7 cell lines was subjected to the TUNEL assay (as 
outlined in Section 2.5.9). Following this assay, cells were counterstained with 
bisbenzimide H 33342 -  also known as Hoechst stain -  before being examined by 
fluorescent microscopy. Hoechst stain has a very similar mechanism o f action to DAPI, 
giving rise to blue fluorescence when bound to AT-rich DNA sequences (Otto and 
Tsou, 1985), but has also been shown to increase in fluorescent intensity when bound to 
fragmented DNA and hence is useful for identifying apoptotic nuclei (Hardin et al., 
1992).
Sample images from these experiments are shown in Figure 5.11. It can be seen by 
Hoechst staining that cells undergoing apoptosis (either from treatm ent with rhsFasL or 
with staurosporine) showed nuclear condensation and fragmentation. Such apoptotic 
cells were positively labelled by the TUNEL assay. As expected, the cell lines 
expressing wild-type Fas, Fas-K247A and Fas-K280A all contained TUNEL positive 
nuclei upon treatment with rhsFasL whereas the cell-line expressing Fas-D244A 
showed very few such positively labelled cells. On the other hand, all cell lines 
produced TUNEL positive cells upon treatment with staurosporine. These experiments, 
taken together with the caspase-8 inhibitor data strongly suggest that Huh7 cells re­
engineered to express Fas undergo apoptosis following exposure to rhsFasL.
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Figure 5.11: Sample fluorescence images o f  TUNEL and H oechst staining o f  Fas
expressing Huh7 cell lines. M onolayers o f  cells on chamber slides were treated with 
rhsFasL, staurosporine (ssp) or left untreated. A fluorescent TUNEL assay was then 
carried out to label fragmented D N A  with FITC and cells were couterstained with  
Hoechst. The pairs o f  im ages seen here are o f  the same cells with the green, TUNEL- 
positive, fragmented nuclei superimposed with the blue H oechst-staining in the top 
image and the Hoeshct staining by itse lf below.
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For semi-quantitative analysis o f cell death in these experiments, at least 3000 Hoechst- 
stained cells from each experiment were counted and the num ber o f TUNEL-positive 
cells recorded. From the data presented in Table 5.1, it can be seen that the relative level 
of apoptosis detected by the TUNEL assay in these cell lines correlates well with the 
amount o f cell death determined by the MTT assay. In untreated cultures, the level o f 
apoptosis was close to zero, but when treated with rhsFasL the cells expressing wild- 
type Fas or Fas-K247A underwent similarly high levels o f  apoptosis, the Fas-K280A 
expressing cells underwent a lower but still significant amount o f death and the Fas- 
D244A expressing cells showed no increase above the background level o f apoptosis. 
Importantly, significant apoptosis was detected in all cell lines upon treatment with 
staurosporine. In control experiments, without the TdT enzyme no TUNEL positive 
cells could be found.
Huh7T-Fas Huh7T-Fas-
D244A
Huh7T-Fas-
K247A
Huh7T-Fas-
K280A
+ FasL 318 3 339 173
- FasL 3 5 1 10
+ ssp 158 96 106 83
-T dT 0 ND ND ND
Table 5.1: Quantification of TUNEL assay experiments. The number of TUNEL positive 
cells was counted from a population of at least 3000 cells chosen randomly from two 
chambers of each experiment (ND -  not determined).
5.10 Conclusions from functional assay development
Following the in vitro mutagenesis studies o f the interaction between Fas-DD and 
FADD-DD, it was necessary to develop an assay that could probe this interaction in the 
context o f the biological roles o f  these two proteins.
To achieve this, three putatively Fas negative, human cell lines, A549, Hep3B and Huh7 
were initially chosen. All three cell lines were shown to be resistant to FasL-induced 
death. A combination o f Western blotting analysis and im munocytochemistry indicated 
that these cell lines did not express the Fas receptor protein but did express caspase-8 
and FADD. It was necessary to use ICC to test for FADD expression as the anti-FADD
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antibody could not be successfully used to probe W estern blots. The incompatibility o f 
this antibody with Western blotting stems from the nature o f  the experiments being 
conducted. For example, some antibodies rely on the correctly folded shape o f their 
target protein for recognition and, since Western blotting results in protein denaturation, 
such antibodies will no longer be able to bind to their target protein in these 
experiments, in the case o f the anti-FADD antibody used in this study, Western blotting 
did not work, but subsequent ICC experiments were successful and the three cell lines 
were shown to express the FADD protein.
The Tet-on expression system was then used to generate four individual, stably 
transfected cell lines that express the wild-type or one o f  three death domain mutants o f 
the Fas receptor. A single Huh7-Tet-on clone was chosen to express the Fas constructs 
as this cell line showed the greatest response to doxycyclin induction.
Although the expression o f  Fas in the four cell lines was initially different, the Tet-on 
system allowed equalisation o f  these expression levels by titration with doxycyclin. 
Interestingly, during the W estern blotting analysis that was used to follow this titration 
process, it was notable that the Fas signal in the control A20 cell lysate was regularly 
observed at 43 kDa -  8 kDa higher than the recombinantly expressed Fas in the Tet- 
responsive cell lines (35 kDa). These two molecular weights are consistent with the 
glycosylated and unglycosylated forms o f the receptor respectively. It is probable that, 
for an unknown reason the recombinantly expressed Fas is not being fully glycosylated 
by the transfected cell line. However it is unlikely that this absence o f  glycosylation 
affected Fas activity as there have been no reports o f glycosylation being important for 
the function o f this receptor, and subsequent experiments were entirely consistent with 
this receptor being competent to induce apoptosis. A second interesting feature o f  the 
western blots for ectopically expressed Fas was the consistent appearance o f several 
smaller bands above the main 35kDa signal (see Figures 5.6 and 5.7). The reason for the 
appearance o f such bands is unclear since they may correspond to non-specific binding 
o f the 1° antibody. However there is also a possibility that these additional bands are 
due to post-translational modification o f the Fas protein in the Huh7 cells. The Fas 
protein may be phosphorylated, (partially) glycosylated or SUM Oylated following its 
expression resulting in a series higher molecular weight species being observed on the 
western blots.
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These experiments showed the utility o f inducible expression systems in allowing the 
parallel expression o f different proteins in four individual, stably transfected cell lines to 
be titrated to the same level. Having established that the expression o f  Fas and the three 
Fas mutants could be controlled and equalised, the rem aining cell death experiments 
could be quantitatively analysed to assess the effects o f  Fas m utants on the ability o f Fas 
to induce apoptosis.
To achieve this, it was first shown that the expression o f  the wild-type Fas receptor in 
Huh7 cells sensitised the cells to death induced by recom binant Fas ligand. These Fas- 
expressing cells, when treated with rhsFasL, could be partially rescued from cell death 
by the use o f z-IETD-fmk, a specific caspase-8 inhibitor, and were shown to undergo 
DNA fragmentation by the use o f  a fluorescent TUNEL assay. The TUNEL-positive 
cells in this assay were seen to exhibit shrunken and fragmented nuclei, consistent with 
the morphological changes caused by apoptotic cell death. M oreover, the same cells, 
when treated with staurosporine, underwent the same DNA fragmentation and 
morphological changes, but this death could not be inhibited by z-IETD-fmk. It is 
almost certain, therefore, that the treatment o f Fas-expressing Huh7 cells with Fas 
ligand resulted in caspase-8-dependent apoptosis.
Previous studies o f  the specific signal transduction pathway initiated by the interaction 
between Fas and FasL have shown that this form o f caspase-8 dependent apoptosis is 
dependent on the interaction between the death domains o f Fas and FADD (e.g. Yeh et 
al., 1998). The cell-based assay developed here can therefore serve effectively as an 
assay for the interaction between these two domains. Three Fas-DD mutants, D244A, 
K247A and K280A, were tested for their effects on Fas-induced apoptosis. The results 
showed that the K247A mutation had little or no effect on the activity o f Fas, but the 
D244A mutation completely abrogated Fas-induced apoptosis, while the K280A 
mutation resulted in a significant reduction in the amount o f cell death.
A significant correlation was noted between the effects o f the three mutations chosen 
for analysis in the cell-based assay and their effects on FADD-DD binding in the NMR 
and yeast-based experiments. In each case the K247A mutant exhibited similar effects 
as the wild-type Fas, the D244A mutation knocked out the activity o f  the wild-type 
protein and the K280A mutant showed an intermediate behaviour (either weakened
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FADD-DD binding or significantly reduced apoptosis). This correlation serves to 
strengthen the conclusions from the NMR-based assay, the yeast two-hybrid analysis 
and the cell-based assay.
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Chapter 6
Discussion
THE data I have presented in this thesis serve to illustrate several key points regarding the nature o f  the interaction between the death domains o f the Fas 
receptor and its adaptor protein FADD. This interaction plays a key role in the initiation 
o f apoptosis o f certain cell types though the extrinsic pathway leading to the activation 
o f caspase-8 and caspase-10. Using a combined, m ultidisciplinary approach, involving 
structural and cell biological methods, this interaction has been probed in the context o f 
the two isolated death domains as part o f a wider effort to understand the molecular 
basis for the signal transduction carried out following ligation o f  the Fas receptor. The 
remainder o f this discussion will focus on achievements o f this study and outlines the 
possibilities for the future o f the project.
In Chapter 3 it was initially confirmed, using the yeast two-hybrid assay, that Fas-DD 
and FADD-DD productively interact in a cellular environment and that this interaction 
can be effectively abrogated by the D244A substitution in Fas-DD. It was then shown 
how these two death domains could be produced in a tractable form for studies with 
biomolecular nuclear magnetic resonance spectroscopy. The requirement for such 
NMR-based studies is the production o f  multi-milligrams o f protein that is stable at 
millimolar concentrations. As shown by the attempts to produce Fas-DD in a form that 
was suitable for interaction studies with FADD-DD there are often problems associated
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with the production o f proteins for structural biology. Several approaches were taken to 
overcome the self-aggregation o f wild-type human Fas-DD w hich occurred during 
attempts to concentrate this protein in buffers at physiological pH. These approaches 
included the use o f  different fusion protein partners (namely GST and G bl), alteration 
o f the amino-acid sequence boundaries o f the death domain and site-directed 
mutagenesis o f solvent-exposed residues. Fas-DD was produced in a suitable form by 
through both the use o f  the G bl fusion partner (to create G bl-Fas-D D ) and by using the 
Fas-DD-K247A mutant. The fact that it was necessary to apply such a wide range o f 
strategies to solve this problem is an illustration o f  the general non-generic nature o f 
proteins and protein fragments. It is still largely impossible to accurately predict the 
properties o f  a protein in solution from its primary sequence or, once a protein is 
produced, to predict the effects o f any changes in the DNA construct used to encode that 
protein, or the consequences o f changes in the buffer used to solublise that protein. 
There are numerous examples o f how all three o f the approaches used in the attempts to 
increase the expression yield and solubility o f  Fas-DD, along with other strategies not 
attempted in this work, have been applied successfully to the production o f other 
proteins or protein domains (reviewed in (Georgiou and Valax, 1996; Waldo, 2003)). 
Such issues are highlighted by the difficulties being encountered by the highly 
resourced efforts in structural genomics (SG) projects around the world. The aim o f SG 
initiatives is to solve the three dimensional structures o f all (or a representative number) 
o f the proteins synthesised from a variety o f species. Initial estimates o f  the success o f 
rates o f these projects suggested that each one would solve the structures o f 10-15% o f 
their targets (Thornton, 2001; Service, 2002). In fact these seemingly conservative 
targets are now seen as overestimates and, at the time o f w riting this thesis, only 1587 
out o f 84938 selected gene targets have produced three dimensional structures that have 
been submitted to the RSCB protein data bank (PDB) database (data taken from 
Targetdb -  http://targetdb.pdb.org/). This amounts to an overall success rate o f less than 
2%. It is clear that the typical generic, high-throughput “pipeline” nature o f these 
initiatives is, at present, incompatible with the non-generic nature o f  individual 
polypeptide chains. For example, an analysis o f one set o f SG target proteins showed no 
correlation between the primary amino-acid sequence (or composition) and the 
tractability o f that polypeptide as a viable structure determination candidate as defined 
by the quality o f a 2D [^N -'H j-H SQ C  NMR spectrum (Yee et al., 2002).
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Having successfully produced the wild-type human FADD-DD and Fas-DD proteins in 
such a form that is suitable for structural studies, a series o f  titrations, monitored by 
[^N -’Hl-HSQC NM R spectroscopy, was carried out in an attempt to characterise the 
interaction between these two domains in solution. Titration o f  either unlabelled G bl- 
Fas-DD into 15N-FADD-DD, or unlabelled FADD-DD into 15N -G bl-Fas-D D , resulted 
in the monotonic loss o f the NMR signals from the 15N-labelled death domain 
component. The resultant complex was evidently itself soluble as indicated by the 
presence o f signals from mobile elements in the isotope-labelled component o f the 
titration (either the terminal residues and side-chain carboxyamide groups from 15N- 
FADD or the entire G bl domain o f 15N-Gbl-Fas-DD). The interaction was also shown 
to be specific to the death domains -  as it could be essentially abrogated by the use o f 
the Fas-DD-D244A mutant -  and at least partially governed by electrostatic interactions 
as it could be disrupted by increasing the ionic strength o f  the buffer. However, the 
hydrodynamic size o f  the resultant complex, as well as its component stoichiometry, 
remains unknown and requires to be investigated by further biophysical analysis.
In Chapter 4 I presented a mutational analysis o f the Fas death domain. In this study 
several previously reported Fas-DD mutants along with a range o f  novel mutants were 
analysed for their ability to interact with FADD-DD. This analysis was carried out using 
both yeast two-hybrid and NMR-based interaction assays. The yeast two-hybrid 
analysis established twelve Fas-DD mutants that appear to not interact with FADD-DD. 
These twelve mutants were further analysed by 2D [^N -'H j-H SQ C  N M R spectroscopy 
and the residue substitutions were all found not to disrupt the three dimensional fold of 
Fas-DD. Hence the substituted side-chains could be identified as being important for 
Fas-DD/FADD-DD interaction because o f their effect in the yeast two-hybrid assay. 
Among this list o f twelve mutants, four correspond to substitutions that have been 
previously reported to cause ALPS type la, a human lymphoproliferative disorder 
caused by defective Fas-induced apoptosis. The molecular basis o f  this disease is, in 
many cases, the disruption o f the Fas/FADD interaction which is vital for apoptosis to 
occur through the Fas pathway (Martin et al., 1999). In addition to these four, another 
six residues on the surface o f Fas-DD were newly identified as being important for 
FADD-DD binding. This data represents an extension o f our knowledge o f the surface 
regions o f Fas-DD that are important for FADD-DD interaction. Previous reports have 
shown that the surfaces o f the a 2  and a3  helices o f Fas-DD constitute at least part o f
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the FADD-binding surface (Huang et al., 1996; Lahm et al., 2003), however the 
mutational analysis presented here has established that there are residues on the surfaces 
o f a-helices 2, 3, 4, 5 and 6 that can modulate this interaction, at least in vitro. The 
extension o f the Fas-DD interaction surface complements the data o f Hill et al. who 
discovered, using a mutational analysis coupled with both in vitro pull-down and cell- 
based functional assays, an “expanded binding surface on the FADD death domain” that 
mediates the Fas-DD/FADD-DD interaction (Hill et al., 2004).
To date, there are two published three dimensional structures o f  homotypic complexes 
o f death fold family members -  namely the Drosophila Pelle/Tube death domain 
complex (Xiao et al., 1999) and the APAF-l/caspase-9 CARD complex (Qin et al.,
1999). Structures o f  the death domains o f Fas and FADD were modelled onto the 
individual domains o f  these two complexes and the inventory o f  residues found at the 
interfaces in these simple models was compared to the list o f  residues that, when 
mutated, were found to disrupt the interaction between Fas-DD and FADD-DD. This 
analysis ultimately proved inconclusive and suggested that the 1:1 heterodimer 
structures o f the Pelle-D/Tube-DD and A PAF-l-CARD/caspase-9-CARD complexes 
are o f not good starting points to use as templates for the creation o f a model o f the Fas- 
DD/FADD-DD interaction consistent with all the findings.
Evidence from the existing DD and CARD complex structures and the Fas-DD/FADD- 
DD interaction analysis points towards a non-conserved mode o f  homotypic interaction 
for the death fold domains. The Pelle-DD/Tube-DD interface consists o f  residues from 
a-helices 1, 3, and 4 o f  Pelle-DD and a-helices 1, 2 and 4 o f Tube-DD along with the 
Tube-DD C-terminal extension that binds to the a4 -a5  and a 2 -a 3  loops o f Pelle-DD. 
The CARD complex interface consists o f mainly charged residues in a-helices 1 and 4 
o f caspase-9 CARD and a-helices 2 and 3 o f  APAF-1 CARD. It has been established by 
this work and that o f Hill et al., that Fas-DD and FADD-DD utilise residues from 
essentially each one o f their respective helices (with the possible exception o f the Fas- 
DD a l  helix). Moreover, there is extensive experimental evidence that the formation of 
these homotypic death fold complexes is dominated by electrostatic interactions (e.g. 
Zhou et a l ,  1999; Bang et al., 2000; Kauffnann et al., 2002; Hill et al., 2004). It is 
perhaps unsurprising then, that given the heterogeneity o f the surface charge
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distributions exhibited by these domains (see Figure 1.9), a com mon mode o f 
interaction might not be established.
The data presented here, in Chapters 3 and 4, point to the formation o f  a multivalent 
complex between the death domains o f Fas and FADD. The mutational analysis o f Fas- 
DD revealed that several surface regions o f the death dom ain are involved in its 
interaction with FADD-DD and, indeed, multiple surface regions o f  both Fas-DD and 
FADD-DD would be necessary for the formation o f the large, mulitmeric complex 
suggested by the NM R-based titration studies o f  the two proteins.
In order to reinforce the in vitro mutational analysis o f Fas-DD, Chapter 5 described the 
development o f  a functional, cell-based assay to analyse the effect o f  Fas mutations on 
the ability o f the receptor to induce apoptosis. W ild-type Fas and three mutant forms 
(D244A, K247A and K280A) were introduced in the human Fas negative Huh-7 cell 
line utilising the fine control o f  expression level provided by the Tet-on expression 
system. FasL was shown to induce death in the cell line expressing wild-type Fas, Fas- 
K247A and, to a lesser extent, Fas-K280A but not in the cell line expressing Fas- 
D244A. Importantly, the cell death induced by FasL in these cultures was shown to be a 
result o f caspase-8 dependent apoptosis by a combination o f specific caspase-8 
inhibition and in situ  DNA fragmentation assays. The pattern o f  functional data 
established via the cell-based assay correlated well with in vitro analysis o f the same 
three Fas-DD mutants. Such a correlation serves to highlight the utility o f a 
multidisciplinary approach to the dissection o f receptor-based signal transduction 
pathways.
Since the initiation o f apoptosis through Fas depends on the activation o f  caspase-8, 
which in turn depends on the recruitment o f FADD to the death receptor, the interaction 
between these two proteins is vital for the function o f  this apoptotic pathway. There is, 
at present, little understanding o f the precise mechanism by w hich the effect o f FasL 
ligation o f the Fas receptor is transduced across the cell membrane. However, recent 
work identifying a specific series o f events that follow Fas activation has increasingly 
suggested that the aggregation o f Fas receptors in the membrane may be vital for the 
activation o f sufficient quantities o f caspase-8 to induce apoptosis (see Figure 6.1). 
First, high molecular weight oligomers o f Fas have been reported to form as quickly as
176
5 seconds after FasL-binding. These oligomers are o f  unknown m olecular weight as 
they have only been identified by W estern-blotting techniques from whole-cell lysates 
(e.g. Algeciras-Schimnich et al., 2002; Holler et al., 2003) -  curiously though, these Fas 
“micro-aggregates” are SDS-stable and, as such, may represent some form o f covalently 
modified receptor. W ithout knowledge o f the precise composition and oligomeric state 
o f such micro-aggregates (or how, if  at all, they are modified), it is hard to speculate 
upon their function in the signalling process. This issue is further confused by reports o f 
the self-association o f  Fas receptors before ligand binding occurs and the subsequent 
identification o f the pre-ligand assembly domain (PLAD) in the N-terminus o f the 
extracellular domain o f  Fas (Siegel et al., 2000). The Fas receptors may, therefore, 
undergo a form o f  structural rearrangement in the plasma m embrane upon ligation with 
FasL that leads to or is coupled with micro-aggregate formation and receptor clustering, 
a hypothesis that is given weight by reports that disruption o f the actin cytoskeleton can 
inhibit this process (Algeciras-Schimnich et al., 2002).
Following these initial FasL-dependent events, FADD is rapidly recruited to the death 
domain o f Fas reaching maximal levels o f co-localisation after approximately 15 
minutes (Kischkel et al., 1995). A recent report by Siegel et al. indicates that FADD 
recruitment further drives the clustering o f  the Fas receptor in the cell membrane, 
allowing the detection o f  Fas aggregates using fluorescence confocal microscopy 
(Siegel et al., 2004). M oreover, this process was found to be independent o f caspase-8 
recruitment but could be disrupted by overexpression o f the ALPS mutation Fas-D244V 
and was independent o f  whether the apoptotic cell type was Type I or Type II (see 
Chapter 1).
In the next stage o f apoptotic Fas signalling, caspase-8 is recruited to FADD to form the 
DISC thereby becoming activated to initiate the “caspase cascade”. At this point Fas is 
further clustered (at least in Type I cells) (Barnhart et al., 2003) to form receptor “caps” 
on the cell surface, in a caspase-dependent process (Siegel et al., 2004). This receptor 
capping is also associated with ceramide production and acid sphingomyelinase activity 
and is, as such, thought to require lipid rafts (Cremesti et al., 2001; Grassme et al., 
2001a). Finally these receptors are recycled via an uncharacterised endocytosis pathway 
(Algeciras-Schimnich et al., 2002).
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Figure 6.1: Stages of Fas receptor signalling and DISC formation. Fas receptors may be
constitutively dimerised (based on the TNF-receptor structure -  see Figure 1.9) or pre-associated 
in some other manner in the cell membrane via the PLAD region (a). Following FasL binding 
(b), the receptors form SDS-stable micro-aggregates that can be detected by Western blotting. A 
second stage of receptor clustering is dependent on FADD recruitment and actin filaments, and 
can be detected by fluorescent microscopy (c). In the final stage of DISC formation (d), 
procaspase-8 is recruited and activated. During this stage the receptors are further aggregated 
into polarised "‘caps” on one region of the cell surface. Receptor capping is dependent on both 
caspase-8 activation and the actin cytoskeleton and may involve the formation of lipid rafts. 
Following caspase activation DISCs are internalised by endocytosis.
Taking these data at face value it seems that there are at least three independent stages 
o f Fas aggregation before caspase-8 activation occurs at the DISC. Coupled with the 
observation that, almost certainly, induced proximity o f  procaspase-8 is sufficient to 
induce caspase-8 activation (Donepudi et a l , 2003; Boatright et al., 2003), it may be 
assumed that the scaffold produced by the aggregation o f  Fas receptors in the membrane 
allows the local concentration o f  activated caspase-8 molecules to significantly increase. 
If, as suggested by the data presented in this thesis, the interaction between Fas-DD and 
FADD-DD involves the co-aggregation o f Fas receptors and full length FADD 
molecules, then this event may conceivably drive the clustering o f Fas receptors post- 
FasL binding but before procaspase-8 recruitment. This hypothesis is given weight by 
the observations that the activation o f other caspases is driven by the aggregation o f 
various different death fold domain-containing proteins. For example it was shown in
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Chapter 1 that the activation o f caspase-9 occurs via a two-stage process driven by 
CARD/CARD interactions. Initially the CARD domain o f  APAF-1 homo-oligomerises 
during the formation o f the apoptosome and this is followed by procaspase-9 
recruitment via APAF-l-CARD/caspase-9-CARD hetero-dimerisation. It has also been 
shown that the homotypic oligomerisation o f pyrin domains o f  Asc and NALP1 is 
important in the activation o f the inflammatory caspases-1 and -5 (Martinon et al., 
2002) and that caspase-2 is activated in a complex with two death domain-containing 
proteins, PIDD and RAIDD (Tinel and Tschopp, 2004). There may, therefore, exist a 
generalised mode o f  proximity-induced caspase activation that involves the formation o f 
a “scaffold” that is provided by interactions between death-fold domain containing 
proteins and the aggregation o f  Fas receptors with FADD, effected by the homotypic 
death domain interaction, helps to provide part o f such a scaffold that is necessary for 
the activation o f  caspase-8 and caspase-10.
Using a combination o f  the protein reagents and stable cells lines developed in this work 
there is a wide range o f  possibilities for the future o f this project. For example, attempts 
to understand the interaction between Fas-DD and FADD m ay be extended by working 
with full length FADD protein in place o f the isolated death domain. Indeed, there have 
been reports that both the death domain and the death effector domain are required for 
efficient recruitment o f  FADD to the Fas receptor (Thomas et al., 2004). Further to this, 
characterisation o f  the homotypic FADD/caspase-8 death effector domain interaction 
may lead to greater understanding o f the precise molecular mechanism o f caspase-8 
activation, especially if  this can be carried out in the context o f  the Fas/FADD 
interaction as a minimal in vitro reconstituted DISC.
In parallel to such efforts, utilisation o f the stable Fas and Fas mutant expressing cell 
lines could enable comparative studies o f the Fas receptor clustering and DISC 
formation using a combination o f fluorescence microscopy and proteomic analysis. 
Although there have been reports o f  numerous other proteins involved in DISC 
formation such as FLIP, RIP, Daxx, FAP-1, FLASH, FAF-1, etc. (Peter et a l ,  2003), 
none have been fully characterised in terms o f their functional roles in Fas signalling or 
their precise molecular interactions. It is potentially feasible to “capture” the DISC 
proteome at varying points in the progression o f its signalling by a combination o f Fas 
activation and immunoprecipitation - as recently demonstrated for the TNF-R1
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signalling complex (Kuai et al., 2004). The availability o f  a cell-line expressing the 
wild-type Fas receptor along with others expressing a range o f  Fas mutants (including 
the D244A “knockout” mutant), would enable comparative studies to be carried out in 
parallel in order to decipher the precise functional role that each o f  these proteins may 
play with potential to reveal mechanistic details relevant to our understanding o f health 
an in disease.
In summary, a com bination o f  in vitro experiments using the yeast two-hybrid assay, 
NMR spectrsoscopy and point-mutation analysis indicated that an extended surface o f 
the Fas death domain is required for its homotypic interaction with the FADD death 
domain, an interaction that provides the first step in the apoptotic signalling pathway o f 
this death receptor. These results were reinforced by the development o f a mammalian 
cell-based assay to test the effects o f Fas-DD mutations on the efficiency o f FasL- 
induced apoptosis. The biological assay yielded complementary data for several o f the 
mutations tested in vitro. Therefore, this study has improved the understanding if  the 
interaction between the death domains o f the Fas receptor and the adaptor protein 
FADD and provided a basis for further structural and functional analyses.
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Appendix
Appendix 1: The standard genetic code
First
Position
Second Position Third
Position
T C A G
TTT P he TCT Ser TAT T y r TGT C ys T
T TTC P he TCC Ser TAC T y r TGC C y s C
TTA Leu TCA Ser TAA S top TGA S to p A
TTG L eu TCG Ser TAG S top TGG T rp G
CTT L eu CCT Pro CAT H is CGT A rg T
C CTC L eu CCC Pro CAC H is CGC A rg C
CTA L eu CCA Pro CAA G in CGA A rg A
CTG L eu CCG Pro CAG G in CGG A rg G
ATT l ie ACT T hr AAT A sn AGT S er T
A ATC l ie ACC T hr AAC A sn AGC S er C
ATG He ACA T hr AAA L ys AGA A rg A
ATG M et ACG T hr AAG Lys AGG A rg G
GTT V al GCT A la GAT A sp GGT G ly T
G GTC V al GCC A la GAC A sp GGC G ly C
GTA V al GCA A la GAA G lu GGA G ly A
GTG V al GCG A la GAG G lu GGG G ly G
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Appendix 2: Amino-acid one and three letter codes
A Ala Alanine M Met M ethionine
C Cys Cysteine N Asn Asparagine
D Asp Aspartic acid (Aspartate) P Pro Proline
E Glu Glutamic acid (Glutamate) Q Gin Glutam ine
F Phe Phenylalanine R Arg Arganine
G Gly Glycine S Ser Serine
H His Histidine T Thr Threonine
I lie Isoleucine V Val Valine
K Lys Lysine W Trp Tryptophan
L Leu Leucine Y Tyr Tyrosine
Amino-acid nomenclature used in this thesis
D 101: Aspartate residue number 101
D101 A: Aspartate 101 mutated to alanine
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Appendix 3: PCR cloning primers
Shown in the table below are the 5' to 3’ base sequences o f  all oligonucleotide primers 
used in this project. Mutagenic bases are coloured red. When in pairs the forward (3’) 
primer is listed first followed by the reverse (5 ') primer.
Primer
Name
Purpose Sequence
1 .. Yeast 2 hybrid -Fas-D D AATTCCACiCTGACCACCATGGAAACAGTGGCAATAAATT
2 Yeast 2 hybrid -Fas-D D G ATC'CCCGGG AATTGCC ATGTT AG ACC AAGCTTTGG ATTIC
3 Yeast 2 hybrid -FADD-DD ATTTCCAGCTGACCACCATGGGGGAAGAAGACCTGT
4 Yeast 2 hybrid -FADD-DD GATCCCCGGGAATTGCCATGTTAGGCCCCACTCCTG
5 Yeast 2 hybrid -  Re-PCR CTATCTATTCGATGAAGATACCCCACCAAACCCAAAAAAA 
G AG ATCG AATTCC AGCT G ACCACCAT G
6 Yeast 2 hybrid -  Re-PCR GTACCGTTAAGGGCCCCTAGGCAGCTGGACGTCTCTAGA
TACTTAGCATCTATGACTTTTTGGGGCGTTC
7 His-Fas-DD PCR CCGGCATATGGAAACAGTGGCAATAAAT
8 His-Fas-DD PCR GCGCGGATCCTTATCTTGAGTCACTAGT
9 GST-Fas-DD PCR CGGCGCGGATCCGAAACAGTGGCAATAAAT
10 GST-Fas-DD PCR GCGGCCGGAATTCTTAGACCAAGCTTTGGA
11 GST-Fas-DD PCR GGCGCGGATCCCTGAACCCGGAAACAGTGGCAATAAAT
12 GST-Fas-DD PCR GGCGCGGATCCTCCCCGACCCTGAACCCGGAAACAGTG
13 GST-Fas-DD PCR GGCGCGGATCCCACGAATCCCCGACCCTGAACCCGGAA
14 GST-Fas-DD PCR GCGGCCGGAATTCTTATTCTGAGTCACTAGT
15 Fas-DD-D244A mutation GTCAAT GAAGCCAAAATAGCT GAGAT CAAG AAT G
16 Fas-DD-D244A mutation C ATT CTT GAT CT CAG CTATTTT G G CTT C ATT G AC
17 Fas-DD-K247A mutation GCC AAAATAG AT GAGAT CG C G AAT G AC ATT G T CC AA
18 Fas-DD-K247A mutation GTCTT GGACATT GT CATT CGC GAT CT CAT CTA1 1 TT
19 G bl-Fas-D D  PCR GCCGGGATCCGAAACAGTGGCAATAAAT
20 G bl-Fas-D D  PCR GGCCGGATCCTTATTCTGAGTCACTAGT
21 Fas-DD-S227A mutation GGAGT CAT GACACTAG C T CAAGTTAAAGGCTTT G
22 Fas-DD-S227A mutation CAAAGCCTTTAACTTGAGCTAGTGTCATGACTCC
23 Fas-DD-R234A mutation GTTAAAGGCTTTGTTGCAAAGAATGGTGTCAATG
24 Fas-DD-R234A mutation CATTGACACCATTCTTTGCAACAAAGCCTTTAAC
25 Fas-DD-N239Q mutation CGAAAGAATGGT GTCC AAGAAGCCAAAATAGAT G
26 Fas-DD-N239Q mutation CATCTAI ITTGGCTTCTTGGACACCAI ICr iTCG
27 Fas-DD-E240A mutation G AAAG AATGGTGT CAATGC AGCCAAAATAG AT GAG
28 Fas-DD-E240A mutation CT CAT CT ATTTT G G CTG C AI 1GACACCATTCT1 TC
29 Fas-DD-E240Q mutation GAAAGAATGGTGTCAATCAAGCCAAAATAGATGAG
30 Fas-DD-E240Q mutation CTCATCTATTTTGGCTTGA1 1GACACCATTCTTTC
31 Fas-DD-A241D mutation G AATGGT GT CAAT G AAGACAAAATAGAT GAGAT CAAG
32 Fas-DD-A241D mutation G AAT G GTGT CAAT G AAGA C AAAATAG AT GAGAT CAAG
33 Fas-DD-K242A mutation GGT GTCAAT GAAGCCG CAATAGAT GAGAT CAAG
34 Fas-DD-K242A mutation CTTGATCTCATCTATTGCGGCTTCATTGACACC
35 Fas-DD-N248Dmutation GAT GAGAT CAAGG AT G ACAAT GTCCAAGAC
36 Fas-DD-N248D mutation GT CTTGGACATT GT CATC CTT GAT CT CAT C
37 Fas-DD-V251Q mutation GAT CAAGAAT GACAATCAG CAAGACACAGCAGAAC
38 Fas-DD-V251Q mutation GTT CTGCT GTGTCTT GCAG ATTGTCATT CTT GAT C
39 Fas-DD-Q252Amutation GAGAT CAAGAAT GAG CAT GT CCAAGACACAGCAGAAC
40 Fas-DD-Q252A mutation GTTCTGCTGTGTCTGC G ACATT GT CATT CTTG ATCTC
41 Fas-DD-E256Q mutation CAAT GTCC AAG AC ACAG CAC AAC AG AAAGTT C AAC
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42 Fas-DD-E256Q mutation GTTGAACTTTCTGTTGTGCTGTGTCTTGGACATTG
43 Fas-DD-R263A mutation G AAAGTTCAACTG CTTG C TAATTG G CATCAACTTC
44 Fas-DD-R263A mutation GAAGTT GATGCCAATTAGC AAGCAGTT GAACTTTC
45 Fas-DD-Q276E mutation CTTCGTAATTGGCATGAACTTCATGGAAAGAAAG
46 Fas-DD-Q267E mutation CTTTCTTTCCATGAAGTTCATGCCAATTACGAAG
47 Fas-DD-K272A mutation C AACTT CAT G G AAAGG C AG AAG C G TAT G AC ACATT G
48 Fas-DD-K272A mutation CAAT GTGT CATACG CTT CTG C CTTTCCAT GAAGTT G
49 Fas-DD-D276N mutation GGAAAGAAAGAAGCGTATAACACATTGATTAAAGATC
50 Fas-DD-D276N mutation GAT CTTT AAT CAAT GTTT CAT ACGCTTCTTT CTTT CC
51 Fas-DD-K280A mutation GCGTATGACACATTGATTGCAGATCTCAAAAAAGCC
52 Fas-DD-K280A mutation GGC 1 1 1 ITTGAGATCTGCAATCAA1 G 1G 1CA 1ACGC
53 Fas-DD-K284Q mutation GATTAAAGATCTCAAACAAGCCAATCTTTGTACTC
54 Fas-DD-K284Q mutation G AGTACAAAGATT GGCTTG TTT G AGAT CTTTAAT C
55 Fas-DD-N286K mutation CT CAAAAAAGCCAAG CTTTGTACTCTT G CAGAG
56 Fas-DD-N286K mutation CT CTGCAAGAGTACAAAGCTT GGCTTTTTT GAG
57 Fas-cDNA PCR CCGCACGCGTGCCATGCTGGGCATCTGGACC
58 Fas-cDNA PCR GTCAGCGGCCGCTCAGACCAAGCTTTGGATTTC
197
Appendix 4: Recombinant protein expression plasmids
Shown below are diagrammatical representations o f the plasm id vectors used in this 
project. Each includes the following features: open reading frames (grey boxes), 
promoters (clear boxes) and unique restriction enzyme sites used for cloning.
Pvuti -8415-CAG’CTG EcoRI - 127 - G'AATT C
EcoRI - 8407 - G'AATT C
pOAD 
8429 bp
PvuW -135 - CAG’CTG
BD
pOBD-2 
7167 bp
BamHI - 930 - G'GATC_C 
EcoRI - 940 - G'AATT_C
pGEX-2T 
4948 bp
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SamHI - 319 - G^ATC.C 
/ „ Ndei - 331 - CA'TA_TG BamHl - 222 - G'GATC C
pET15b 
5708 bp pET30a-Gb1 5473 bp
pTET-on 
7391 bp
6/a
N ot - 502 - GC'GGCC_GC
pTRE2-hyg 
5325 bp
Key:
O R Fs P rom oters
AD GAL4 activation domain ADH Constitutive yeast promoter
BD GAL4 DNA binding domain tac Hybrid tac/lac E. coli promoter
bla Ampicillin resistance T7 T7 promoter
lacl Lac repressor CMV Constitutive mammalian promoter
Leu2 Leucine auxotrophic gene TetRE Tet response element
TRP1 Tryptophan auxotrophic gene
GST Glutathione-S-Transferase
His6 His-tag coding sequence
Gbl B1 domain o f  protein G
Kan Kanamycin resistance gene
Neo Neomycin resistance gene
Hygro Hygromycin resistance gene
rtTA Tet-responsive transcription 
activator
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Appendix 5: DNA and protein sequences of recombinantly expressed 
proteins
Below are listed the DNA and amino-acid sequences for all recom binantly expressed 
protein constructs used in this project. Bold lettering indicates the death domain 
sequences o f Fas-DD or FADD-DD. Blue lettering indicates the specific tags as 
expressed from individual vectors. Red letters indicate sites o f  those point mutations 
produced and used in this study.
1: His6-FADD-DD -  residues 93-192 in pET-15b: 14.5 kDa
ATGAGCCATCATCATCATCATCACAGCAGCGGCCTGGTGCCGCGCGGCAGCCATATGGGG
M S H H H H H H S S G L V P R G S H M G
GAAGAAGACCTGTGCGCAGCATTTAACGTCATATGTGATAATGTGGGGAAAGATTGGAGA
E E D L C A A F N V I C D N V G K D W R
AGGCTGGCTCGTCAGCTCAAAGTCTCAGACACCAAGATCGACAGCATCGAGGACAGATAC 
R L A R Q L K V S D T K I D S  I E D R Y
CCCCGCAACCTGACAGAGCGTGTGCGGGAGTCACTGAGAATCTGGAAGAACACAGAGAAG 
P R N L T E R V R E  S L R I W K N T E  K
GAGAACGCAACAGTGGCCCACCTGGTGGGGGCTCTCAGGTCCTGCCAGATGAACCTGGTG
E N A T V A H L V G A L R S C Q M N L V
GCTGACCTGGTACAAGAGGTTCAGCAGGCCCGTGACCTCCAGAACAGGAGTGGGGCCTGA
A D L V Q E V Q Q A R D L Q N R S G A *
2: His6-Fas-DD -  residues 202-307 in pET-15b: 14 kDa
ATGAGCCATCATCATCATCATCACAGCAGCGGCCTGGTGCCGCGCGGCAGAAACA
M S H H H H H H S S G L V P R G S E T
GTGGCAATAAATTTATCTGATGTTGACTTGAGTAAATATATCACCACTATTGCTGGAGTC
V A I N L S D V D L S K Y I T T I A G V
ATGACACTAAGTCAAGTTAAAGGCTTTGTTCGAAAGAATGGTGTCAATCAAGCCAAAATA
M T L S Q V K G F V R K N G V N Q A K I
GATGAGATCAAGAATGACAATGTCCAAGACACAGCAGAACAGAAAGTTCAACTGCTTCGT 
D E  I K N D N V Q D T A E Q K V Q L L R
AATTGGCATCAACTTCATGGAAAGAAAGAAGCGTATGACACATTGATTAAAGATCTCAAA
N W H Q L H G K K E A Y D T L I K D L K
AAAGCCAATCTTTGTACTCTTGCAGAGAAAATTCAGACTATCATCCTCAAGGACATTACT 
K A N L C T L A E K I Q T I  I L K D I  T
AGTGACTCAGAATAA 
S D S E *
200
3: GST-Fas-DD-1 -  residues 202-307 in pGex-2T: 39 kDa (m onom er mass)
A T G TC C C C TA TA C TA G G TTA TTG G A A A A TTA A G G G C C TTG TG C A A C C C A C TC G A C TTC TT
M S P I L G Y W K I K G L V Q P T R L L
TTGGAATATCTTGAAGAAAAATATGAAI-AGCATTTGTATGAGCGCGATGAAGGTGATAAA
L E Y L E E K Y E E H L Y E R D E G D K
TGGCG AAA A'AA AAA GTTTGAA TTGG GTTTGG AGTTTCCCA ATC TTCCTTATTATATTG AT 
W R N K K F E L G L E F P N L P Y Y I  D
GGTGATGTTAAATTAACACAGTCTATGGCCATCATACGTTATATAGCTGACAAGCACAAC 
G D V K L T Q S M A I  I R Y I A D K H N
ATGTTGGGTGGTTGTCCAAAAGAGCGTGCAGAGATTTCAATGCTTGAAGGAGCGGTTTTG
M L G G C P K E R A E I S M L E G A V L
GATATTAGATACGGTGTTTCGAGAATTGCATATAGTAAAGACTTTGAAACTCTC AAAGT T 
D I R Y G V S R I A Y S K D F E T L K V
GA TTTTC TTAGCAAGCTACCTGAAATGCTGAAAATGTTCGAAGATCGTTTATGTCATAAA
D F L S K L P E M L K M F E D R L C H K
A C A TA TTTAAA TGG TG ATC ATGTAAC C C A TC C TGA C TTC ATGTTGTATGAC G C TC TTGAT
T Y L N G D H V T H P D F M L Y D A L D
G TTGTTTTA TA C ATGGA C C C AATGTGC C TGG ATGC GTTC C C AAA ATTA GTTTGTTTTAAA 
V V L Y M D P M C L D A F P K L V C  F K
AAACGTATTGAAGCTATCCCACAAATTGATAAGTACTTGAAATCCAGCAAGTATATAGCA
K R I E A I P Q I D K Y L K S S K Y I A
TGGCCTTTGCAGGGCTGGCAAGCCACGTTTGGTGGTGGCGACCATCCTCCAAAATCGGAT
W P L Q G W Q A T F G G G D H P P K S D
C TGGTTCCGCGTGG ATCCGAAACAGTGGCAATAAATTTATCTGATGTTGACTTGAGTAAA
L V P R G S E T V A I N L S D V D L S K
TATATCACCACTATTGCTGGAGTCATGACACTAAGTCAAGTTAAAGGCTTTGTTCGAAAG 
Y I  T T  I A G V M T L S Q V K G F V R K
AAT GGT GT C AATC AAGCC AAAAT AGAT GAGATCAAGAATGACAATGTCCAAGACACAGCA 
N G V N E  A K  I  D1 E I K 2 N D N V Q D T A
GAACAGAAAGTTCAACTGCTTCGTAATTGGCATCAACTTCATGGAAAGAAAGAAGCGTAT
E Q K V Q L L R N W H Q L H G K K E A Y
GACACATTGATTAAAGATCTCAAAAAAGCCAATCTTTGTACTCTTGCAGAGAAAATTCAG
D T L I K D L K K A N L C T L A E K I Q
ACTATCATCCTCAAGGACATTACTAGTGACTCAGAATAA 
T I I L K D I T S D S E *
D244 
2: K247
201
4: Gbl-Fas-DD-His6 -  residues 202-307 in pET30a-G bl: 20 kDa
ATGCAGTACAAACTGATCCTGAACGGTAAAACCCTGAAAGGTGAAACCACCACCGAAGCT
M Q Y K L I L N G K T L K Y E T T T E A
GTTGACGCT GCTACCGCGGAAAAAGTTT rCAAACAG TA CGCTAACG ACAA CGGTGTTGAC 
V D A Y ' A E K V r K Q Y A N E N G V D
GGTGAATGGACGTACGACGACGCTACCAAAACCTTCACCGTTACCGAAGGATCCGAAACA 
G E Y :  E G A T K T E T V T E G S E T
GTGGCAATAA ATTTATCTG ATGTTG ACTTG AGTAAA TA TA TCA CCACTATTG CTG GAG TC 
V A I N L S D V D L S K Y  I  T T  I  A G V
ATGACACTAAGTCAAGTTAAAGGCTTTGTTCGAAAGAATGGTGTCAATCAAGCCAAAATA 
M T L S 1 Q V  K G F V R2 K N G V N3 E 4 A 5 K6 I
GATGAGATCAAGAATGACAATGTCCAAGACACAGCAGAACAGAAAGTTCAACTGCTTCGT 
D7 E I  K8 N9 D N V 10 Q11 D T A E12 Q K V  Q L L R13
AATTGGCATCAACTTCATGGAAAGAAAGAAGCGTATGACACATTGATTAAAGATCTCAAA 
N W H Q14 L H G K K15 E A Y D16 T L I  K17 D L K
A A AGCCAATCTTTGTACTCTTGCAGAGAAAATTCAGACTATCATCCTC AAGGACATTACT 
K1 8 A N 1 9 L C T L A E K I Q T I  I L K D  I  T
AGTGACTCAGAAGGATCCCACCACCACCACCACCACTAA
S D S E G S H H H H H H *
S227 8. K247 15: K.272
2: R234 9. N238 16: D267
3: N239 10 V251 l7: K280
4: E240 11 Q252 18: K284
5: A241 12 E256 l9: N286
6: K242 13 R263
7: D244 14 Q267
202
5: Fas -  residues 1-319 in pTRE2-hyg: 35 kDa
AT G C T G G G C A T C T G G A C C C TC C T A C C TC T G G T T C TT A C G TC T G T T G C T A G A TT A T C G T C C  
M L G I W T L L P L V L T S V A R L S  S
AAAAGTGTTAATGCCCAAGTGACTGACATCAACTCCAAGGGATTGGAATTGAGGAAGACT
K S V N A Q V T D I N S K G L E L R K T
G T T A C T A :‘AG:TGA GAC TC AG AAC TTGGA AGG C C TG C ATC ATGATGG C C AATTC TG C C AT
V T T V E T Q N L E G L H H D G Q F C H
AAGCCCTGTCCTCCAGGTGAAAGGAAAGCTAGGGACTGCACAGTCAATGGGGATGAACCA 
K P C P P G E R K A R D C T V N G D E  P
GACTGCGTGCCCTGCCAAGAAGGGAAGGAGTACACAGACAAAGCCCATTTTTCTTCCAAA 
D C V P C Q E G K E Y T D K A H F S  S K
TGCAGAAGATGTAGATTGTGTGATGAAGGACATGGCTTAGAAGTGGAAATAAACTGC ACC 
C R R C R L C D E G H G L E V E  I N C T
CGG ACCCAGAATACC AAGTGCAGATGTAAACCAAACTTTTTTTGTAACTCTACTGTATGT
R T Q N T K C R C K P N F F C N S T V C
GAACACTGTGACCCTTGCACCAAATGTGAACATGGAATCATCAAGGAATGCACACTCACC
E H C D P C T K C E H G I I K E C T L T
AGCAACACCAAGTGCAAAGAGGAAGGATCCAGATCTAACTTGGGGTGGCTTTGTCTTCTT 
S N T K C K E E  G S R S N L G W L C L L
CTTTTGCCAATTCCACTAATTGTTTGGGTGAAGAGAAAGGAAGTACAGAAAACATGCAGA 
L L P I  P L  I V W V K R K E V Q K T C R
AAGCACAGAAAGGAAAACCAAGGTTCTCATGAATCTCCAACCTTAAATCCTGAAACAGTG 
K H R K E N Q G S H E S P T L N P E  T V
GCAATAAATTTATC TGATGTTGACTTGAGTAAATATATCACC ACTATTGCTGGAGTCATG
A I N L S D V D L S K Y I T T I A G V M
ACACTAAGTCAAGTTAAAGGCTTTGTTCGAAAGAATGGTGTCAATGAAGCCAAAATAGAT
T L S Q V K G F V R K N G V N E A K I D 1
GAGAT C AAGAAT GAC AAT GT C C AAGACAC AGC AGAAC AGAAAGT T C AAC T GC T T C GT AAT
E i k 2 n d n v q d t a e q k v q l l r n
TGGCATCAACTTCATGGAAAGAAAGAAGCGTATGACACATTGATTAAAGATCTCAAAAAA
w h q l h g k k e a y d t l i k 3 d l k k
GCCA ATCTTTGTACTCTTGCAGAGAAAATTCAGACTATCATCCTCAAGGACATTACTAGT
A N L C T L A E K I Q T I I L K D I T S
GACTCAGAAAATTCAAACTTCAGAAATGAAATCCAAAGCTTGGTCTAG 
D S E N S N F R N E  I Q S L V *
D244 
2: K247 
3: K280
203
